CA2085954A1 - Substituted pyridine n-oxides, processes for their preparation, and their use - Google Patents
Substituted pyridine n-oxides, processes for their preparation, and their useInfo
- Publication number
- CA2085954A1 CA2085954A1 CA002085954A CA2085954A CA2085954A1 CA 2085954 A1 CA2085954 A1 CA 2085954A1 CA 002085954 A CA002085954 A CA 002085954A CA 2085954 A CA2085954 A CA 2085954A CA 2085954 A1 CA2085954 A1 CA 2085954A1
- Authority
- CA
- Canada
- Prior art keywords
- alkoxy
- alkylamino
- alkyl
- radical
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Abstract Substituted pyridine N-oxides, processes for their preparation, and their use Pyridine N-oxides which are substituted by ester and/or amide groups in the 2 and 4 or 5 positions, and a process for their preparation, are described. The compounds mentioned act as inhibitiors of lysine hydroxylase and proline hydroxylase.
Description
HOECHST AKTIENGESELLSCHAFT HOE 91/F 415 Dr.FI
Substituted pyridine N-oxides, processes for their preparation, and their use Compounds which inhibit the enzymes proline hydroxylase and lysine hydroxylase have the e~fect of a very select-ive inhibition of collagen biosynthesis by influencing the collagen-specific hydroxylation re~ctions. In the course therev, protein-bound pxoline or lysine is hydroxylated by the enzymes proline hydroxylase or, respectively, tysine hydroxylase. If this reaction is suppressed by inhibitors, a non-functional, hypohydroxyl-ated collagen molecule is formed, which can be released by cells into ~he extracellular space in only a small amount. The hypohydroxylated collagen moreover cannot be incorporated into the collagen matrix, and is very readily broken down proteolytically. As a consequence of these effects, the total amount of collagen deposited in the extracellular space is reduced.
Inhibitors of proline hydroxylase are therefore suitable substances in the therapy of diseases in which the deposition of collagen contributes decisively to the syndrome. These include, inter alia, fibroses of the lung, liver and skin (scleroderma), as well as atherosclerosis.
It is known that inhibition of proline hydroxylase by known inhibitors, such as ~ dipyridyl, leads to an inhibition of the Clq biosynthesis of macrophages (W. Muller et al., FEBS Lett. 90 (1978~, 218;
Immunobiology 155 (1978), 47). This results in a failure of the classical route of complement activation. Inhibit oxs of proline hydroxylase therefore also act as immuno-suppressants, for example in cases of immune complex diseases.
It is known that the enzyme proline hydroxylase is inhibited effectively by pyridin~-2,4- and rj -2,5-dicarboxylic acid (K. Majamaa et al., Eur. J.
Biochem. 13B (1984) 239-24$). Elowever, these compounds are active as inhibitors in the cell culture only in very high concen-trations (Tschank, G. et al., Biochem. J. 238 (1987) 625-633).
Pyridine-2,4- and -2,5-dicarboxylic acid diesters having 1-6 carbon atoms in the ester alkyl part are described in DE-A 34 32 094 as medicaments for inhibition of proline hydroxylase and lysine hydroxylaseO
These lower-alkylated diesters have the disadvantage, however, that they are split into the acids too quickly in the organism, and do not arrive at their action site in the cell in a sufficiently high concentration, and are therefore not particularly suitable for possible adminis-tration as medicaments.
DE-A 37 03 959, DE-A 37 03 962 and DE-A 37 03 963 de-scribe in general form mixed esters/amides, highe:r-alkyl-ated diesters and diamides of pyridine-2,4- and ~2,5-dicarboxylic acid which effectively inhibit collagen biosynthesis in an animal model.
2,4- and 2,5-disubstituted pyridine N-oxides are de-scribed in German Patent Application P ~0 20 570.3.
It has now been found that substituted pyridine N-oxides of the following formula I and the physiologically tolerated salts also effecti~ely inhibit lysine hydroxyl-ase and proline hydro~ylase.
The invention therefore relates to substituted pyridine N-oxides of the general formula I
_ 3 ~ 5 l~
R 4 J`-~Y, R ~
5 ~\ ~ (I) in which R1 and R3 or R4 are -C(O)-X-R6, in which X is O or -N(R7)- and 5 R5 and R7 are identical or different, and A are a branched or unbranched, aliphatic or cycloali-phatic (C1 C12)-alkyl radical or (C1-C1~3-alkenyl radi-cal or a (C1-C12)-alkynyl radical, which is unsubstituted or mono- or polysubstituted, preferably mono- or disubstituted, by halogen/ in par-ticular fluorine, chlorine or bromine, hydroxyl, cyano, carboxyl, (C1-C8)-alkoxy, (C1-C8)-alkoxycarbonyl, (C1-C8)-alkoxycarbonyloxy, (C1-C8)-alkoxy-(C1-C8)-alkoxycarbonyl-oxy, (C6-Cl2~-aryloxycarbonyloxy, (C7-Cll~-aralkyloxycar-bonyloxy, (C7-C11)-aralkylcarbonyloxy, cinnamoyl, cinna-moyloxy,(C8-C12)-arylcarbonyloxy,( C3 C8 ) - alkenylcarbonyl-oxy, (C3-C8)-alkynylcarbonyloxy, (C3-C8)-cycloalkylcarbon-yloxy, ~Cl-Cl2) alkoxy-(Cl-Cl2)-alkoxy, (Cl-Cl2)-alkoxy-amino, (Cl-Cl2)-alkoxy-N-(Cl-C6)-alkylamino, (Cl-cl2)-alkoxy-N,N-(C1-C6)-dialkylamino, carbamoyloxy, N-(Cl C8)-alkylcarbamoyloxy, N,N-di-(Cl-C8)-alkylcarbamoyl, N-(C3-C8)-cycloalkylcarbamoyl, N-(C8-C12)-arylamino, N-(C7-C11)-aralkylamino, N-alkyl-axalkylamino, N-alkyl-arylamino, (C3-C8)-cycloalkanoylamino, (C1-C8)-alkanoyl-amino, (C8-C12)-aroylamino, (C7-C11)-aralkanoylamino, (C1-C8)-alkanoyl-(C1-C8)-alkylamino,(C3-C8)-cycloalkanoyl-(cl-cs)-alkylamino~ (C8~cl2)-aroyl-(cl-c8)-alkylamino~
d, ~ 9 ~ l~
(C,-C~ aralkanoyl-(Cl-C8)-alkylamino, (Cl-C8)-alkylmercap~
to, (Cl-C8)-alkylsulfinyl, (Cl-Ca)-alkylsulfonyl, (Cl-Ca)-alkylcarbonyl, (C3-C8)-cycloalkylcarbonyl, nitro, tri-fluoromethyl, phenylmercapto, phenylsulfonyl, phenylsul-finyl,sulfamoyl,N~(Cl-C6)-alkylsulfamoyl,N,N-di-(C1-C6)-alkylsulfamoyl, (C1-C8)-alkyl-sulfonamido or a.rylsulfon-amido, in which the aryl and aralkyl radicals present in the above substituents can also he hetexocyclic in nature and/or, as is also the case for alkyl, a.re substituted by 1, 2, 3, 4 or 5 identical or different subs~ituentæ from the series comprising halogen, cyano, nitro, trifluoro-methyl, (Cl-C6)-alkyl, hydroxy, (Cl-C6)-hydroxyalkyl, (Cl-C6)-alkoxy, -O-[CH2-}xCyH(2frl-B)Fg~ -OCF2Cl, -O-CF2-CHFCl, trifluoromethyl, (C1-C6)-alkylmercapto, (Cl-C6)-alkylsul-finyl, (C1-C6)~alkylsulfonyl, (C1~C6)-alkylcarbonyl, (Cl-C6)-alkoxycarbonyl, carbamoyl, N~(Cl-C4)-alkylcar-bamoyl, N,N-di-(Cl-C4)-alkylcarbamoyl, (Cl-C6)-alkylcar-bonyloxy~ (C3 Ca)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, NR'-R", phenylmercapto, phenylsulfo:nyl, ~0 phenylsulfinyl, sulfamoyl, N-(C1-C4)-alkylsulfamoyl and N,N-di-(C1-C4)-alkylsulfamoyl, in particular by up to 3 of the abovemen~ioned identical or different substituents, and a CH2 group of the alkyl chain is optionally replaced by 0, S, SO, SO2 or NR', or by an unsubstituted or substituted (C6-Cl2)~aryl radical or heteroaryl radical which carries 1, 2, 3, 4 or 5 identi-cal or different substituents from the series comprising halogen, nitro, cyano, carboxyl, hydroxyl, trifluorometh-yl, (cl-c6)-hydroxyalkyl~ --[cH2~xc~H(2f+l8~F~ -OCF2Cl~
-OCF2-CHFCl, (C1 C6)-alkylmercapto, (C1-C6)-alkylsulfinyl, (cl-c6)-alkylsulfonyl~ (Cl-C8)-alkoxy, (Cl-Ca)-alkyl, (Cl-C6)-alkylcarbonyl, (C1-C6)~alkoxycarbonyl, carbamoyl, N-(Cl-C4)-alkylcarbamoyl, N,N-di-(Cl C4 ) -alkylcarbamoyl, (Cl-C6)-alkylcarbonyloxy, ~ C3-C8 ) -CyC1 oalkyl, phenyl, benzyl, phenoxy, benzyloxy, ~R~-R", phenylmercapto~
phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(Cl-C4)-alkylsulfamoyl, N,N-di-(C1-C4)-alkylsulfamoyl, 3 'j 9 '3 ~
(Cl-CD)-alkoxycarbQnyloxy, (Cl-C~)-alkoxy-(Cl-Ca)-alkoxy-carbonyloxyr (Ca-Ci2)~aryloxycarbonyloxy, (C7-Cll)-aralkyl-oxycarbonyloxy, (C7-C1l)-aralkylcarbonyloxy, cinnamoyl, cinnamoyloxy,(C6-C12)-arylcarbonyloxy,(C3-C~)-alkenylcar-S bonyloxy, (C3-C8)-alkynylcarbonyloxy, (C3-C8)-cycloalkyl-carbonyloxy, (Cl-C~2)-alkoxy-(C1-C12)-alkoxy, (Cl~cl2)~
alkoxy-amino, (cl-cl2)-alkoxy-N-(cl-c6)-alkylamino~
(cl-cl2)-alkoxy-N~N-(cl-c6)-dialkylamino~ carbamoyloxy, ~-(Cl-C8)-alkylcarbamoyloxy, N,N-d.i-(Cl-C~)-alkylcarbamoyl~
N-( C3-C~ ) -cyc.loalkylcarbamoyl, N-( C6-c12 )-arylamino r N-(C7-Cl1)-aralkylamino, N-alkyl-aralkylam.ino, N-alkyl-arylamino, (C3-C8)-cycloalkanoylamino, (C1-C8)-alkanoyl-amino, (C6-C12)-aroylamino, ( C7-C 11 )-aralkanoylamino, (Cl-C8) alkanoyl-(Cl-C8)-alkylamino,(C3-C8)-cycloalkanoyl-(C1-C8)-alkylamino, (C8-C12)-aroyl-(C1-C8)-alkylam:ino, (C7-Cll)-aralkanoyl-(Cl-C8)-alkylamino, (Cl~C8)-alkylmer-cap~o, (cl-c8)-alkylsulfinyl r ( Cl-C8 ) -alkylsulfonyl, (C1-C8)-alkylcarbonyl, (C3-C8)-cycloalkylcarbonyl, nitro, trifluoromethyl, phenylmercapto, phenylsulfonyl, phenyl~
sulfinyl, sulfamoyl, N-(C1-C6)-alkylsulfamoyl, N,N-di-(cl-c8)-alkylsulfamoyl, (Cl-C8)-alkyl-sulfonamido and arylsulfonamido, in which the aryl and aralkyl radicals present in the above substituents can also be heterocyc-lic in nature and/or, as is also the case for alkyl, can be substituted by 1,2,3,4 or 5 identical or different substituen~s from the series comprising halogen, cyano, nitro, trifluoromethyl, (C1-C6)-alkyl, hydroxyl, (C1-C6)-hydroxyalkyl and (C1-C6)-alkoxy, or by an unsubstituted or substituted (C6-C12)-aryloxy radical, (C7-C~ aralkyloxy radical or heteroaryloxy radical, which carries 1, 2, 3~ 4 or 5 identical or different substituents from the series comprising hydroxyl, halo-gen, cyano, nitro, trifluoromethyl, (Cl-C6)-alkyl, (C1-C6)-hydroxyalkyl, (C1-C6)-alkoxy, ~CH2~~xCfH(2fl1-s) -OCF2-CHFCl, (C1-C6)-alkylmercapto, (C1-C6)-alkylsulfinyl, (cl-c6)-alkylsulfonyl~ (cl-c6)-alkylcarbonyl~ (C1-C6)-alkoxycarbonyl, carbamoyl, N-(C1-C4) alkylcarbamoyl, N,N-di-( Cl-c4 )-alkylc:~arbamoyl, (Cl-C6)-alkylcarbonyloxy, (C3-Ca) cycloalkyl, carboxyl, phenyl, benzyl, phenoxy, benzyloxy, NF~'-R, phenylmercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(Cl-C4)-alkylsulfamoyl, N,N~
5 di.-(C1-C4)-alkylsulfamoyl, am.inoalkyl/ ~-(C1-C8)~alkyl-amino-(Cl-C 12 ) -alkyl and N-di-(Cl-C8)-alkylamin-(Cl-cl2)-alkyl, is optionally substituted by up to 3 of the abovementioned identical or di:E:ferent substituent~, and a C~z group of the alkyl chain is optionally replaced by lO 0, S, SO, SO2 or NR', or by a radical of the general formula II
O R8 (II~
in which R3 is an amino acid bonded via its acyl radica:L, a derivative of this amino acid or an alcohol-protect-ive ~roup, B are an unsubstituted or substituted (C8-C12)-aryl radical or ( C7 C11)-aralkyl radical or a heteroaryl radical, which is mono- or polysubstituted, preferably 20 mono- or disubstituted, by hydroxyl, halogan, cyano, carboxyl, amino, (Cl-C8)-alkyl, (Cl-C8)-alkoxy, (Cl-C8)-alkoxycarbonyl, tCl-C8)-alkylcar-bonyl, (C1-C8)-alkylcarbonyloxy, (Cl-C8)-alkylamino, di-( C1-C8) -alkylamino, ( C1-C6) -hydroxyalkyl, 25 -O-[CH2-]XCfH(2f.t1 ~,F~, -OCF2Cl, -OCF2-CHFCl, ca.rbamoyl, N-(Cl-C8)-alkylcarbamoyl, N,N-di-(C1-C8) al3cylcarbamoyl, (cl-c8)-alkylcarbonyloxy~ (C3-C8)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, aminoalkyl, N-(C1-C8)-alkyl-amino-(C1-C 12 ) alkyl or N,N-di-(C1-C8)-alkylamino-(C1-Cl2)-30 alkyl, (C1-C8)-alkoxycarbonyloxy, (C1-C8)-alkoxy-(C1-C8)-alkoxycarbonyloxy, (C8-C12)-aryloxycarbonyloxy, (C7-C11)-aralkyloxycarbonyloxy, (C7-C11)-aralkylcarbonyloxy, - 7 _ ~3 ~j ~
cinnamoyl, cinnamoyloxy, (c6-cl2)~arylcarbonyloxy, (C3 C8)-alkenylcarbonyloxy, (C3-C8)--alkynylcarbonyloxy, (C3-C8)-cycloalkylcarbonyloxy, (Cl-~l2)-alkoxy-(cl-c}2)-alkoxy, (cl-cl2)-alxoxy-aminol (C1-Cl2)-alkoxy-N-(C1-C6)-S alkylamino, (C1-Cl2)-alkoxy-N,N-(Cl C6)-dialkylamino, carbamoyloxy, N-(C~-CB)-alkylcarbamoyloxy, N,N-di-(Cl-C8)-alkylcarbamoyl, N-(C3-C8)~cycloalkylcarbamoyl, N-~C6-C12)-arylamino, N-( C7 Cll)-aralkylamino, N alkyl-aralkylamino, N-alkyl-arylamino, (C3-C8)-cycloalkanoyla~ino, (Cl-C6)-alkanoylamino, (C 6-C12)- aroylamino, ( C7-C~ aralkanoyl-amino, (C1-C8)-alkanoyl-( C1_CB ) -alkylamino, (c3-C8)-cyclo-alkanoyl-(Cl-Ca)-alkylamino, (C6-C12)-aroyl--(C1-C8)-alkyl-amino, (C7-Cll)-aralkanoyl-(Cl-C3)-alkylamino, (Cl-Ca)-alkylmercapto, (C1-C8)-alkylsulfinyl, (C1-C8)-alkylsul-fonyl, (C1-C8)-alkylcarbonyl, (C3-C8)-cycloalkylcarbonyl, nitro, trifluoromethyl, phenylmercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C6)-alkylsulfamoyl, N,N-di-(C1-C8)-alkylsulfamoyl, (Cl-Ca)-alXyl-sulfonamido or arylsulfonamido, C in the case where X = -N(R7)l are an unsubstituted or substituted (C1-C12~-alkoxy raclical, (C3-C8)-cycloalkoxy radical or (C6-C12)-aryloxy radical or a (C7-C11)-aralkyl-oxy radical, which is mono- or polysubstituted, preferab~
ly mono- or disubstituted, by halogen, trifluoromethyl, (Cl-C6)-alkoxy, hydroxyl, (C1-C6)-hydroxyalkyl, NR'R" or cyano, in which, in each case, R' and R" are identical or different and are hydrog2n, (c6-cl2)~aryl~ (cl-cs)~alkyl~ (C1-C8)~alkylcarbonyl, (C7-C11)-aralkylcarbonyl or (C6-C12)-arylcarbonyl or form a saturated heterocyclic ring, preferably a 5- or 6-membered ring, with the nitrogen, ~ 13.,~ A
and R2, R5 and R4 or R3, if R4 or R3 has not already been defined above, are identical or different and D are hydrogen, at least one radical R2, R5 and R4 or R3 being other than hydrogen, halogen, in particular fluorine, chlorine or bromine, cyano, nitro, krifluoro-methyl, (cl-C12)-alkyl, -o-[CH2-]yCyH(2t1-8)F8~ -OCF2Cl~
-O-CF2-C}IFCl,(C1-C8)-alkylmercapto,(C1-C8)-alkylsulfinyl, (C1-C8)-alkylsulfonyl,(C1-C8)-alkylcarbonyl~carbamoyl,N-10 ( Cl-C4 ) -alkylcarbamoyl, N,N-di-( Cl-C4 ) -alkylcarbamoyl~
(c3-c8)-cycloalkyl~ phanylmercap~o, phenylsulfonyl, phenylsulfinyl, (C1~C12)-alkoxycarbanoyl, (C1-C12)-alkyl-carbanoyloxy, amino, N-lCl-C1O)-alkylamino, di-N,N-(Cl-C10)-alkylamino, N,N-(C3-C8)-alkanediylamino, such as, for example, pyrrolidino, piperidino or their hetero-cyclic derivatives morpholino and thiomorpholîno, N-( C6-C12 ) - arylamino, N-(C6-Cl2) aryl-N (C1-CIO)-alkylamino, N-(C7-C11)-aralkylamino, N-( C7 Cll ) -aralkyl-N-(C1-C1O)~alkyl-amino, (Cl-Cl2)-alkanoylamino, (C3-C6)-cycloalkanoylamino-( Cl-C 12 ) - hydroxyalkanoylamino, (C1-c8)-alkoxy-(cl-cl2) alkanoylamino, (C6-Cl2)-arylcarbonylamino, (C7-Cll)-aralk-ylcarbonylamino, (Cl-C8)-alkoxycarbonyloxy, (Cl-C8)-alkoxy-(cl-c8)-alkoxycarbonyloxy, (C6-Cl2)-aryloxycarbonyloxy, (C7-Cll)-aralkyloxycarbonyloxy, (C7-Cll)-aralkylcarbonyloxy, (C~-C12)-arylcarbonyloxy, (C3-C8)-alkenylcarbonyloxy, (C3-C8)-alkynylcarbonyloxy,(C3-C8)-cycloalkylcarbonyloxy, (C1-C12)-alkoxy-(C1-C12)-alkoxy, (C1-C12)-alkoxy-amino, ~Cl-cl2)-alkoxy-N-(cl-c6)-alkylamino~ (Cl-Cl2)-alkoxy-N,N-(Cl-C6)-dialkylamino, carbamoyloxy, N-(C1~Ca)-alkylcar-bamoyloxy, N,N-di-(C1-C8)-alkylcarbamoylox~, N-(C3-C8)-cycloalkylcarbamoyloxy, NR'R", (Cl-C8)-alkylmercapto, (Cl-C8)-alkylsulfinyl, (cl-c8)-alkylsulfonyl~ (Cl-C8)-alkylcarbonyl, (C3-C8)-cycloalkylcarbonyl, sulfamoyl, N-(Cl-C6)-alkylsulfamoyl, N,N-di-(Cl-C6)-alkylsulfamoyl, (C1-C8)-alkylsulfonamido or arylsulfonamido, in which the aryl and aralkyl radicals present in the above 9 ~ 5 ~
substituents can also be hete.rocyclic in nature and/or are substit~lted, as is also the case for alkyl, with 1, 2, 3, 4 or 5 identical or different substituents from the series comprising halogen, cyanor nitro, trifluoromethyl, (C,-C6)-alkyl, hydroxyl, (C1-C6)-hydroxyalkyl, (C1-C6)-alkoxy~ --[CH2-~CfH(2f+~8~F~ -OCF2Cl, -O-CF2-CHFCl, tri-fluoromethyl, (C~-C6)-alkylmercapto, (C~-C6)-alkylsulfinyl, (C~-C6)-alkylsulfonyl, (C~-C6)-alkylcarbonyl, ~Cl-C6)-alkoxycarbonyl, carbamoyl, N-( Cl-c4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (Cl-C6) alkylcarbonyloxy, (C3-C8)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, NR'-R", phenylmercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(Cl-C4)-alkylsulfamoyl and N,N-di-(C~-C4)-alkylsulfamoyl, in particular by up to 3 of the abovemen-tioned identical or different substituents, and a CH2group of ~he alkyl chain is optionally replaced by O~ S, SO, SO2 or NR', or E are an alkyl, alkenyl or alkynyl radical having up to 9 carbon atoms~ which i5 optionally substitu~ed by 1, 2, 3, 4 or S identical or dif~erent substituents from the series comprising hydroxyl, halogen, cyano, nitro, trifluoromethyl, ~C1-C6)-hydroxyalkyl, (C1-C6)-alkoxy, [CH2~]xcfH(2ftl-B)Fs~ -OCF2CHFCl, (C1-C6)-alkylmercapto, (Cl-C6)-alkylsulfinyl, (C~-C6)-alkylsulfonyl, (Cl C6)-alkylcarbonyl, (C1 C6)-alkoxycarbonyl, carbamoyl, N-(Cl-C4)-alkylcarbamoyl, N,N-di-(Cl-C4)-alkylcarbamoyl, (C1~C6)-alkylcarbonyloxy, (C3-C8)-cycloalkyl, carboxyl/
phenyl, benzyl, phenoxy, benzyloxy, phenylmercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C4~-alkylsulfamoyl, N,N-di-(C1-C4)-alXylsulfamoyl, amino, N-(C1-C10)-alkylamino, di-N,N-(C1 C10)-alkylamino, N,N-(C3-C8)-alkanediylamino, such as, for example, pyrroli-dino, piperidino or their het~rocyclic derivatives morpholino and thiomorpholino, N-(C6 Cl2)-arylamino, - lO ~ J~
N-(C~-C~2)-aryl-N-(Cl-C~O)-alkyl~nino, N-(C7-Cll)-aralkyl-amino~ N-(c7-cll)-aralkyl-N-(cl-c~ alkylamino~ (C~-Clz)-alkanoylamino, (C3-C8~-cyclo-alkanoylamino, (Cl-cl2)-hydrQxyalkanoylamino, (C~-C8)-alkoxy-(C,-C~2)-alkanoyl-amino, (C6-C12)-arylcarbonylamino and (C7-C11)-aralkyl-carbonylamino, in particular by up -to 3 of the above-mentioned identical or different substituents, and a CH2 group of the alkyl chain is optionally replaced by 0, S, SO, SO2 or NR', or by an unsubstituted or substituted (C6~C12)-aryl radical, tC7-C~l)-aralkyl radical or heteroaryl radical, which carries 1, 2, 3, 4 or 5 identical or different substitu~
ents from the series comprising hydroxyl, halogen, cyano, nitro, trifluoromethyl, (C1-C6)-hydroxyalkyl, (C1-C8)-alkyl r ( Cl-C6 ) -alkoxy, [CH2~]xc~H~2f+l-8)F~ -OCF2C~IFCl, (Cl-C6)-alkylmercapto, (Cl-C6)-alkylsulfinyl, (Cl-C6)-alkylsulfonyl, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxycar~
bonyl,carbamoyl,N-(C1-C4)-alkylcarbamoyl,N,N-di (C1--C4)-~0 alkylcarbamoyl, (C1-C6)-alkylcarbonyloxy, (C3-C8)-cyclo-alkyl, carboxyl, phenyl, benzyl, phenoxy, benzyloxy, phenylmexcapto, phenylsulfonyl, phenylsul~inyl, sul-famoyl, N-(C1-C4)-alkylsulfamoyl, amino, N-(C1~C10)-alkyl-amino, di-N,N-(Cl-C10)-alkylamino, N,~-~C3-C8)-alkanediyl-am.ino, such as, for example, pyrrolidino, piperidino ortheir heterocyclic derivatives morpholino and thiomor-pholino, N-(C6-C12)-arylamino, N-(C6-Cl2)-aryl-N-(C1-ClO)-alkylamino, N-(C7-C~ aralkylamino, N-(C7-C~ aralkyl-N-(C1-C1O)-alkylamino, (Cl-C12)-alkanoylamino~ ( C3 -C8)-cyclo-alkanoylamino, (C1-Cl2)-hydroxyalkanoylamino, (Cl-C8)-alkoxy-(Cl-Cl2)-alkanoylamino, (C6-Cl2)-arylcarbonylamino and (C7-C~1)-aralkylcarbonylamino, in particular by up to 3 of the abovementioned identical or different substitu-ents, and a CH2 group of the alkyl chain is optionally replaced by 0, S, SO, SO2 or NR', or F denote a substituted or unsubstituted (c6-cl2)-ar radical, ~C7-C~ aralkyl radical or heteroaryl radical, in which the aryl and heteroaryl radical mentioned is, .in particular, phenyl, naphthyl, thienyl, furyl, pyrrolyl or pyridine, and which furthermore carries in the aryl part 1, 2, 3, 4 or S iden~ical or different substituents from the series comprising hydrox-yl, halogen, cyano, nitro, tC1--C8)-alkyl, (C1-Cb)-alJcoxy, carboxyl, trifluoromethyl, (C1-C63-hydroxyalXyl, --[CH2~]xC~H(2f~ 8)F8/ -OCF2Cl, -OCF2CHFCl, (C~-C6)- lkylmer-capto, (cl-c6)-alkylsulfonyl~ (C1-c6)-alkYlsulfinyl~
(C1-C6)-alkylcarbonyl, (C1-C6)-alkoxycarbonyl, carbamoyl, N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (C1-C6)-alkylcarbonyloxy, (C3-Ca) cycloalkyl r phe:nyl, benzyl, phenoxy, benzyloxy, amino, N-(Cl-CIo) alkylamino, di-N,N-(C1-C1O)-alkylamino, N,N-( C3_CB )-alkanediylamino, such as, for example, pyrrolidino, piperidino, morpho-lino, thiomorpholino, (cl-clo)-alkanoylaminol (C6-C12)-arylcarbonylamino, (C7-C11)-aralkylcarbonylclmino, phenyl-mercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C4)-alkylsulfamoylorN,N-di-(C1-C4)-alkylsulfamoyl,in particular up to 3 of the abovementioned identical or different substituents, and in which a CH2 group of the aryl chain is optionally replaced by O, S, SO, SO2 or NR', or G are a substituent of the formulae -OR9 or ~M(R9)2l in which R9 is hydrogen, alkyl, alkenyl or alkynyl, in each case having up to 9 carbon atoms, a (C6-Cl2)-aryl radical or a heteroaryl radical, which carries in the aryl part 1, 2, 3, 4 or 5 identical or different substituents from the series comprising hydrox-yl, halogen, cyano, nitro, carboxyl, (C1-C6)-alkyl, (Cl-C6)-alkoxy, trifluoromethyl, (C~-C6)-hydroxyal}cyl, --[CH2-~XCfH(2f+1-B~F8~ -OCF2Cl, -OCF2CHFCl, (Cl C6)-alkylmer-1 ~ 2 i~
capto, ~C1-C~)-alkylsulfonyl, tCl-C8)-alkylsulfinyl, (Cl-C6)-alkylcarbonyl, (Cl-C~)-alkoxycarbonyl, carbamoyl, N-(C1-C4)-alkylcarbamoyl, N,N-di-( Cl-c4 )-alkylcarbamoyl, (Cl-C6)-alkylcarbonyloxy, ( C3-C~ ) -cycloalkyl, phenyl r benzyl, phenoxy, benzyloxy, amino, N-(Cl-C10)-alkylamino, di-N,N-(Cl-C10)-alkylamino, N,N-(C3-Ca)-alkanediylam.ino, such as, for example, pyrrolidino, piperi.dino, morpho-lino, thiomorpholino, (C1-C10)-alkanoylaTn.ino, (C5-C12)-arylcarbonylamino, (C7-C11~-aralkylcarbonylamino, phenyl-mercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C4)-alkylsulfamoylorN,N-di-(C1-C4) alkylsulfamoyl,in particular up to 3 of the abovemen~ioned identical or different substituents, and in which a CH2 group of ~he aryl chain is optionally replaced by O, S, SO, SO2 or NR', and n = 0 or 1, f = 1 to 8, preferably 1 to 5, g = 0.1 to (2f + 1) and x is 0, 1, 2 or 3, preferably 0 or 1, plus all derivatives which carry a corresponding protect-ive group in their amino or hydroxyl groups, and the physiologically active salts.
~ryl, aryloxy, heteroaryl and heteroaryloxy compounds are understood as meaning, in particular, phenyl and naphthyl rings and unsubstituted 5- and 6-memhered heteroaromatic rings having 1 ,2 or 3 nitrogen and/or oxygen and/or sulfur atoms, such as pyridyl, pyridazyl, pyrimidyl, pyrazyl, imidazolyl, triazolyl, thienyl, oxazolyl and thiazolyl derivatives, and benzo-fused derivatives thereof. The radical (C7-C~ aralkyloxy is preferably understood as meaning a substituted phenylalkyloxy - 13 ~ tr~9 5i radical of the formula III
~10 Rl I
~'' -o-lCH2~ Rl2 (III) R 4 Rl3 i hich R10 R11 R12 ~13 and Rl4 are identical or dif-erent and are hydrogen, halogen, cyano, nitro, txi-fluoromethyl, (C1-C6)-alkyl, (C1~C6)-alkoxy, -~[CH2~]xCfH~2~ B)F8r -OCFzCl, -OCF2CHFCl, (C1~C6)-alkylmer-capto, (~ 6)-alkylsulfinyl~ ~Cl-C6)~alkylsulfonyl, (C1-C6) alkylcarbonyl, (Cl-C6)-alkoxycarbonyl, carbamoyl, N-(C1-C4)-alkylcarbamoyl~ N,N-di~(C1-C4)-alkylcarbamoyl, (Cl-C6)-alkylcarbonyloxy, (C3-C8)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, NR'R~, such as amino~ anilino or N-methylanilino/ phenylmercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C4)-alkylsulfamoyl or N,N di-(C1-C4~-alkylsulfamoyl, or two adjacent substitu-ents togethex are a -[CH2-]n or ~C~=C~-CH=C~- chain, in which a CH2 group of the chain is optionally replaced by O, S, SO, SO2 or NR', Y is 1, 2, 3 or 4, preferably 0 or 1, and the other substituents R10, R1lr R12, R13 and R14 are as defined aboYe.
Of the amino acids mentioned, the naturally occurring ~-amino acids are particularly preferred.
Amino-protective groups are understood as meaning, in particular, tho~e groups which are described in R. Geiger and W. Xonig "The Peptides" Volume 3, ~Protection of Functional Groups in Peptide Synthesis~, E.G. Gross, J. Meienhofer Edit, Academic Press, New York (1981), in particular pages 7 - 46.
- 14 _ 2~5~
Such groups are likewise described in A. Hubbuch, Schutzgruppen in der Peptidsynthese [Protective Groups in Peptide Synthesis], Kontakte 3/79, pages .L4~23.
The following amino-protective groups are pa.rticularly preferred:
acetamidomethyl, l-adamantyloxycarbonyl, l-(l-adamantyl~ me-thyl-ethoxycarbonyl, allyloxycarbonyl, tert-butyloxycarbonyl, 1-(4-biphenylyl)-1-methyl-ethoxycarbonyl, dicyclohexylcarbodiimide, ~ dimethyl-3,5-dimethoxybenzyloxycarbonyl, 4-dihydroxyborylbenzyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, l-hydroxybenzotriazole, 3-hydroxy-4-oxo-3,4-dihydro-1,2,3 benzot.riazine, isobornyloxycarbonyl, l-methyl~cyclobutyloxycarbonyl, 4-methoxybenzyloxycarbonyl, methylsulfonylethyloxycarbonyl, 4-pyridylmethyloxycarbonyl, 2,2,2-trichloro-tert-butyloxycarbonyl, benzyloxycarbonyl, halogen-substitu-ted benæyloxycarbonyl, 4-nitro-benzyloxycarbonyl, 2-phosphonoethyloxycarbonyl, phenylsulfonylethoxycarbonyl, toluenesulfonylethoxycarbonyl, 2,3,5-trimethyl-4-methoxy-phenylsulfonyl and benzotriazol-1-yl-oxy-tris(dimethylamino~phosphonium hexafluorophosphate.
Preferred compounds of the formula I in which the amino groups are protected are those in which the protected amino groups are part of this amino acid Ra.
- 15 ~
Poss.ible alcohol-protec-tive groups are, in particular, substituted or unsubst.ituted methyl ethers, ethyl ethers, ben2yl ethers, silyl ethers, esters, carbonates or sulfonates.
These include the following compounds:
As substituted methyl ethers:
me~hoxymethyl, methylthiomethyl, t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl, benzyloxymethyl, p-methoxybenzyloxymethyl, (4-methoxyphenoxy)-methyl, guaiacolmethyl, t-butoxymethyl, 4-pentenyloxymethyl, siloxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloro-ethoxymethyl, bis-(2-chloroethoxy)methyl, 2-(trLmethyl-silyl)ethoxymethyl,tetrahydropyranyl,3-bromotetrahydro-pyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl, 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl-S,S-dioxo, 1-[2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl, 1,4-dioxan-2-yl, tetrahydrofuranyl and ~etrahydrothiofuranyl.
As substituted ethyl ethers:
1-ethoxyethyl, 1-~2-chloroethoxy)athyl, 1 methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl,2,2,2-trichloroethyl r 2-trimeth-ylsilylethyl, 2-(phenylselenyl)ethyl, t butyl, allyl J p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl and benzyl.
As substituted benzyl ethers:
p-methoxy.benzyl, 3,4-dimethoxyben2yl, o-nitrobenzyl, p-nitrobenzyl, p-halogenobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2- and 4-picolyl, 3-methyl-2-picolyl-N-oxido, diphenylmethyl, p,p'-dinitrobenzohy-dryl, triphenylmethyl, ~-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(-p-methoxyphenyl)phenyl-methyl, tri(p-methoxyphenyl)methyl, 4-(4'-bromophenacyl-oxy)phenyldiphenylmethyl, 4,4',4"'tris(4,5-dichloro~
- 16 - ~J ~ Ll phthalimidophenyl)methyl, 4,4',4"-tristlevulinooxyphen-yl)methyl, 4,4',4'l-tris(benzoyloxyphenyl)methyl, 3-(imidazol-1,4' methyl)bis(4',4"-dLmethoxyphenyl)methyl, 1,1-bis-(4~methoxyphenyl)-1~-pyrenylmethyl, 9-anthryl, 9 (9-phenyl)xanthenyl~ 9-(9-phenyl-lO-oxo)anthryl.
As silyl ethers:
trimethylsilyl, triethylsilyl, triisopropylsilyl, dimeth-ylisopropylsilyl, diethylisopropylsilyl, dimethylthexyl-silyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triben~ylsilyl, tri-p-xylylsilyl~ triphenylsilyl, diphen-ylmethylsilyl and t-butylmethoxyphenylsilyl.
As esters:
formates, benzoylformates, acetates, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyaceta~e, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, p-P-phenylacetate, 3~phenylpro-pionate, 4 oxopentanoate ~levulinate), 4,4-(ethylen~3di-thio)pentanoate, pivaloate, ad~mantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate and 2,4,6-trimethylbenzoate (mes.itoate).
As carbonates:methyl, 9-~luorenylmethyl, ethyl, 2,2,2-tri.chloroethyl, 2-(trimethylsilyl)ethyl, 2-~phenylsulfonyl)ethyl, 2-(triphenylphosphonio)ethyl, isobutyl, vinyl, allyl, p-nitrophenyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenz-yl, o-nitrobenzyl, p-nitrobenzyl, S-ben~yl thiocarbon-ates, 4-ethoxy-1-naphthyl and methyl dithiocarbonates.
Further esters:
2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis-(l,l-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinate, (E)-2-methyl-2-butenoate (tigloate), o-(methoxycarbonyl)benzoa~el p-P-benzoate, ~-naphthoate, nitrate, alkyl N,N,N',N~-tetramethylphos-- 17 - 2 ~ 2~
phorodiamidate, N-phenylcarbamate, bora-tes, dime-thylphos-phinothioy:l and 2,4-dinitrophenylsulfenate.
As sulfonates:
sulfates, me-thanesulfonate ~mesylate), benzylsulfonate and tosylates.
The following protective groups are particularly preferred:
(Cl-C6~-alkanoyl, (Cl-C~)-alkylcarbamoyl, di~(Cl-C8)-alkyl-carbamoyl, N-(C3-C8)-cycloalkylcarbamoyl, (C1-C6)-alko~y-carbonyl, ( C6-cl2 ~ aryloxycarbonyl, ( C7-cll ) -aralkyloxycar-bonyl, in particular benzyloxycarbonyl, (C6-C12)-arylcar-bonyl, (C7-C11)-aralkylcarbonyl, (C1-C6)-alkyl, (C1-C6)-alkoxy-(C1-C6)-alkyl, carbamoyl-(Cl-C6)-alkyl esters, (C1-C10)-acyloxy-(Cl-C6)-alkyl, preferably (Cl-C10)-alkan-oyloxy-( Cl-C6 ) -alkyl, ben~yloxy-( Cl-C6 ) -alkyl, benzyloxy-carbonyloxy-(Cl-C6)~alkyl, (C1-C6)-alkoxycarbonyloxy-(Cl-C6)-alkyl, amino acid esters and tetrahydropyranyl.
Preferred compounds of the formula I are those in which Rl and R3 or ~4 are -C(O)-X-R6, in which X is -N(R7)~.
Compounds of the formula I which are furthermore pre-ferred are those in which R6 is hydrogen or methyl and R7 has the abovementioned meaning, 5 R~ and R7 are.hydrogen and/or methyl, if at least one group R1, R3 or R4 is a radical -C(o)-N(R7) R6, in which R5 and/or R7 have the abovementioned meaning.
If R5 or R7 is not hydrogen or methyl according to the above preferred embodiment, the following compounds are preferred, in which the radicals 2,)(~5~1 - 18 ~
~ are a branched or unbranched (cl-cl~)-alkyl radical, which is unsubstituted or mono- or polysubstituted by halogen, in particular fluorine, chlorinel bromine, hydroxyl, cyano, carboxyl, (Cl-C4)-alkoxy, (cl-c4~-alk carboxyl, (C1-C~)-alkoxycarbonyloxy, (Cl-c8)-alX
(Cl-C8)-alkoxycarbonyloxy, (C6-Cl2)-aryloxycarbonyloxy, (C7-Cl1)-aralkyloxycarbonyloxy, (C7-C~ aralkylcarbonyloxy, ( C7 -Cll ) -arylcarbonyloxy, (C3-C8)-cycloalkylcarbonyloxy, (C1-C12)-alkoxy-(C1-C12)-alkoxy, carbamoyloxy, N-(C1-C8)-alkylcarbamoyloxy, N,N-di-(Cl-C8)-alkylcarbamoyl, N-( C3 -C 8 ~ -CyC loalkylcarbamoyll N-( C7~C 11 )-aralkylcarbamoyloxy or N-~C6~C12)-arylcarbamoyloxy, in wh.ich the aryl and aralkyl radicals present in the above substituents can also be heterocyclic in nature, and/or, as is also the case for alkyl, are substituted by 1 or 2 identical or different substituents from the series comprising halo-gen, trifluoromethyl, hydroxyl, (C1-C3)-alkyl, (C1--C3)-hydroxyalkyl, (C1-C9)-alkoxy, -O [CH2-]xcfH(2f~l-B)F8l -OCF2Cl~
-O-CF2-CHFC1, (C1-C3)-alkoxycarbonyl, carhamoyl, (C1-C5)-alkylcarbonyloxy, (C3-C8)~cycloalkyl, phenyl, benzyl, phenoxy, benÆyloxy, or by an unsubstituted or substituted (C6-C12)-aryl radical or heteroaryl radical, which carries 1 or 2 identical or different substituents from the series comprising halo-gen, nitro, cy~no, carboxyl, hydroxyl, trifluoromet:hyl,(Cl-C3)-hydroxyalkyl, (Cl-C3)-alkoxycarbonyl, carbamoyl, NR'R", N-~Cl-C4) alkylcarbamoyl, N,N-di-(Cl-C4)-alkylcar-bamoyl, (Cl-C8)-alkoxy-(Cl-C8) alkyl, (Cl-C3)-alkylcarbon-yloxy, aminoalkyl and N-(C1-C4)-alkylamino-~C1-C6) alkyl, in which R~ and R~ are identical or differen~ and are hydrogen, (C6-Cl2)-aryl or (C1-C4)-alkyl, or by an unsubstituted or substituted (C5-C10)-aryloxy radical or (C7-C11)-aralkyloxy radical, which carries 1 or 2 identi.cal or different substituents from the series comprising hydroxyl, halogen, trifluoromethyl, - 19 ~ 5~
( C l-C3 ) -alkyl, ~Cl-C3 )-hydroxyalkyl, (Cl-C3)-alkoxy, (Cl-C3)-alkylmercapto, (Cl-C3)-alkylsulfinyl, ( alkylsulfonyl, ~C1-C3)-alkylcarbonyl, (C1-C3)-alkoxycar-bonyl,carbamoyl,N-(C1-C4)-alkylcarbamoyl,N,N~di-tCl-C4)-alkylcarbamoyl/ (Cl-C3)-alkylcarhonyloxy and NR'R", in which R' and R~ are identical or different and are hydrogen, (C6-ClO)-aryl or (Cl-C,,)-alkyl~ or by a radical of the formula II
o Ra (II) in which R8 iS an amino acid bonded via its ~cyl radical, or is a derivative thereof, B denote a (C~-Cl2)-aryl or (c7-cll)-aralkyl radical~
preferahly phenyl~ benzyl or phene~hyl, which are unsub-stituted or monosubstitu~ed by halogen, cyano, carboxyl,hydroxyl, ~Cl-C8)-alkyl, (Cl-C8)-alkoxy, (C1-C8)-alkylcar-bonyl, (Cl-C4)-alkylcarbonyloxy, (Cl-C4)-alkoxycarbonyl, (Cl-C4)-hydroxyalkyl, amino, (Cl-C5~-alkylamino, di-1Cl-Cs)-alkylamino, (Cl-C5)-alkanoylamino, carbamoyl, N-(Cl-C4)-alkylcarbamoyl, N,N-di-(Cl-C4)-alkylcarbamoyl, carbamoyl, N-(Cl-C4)-alkylcarbamoyloxy or N,N-di-(Cl-C4)-alkylcarbamoyloxy or C are an unsubstituted (C1-C6)-alkoxy radical, (C3-C8)-cycloalkoxy radical, (C6-Cl2)-aryloxy radical or (C7-Cll~-aralkyloxy radical.
Particularly preferred compounds of the formula I are those in which R6 and R7, if these are not hydrogen or methyl, as described above, are A an unbranched (Cl-Cl2)-alkyl radical, which is unsub-stituted or monosubstituted by 2f~
hydroxyl, halogen, (C1-C8)-alkoxy r (C1-C~)-alkoxycarbonyl, (Cl-C8)-alkoxycarbonyloxy, (C~-C8)-alkoacy-(Cl-C8)-alkoxy-carbonyloxy, (C6-C12)-aryloxycarbonyloxy, (C7-C~ aralkyl-oxycarbonyloxy, (C7-Cll)-aralkylcarbonyloxy, (C6-cl2)-S arylcarbonyloxy, (C3-C8)-cycloalkylcarbonyloxy, (Cl-C,2)-alkoxy-(Cl-Cl2~-alkos~y, (Cl-Cl2)-alkoxy-amino, (Cl-Cl2~-alkoxy-N-(Cl-C6)-alkylamino, (Cl-Cl2) alkoxy-N,N-(Cl-C6~-dialkyl~mino, N,N-di-(C1-C8)-alkylcarbamoyl, N-( C3-C~ ) -cycloalkylcarbamoyl, N-(C7-Cll)-aralkylcarbonyloxy, N-10 (C8-Cl2)-arylcarbanoyloxy, (Cl-C5)-allcanoylamino, (C3-C6)-cycloalkanoylamino,(C6-C12)-aroylaminoor(C7-Cll)-aralkan-oylamino, in which alkyl, aryl, aryloxy, aralkyl or aralkyloxy in turn are substituted by hydroxyl, halogen, in particular fluorine, (Cl-C3)-alkyl or (Cl-C3)-al~oxy, or by a phenyl radical which is unsukstituted or monosubstitut-ed by a hydroxyl group, ~ phenoxy or benæyloxy radical which is unsubstituted or subskitu~ed by hydroxyl, halogen or (Cl-C4)-alkoxy/ or by a radical o:E the formula II
o Ra (II) in which Ra is an amino acid bonded via its acyl radical, or its derivative subs~ituted on the ~mino group, or B are a (C6-Cl2)-aryl or ~C7-C11)-aralkyl radical, preferably phenyl~ benzyl or phenethyl, which is unsub-stituted or monosubstituted by hydroxyl.
In respect of the substituents R2, Rs and R4 or R3, if R3 or R4 is not already defined as above, compounds in which not more than two of the three radicals are pre~erably other than hydrogen, particularly preferably not more than one of the radicals is other than hydrogen, are preferred.
2 1 f d ~ ~? ~
-Compounds which are furthermore preferred are those in which, independently of one another, R2, Rs and R4 or R3 are other than hydrogen if these are directly adjacent to not more than one other substi~.u4nt R1 and R3 or R4.
S R2, R5 and R4 or R3, lf R4 and R3 are not already defined above and are not to be hydrogen, are preferably D halogen, in particular fluorine, chlorine or brom-ine, cyano, nitro, trifluoromethyl, tC1-C12)-alkyl, --[CH~-]xC~H(2ft1-8)Fg~ -OCF2Cl, -O-CF2-CHFCl, (Cl-C8)-alkyl-carbonyl, carbamoyl, N-(Cl-C4)-alkylcarbamoyl, N,N-dl-(Cl-c4?-alkylcarbamoyl~( C3-CB ) -cycloalkyl~(C1-C12)-alkoxy-carbonyl, ~Cl-Cl2)-alkylcarbonyloxy, amino, N-(C1-Clo)-alkylamino, di-N,N-(C1-C10)-alkylamino or NIN ( C3-~C~ ) -alkanediylamino, such as, for example/ pyrrolidino, piperidino or their heterocyclic derivatives morpholino and thiomorpholino, N-(C6-Cl2)-arylamino, N-(C6-Cl2)~-aryl-N-(C1-C8)-alkylamino, N-(C7-C11) aralkylamino; N-(C7-C11)-aralkyl-N-~Cl-C10)-alkylamino, (C6-Cl2~-arylcarbonylamino, (C7-Cll)-aralkylcarbonylamino, (Cl-C6)-alkoxycarbonyloxy, (C6-C12)-aryloxycarbonyloxy, (C7-Cl1)-aralkylcarbonyloxy, (C6-Cl2)-arylcarbonyloxy, (C3-C8)-alkenylcarbonyloxy, (C3-Ca)-cycloalkylcarbonyloxy, (Cl-Cl2)-alkoxy-(cl~cl2) alkoxy, (Cl-Cl2)-alkoxy-amino, (C1-Cl2)-alkoxy-N-(C1-C6) alkylamino, ( Cl-Cl2 ) -alkoxy-N,N-( Cl-C6 ) -dialkylamino, carbamoyloxy, N-(Cl-C6)-alkylcarbamoyloxy, N,N-di-(Cl-Ca)-alkylcarbamoyloxy, N-(C3-C8~-cycloalkylcarbamoyloxy, NR'R", (Cl-C8)-alkylmercapto, (Cl-C6)-alkylsulfinyl, (C1-C8)-alkylsulfonyl, (C1-C8~-alkylcarbonyl or (C3-C8)-cycloalkylcarbvnyl, in which the aryl and aralkyl radi-cals present in the above substituents can also be heterocyclic in nature and/or, as is also the case for alkyl, are substituted by 1, 2 or 3 identical or dif-ferent substituents from the series comprising halogen, trifluoromethyl, (Cl-C6)-alkyl, hydroxyl, (Cl-C6)-hydro~y-alkyl, (C1-C6)-alkoxy, -o-[cH2-]xcfH(2f~l-6)FBl (C3_CB)_CYC1O_ alkyl, phenyl, benzyl, phenoxy, benzyloxy, NR'R", r~ S ~9 ~ ~
phenylmercapto, phenylsulfonyl, phenylsulfinyl, sul-famoyl, N-(Cl-C4)-alkylsulfamoyl or N,N-di-(C~-C4)-alkylsulfamoyl, or E an alkyl or alkenyl radical having up to 5 carbon atoms, which is optionally substituted by l, 2 or 3 identical or different substi.~uents from the series comprising hydroxyl, halogen, cyano, nitro, trifluoro-methyl, (cl-c6)-hydroxyal]cyl~ (cl-c6)-alkoxy~
10 ,[cH2-]xc~H(2f~l-8~F8r -OCF2-CHFCl, (C~-C6)--alkylcar}:)onyl, (Cl-C6)-alkoxycarbonyl, carbamoyl, N-(C1~C4)-alkylcar-bamoyl, N,N-di-(C1-C~)-alkylcarbamoyl, (Cl-C6)-zlkylcar-bonyloxy, (C3-C8)-cycloalkyl, carboxyl, phenyl, benzyl, phenoxy, benzyloxy, amino, N~(C1-C6)-alkylamino, di-N,N-(C1-C6)-alkylamino or N,N-(C3-C8)-alkanediylamino, such as, for example, pyrrolidino or piperidino, N-(C6-C12)-aryl-amino, N-(C6-C1z)-aryl-:N-(Cl-C6~-alkylamino, N-(C7-~
aralkylamino, N~( C7-C~ )-aralkyl-N-(Cl-C10)-alkylamino, (C~-C6)-alkanoylamino, (C1-C8)-alkoxy-(C1-C6)-alkanoylamino, (C6-C12)-arylcarbonylamino and (C7-C1~)-aralkylcarbonyl-amino, or by an unsubstituted or substituted (C6-C~z)-a.ryl radical, ( C7-C~ ) -aralkyl radical or heteroaryl radical, which ~5 carries 1, 2 or 3 identical or different substituents from the series comprising hydroxyl, halogen, cyano, nitro, trifluoromethyl, (C1-C6)-hydro~yalkyl, (C~-C6)-alkoxy, (cl-c6)-alkoxy~ [cH2-]xcfHt2~+l-8)F8~ (C1-C6) alky bonyl, (C~-C6)-alkoxycarbonyl, carbamoyl, N-( C~-C4 )-alkyl-carbamoyl, N,N-di-(Cl-C4)-alkylcarbamoyl, (Cl-C6)-alky.lcar-bonyloxy, (C3-C8)-cycloalkyl, carboxyl, phenyl, benzyl, phenoxy, benzyloxy, amino, N-(C1-C6)-alkylamino, di N,N-(Cl-C6)-alkylamino or N,N-(C3-C8)-alXanediylamino, such as, for example, pyrrolidino or piperidino, N-(C6~C12)-aryl-35 amino, N-(C6-C12)-aryl-N-(C1-C6)-alkylamino, N-~C7-C11)-~ 3 aralkylamino, N-~C7-C~ aralXyl-N-~C1-C10)-alkylamino, (Cl-C6)-alkanoylamino, (c3-c3)-cycloalkanoylamino~ (Cl-C6)-hydroxyalXanoylamino, (Cl-C6)-alko~y-(Cl C~)-alkanoylamino, (Cg-Cl2)-arylcarbonylamino and (C7-C11)-aralkylcarbonyl-amino, or F an unsubstituted or substituted (C6-Cl2~-aryl radi-cal, (C7-C1l)-aralkyl radical or het~roaryl radical, in which the aryl and heteroaryl radical mentioned is, in particular, phenyl, naphthyl, thienyl, furyl, pyrrolyl or pyridine, and which furthermore carries 1, 2 or 3 identi-cal or differsnt substituents from the series comprising hydroxyl, halogen, cyano, nitro, (Cl-C6)-alkyl, (Cl-C6)-alkoxy, carboxyl, trifluoromethyl, (C1-C6)-hydroxyalkyl, --~CH2-]xCfH~2~+1-g)F6~ (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxy-carbonyl, carbamoyl, N-(C}-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarhamoyl, (C1-Cg)-alkylcarbonyloxy, (C3-C~)~
cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, amino, N-(C1-C10)-alkylamino, di-N,N-(C1-C10)-alkylamino or N,N-(C3-C3)-alkanediylamino, such as, for example, pyrrolidino or piperidino, (C1-C10)-alkanoylamino, (C6~C1z)-aryl-carbonylamino and (C7-Cll)-aralkylcarbonylamino, or G a substituent of the formula -OR9 or -N(R9)2, in which R9 is hydrogen, alkyl or alkenyl having in each case up to 6 carbon atoms, a (C6-C12)-aryl radical or a heteroaryl radical, which carries 1, 2 or 3 identical or different substituents from the series comprising halogen, hydrox-yl, cyano, nitro, carboxyl, trifluoromethyl, (C1-C6)-alkyl, (C1-C6)-hydroxyalkyl, (Cl-C6)-alkoxy, --[CH2-]xCfH(2f+1-g)F6/ (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxy-carbonyl, carbamoyl, N-(Cl-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (C1-C6) alkylcarbonyloxy, (C3-C6)-5 1~
cycloalkyl, phenyl, ben~yl, phenoxy, benzyloxy, amino, N-(Cl-C~ alkylamino, di-N,N-(Cl-C10)-alkylamino or N,N-(C3-C8)~alkanediylamino r such as, ~or example, pyrrolidino or piperidino, (Cl-C10)-alkanoylamino, (C6-Cl2~-aryl-carbonylamino and (C7-C11)-aralkylcar~onylamino.
Of these, compounds of the formula I which are preferred are those in which R2, R5 and R4 or R3, if R4 and R3 are not already defined above and are not to be hydrogen, are D halogen, in particular flllorine, chlorine or brom-ine, trifluoromethyl, (C1-C12)-alkyl, -O-[CH2-3xC~H~2~+l-~)F8 -OCF2Cl, -O-CF2-CHFCl, (Cl-C8)-alkylcarbonyl, ~ C3 C8)~
cycloalkyl, amino, N-(Cl-C1O)-alkylamino, di-N,N-(C1-C,o)-alkylamino,N-~C6-Cl2)-arylamino,N-(C6-Cl2)-aryl-N-(Cl~Ca)~
alkylamino, N-( C7-cll)-aralkylamino or N-( C7-cll )-aralkyl-N-(C~-C1O)~alkylamino, in which the aryl and aralkyl radicals present in the above substituents can also be heterocyclic in nature and/or, as is also the case -for alkyl, can be substituted by 1 or 2 identical or dif-ferent substituents from the series comprising halogen,trifluoromethyl, (C1-C6)-alkyl, hydroxyll (C1-C6)-hydroxy-alkyl, (C1-C6)-alkoxy, -O [CH2-~XC~H(2~18,F~ and NR -R, or E an alkyl or alkenyl radical having up to 5 carbon atoms, which is optionally substituted by 1 or 2 identi-cal or different substituents from the series comprisinghydroxyl, halogen, trifluoromethyl, tCl-C6)-hydroxyalkyl, (Cl-C6)-alkoxy, (C1-C6)-alkylcarbonyl, (Cl-C6)-alkoxycar-bonyl, ~C1-C6)-alkylcarbonyloxy, phenyl~ benzyl, phenoxy, benzyloxy, amino, N-~Cl C5)-alkylamino and di-N,N-(C~-C6)-alkylamino, or by an unsubstituted or substituted (C6-C12)-aryl radical, (C7-Cll)-aralkyl radical or heteroa.ryl radical, which carries 1 or 2 identical or different substituents from _ ~5 _ ~~
the series comprising hydroxyl, halogen, trifluoromethyl, (Cl-C6)-alkyl, (Cl-C6)-hydroxyalkyl, (Cl-C6)-alkoxy, --[CH2-]xCfH~2f~l-8)F~ (C1-C6)-alkylcarbonyl, (Cl-C6)-alkoxy-carbonyl, phenyl, benzyl, phenoxyl ben~yloxy, amino, N-(Cl-C6)-alkylamino, di-N,N-(C1 C6)-alkyl~lino or N,N-(C3-C~)-alkanediylamino, such as, for example, pyrrolidino or piperidi.no, or F an unsubstituted or substituted ~C6-Cl2)-aryl radi-cal, ( C7 C11)-aralkyl radical or hetero ryl radical, in which the aryl and heteroaryl radical mentioned is, in par~.icular, phenylr naphthyl, th.ienyl, furyl~ pyrrolyl or pyridine, and which fur~hermore carries 1, 2 or 3 identi-cal or different substituents from the series comprising hydroxyl, halogen, (Cl C6)-alkyl, (C1-C6~-alkoxy, carbo~yl, trifluoromethyl, (Cl -C8 )-hydroxyalkyl, --[CH2 ]XCfH(2f+1~,Fg, (Cl-C63-alkylcarbonyl, (Cl-C6)-alkoxycarbonyl, amino, N-(C~-C10)-alkylamino and di-N,N-(Cl-C10)-alkylamino, or G a substituent of the formula -oR9 or -N(R~)2, in which R9 is hydrogen or alkyl having in each case up ~o 6 carbon atoms, a (C6-Cl2)-aryl radical or a heteroaryl radical, which contains 1 or 2 identical or different substituents from the series comprising halogen, tri-fluoromethyl, (Cl-C6)-alkyl, (Cl-C6)-alkoxy, -O-~CH2-]xCfH(2f+~8~F~, amino, N-(C,-C10)-alkylamino and di-N,N-(Cl-C10)-alkylamino.
Particularly preferred compounds of the formula I are those in which R2, R5 and R4 or R3, if R4 and R3 are not already defined above and are not to be hydrogen, are D halogen~ in particular fluorine, chlorine or brom-ine, trifluoromethyl, (Cl-Cl2)-alkyl/ --[CH2-]xCfH(2f~l-g)Fg~
-- 2 6 ~ h ~ ) r3 9 ~
-OCF2Cl, -O CF2~CHFCl, (Cl-C~)-alkylcarbonyl, (C3-C8)-cycloalkyl, amino, N-(Cl C10)-alkylamino, di-N,N-(Cl-Clo)-alkylamino~N-(c6-cl2)-arylamino~N-(c6-cl2)~aryl-N-(cl-c~)-alkylamino, N-(C7-Cl,)-aralkylamino or N (C7--Cl1)-aralkyl-N-(C1-C10)-alkylamino, or:
E an alkyl or alkenyl radical having up to 5 carbon atoms, which is optionally substituted by 1 or 2 identi-cal or different substituents from the series comprising hydroxyl, halogen, trifluoromethyl, (Cl-C6)-alkoxy, 10 (Cl-C6)-alkylcarbonyl, (Cl-C6)-alkoxycarbonyl, (Cl-C6)-alkylcarbonyloxy, phenyl, phenoxy, benzyloxy, amino, N-(Cl-C6)-alkylamino and di-N,N-(Cl-Cs)-alkylamino/ or by an unsubstituted or &ubstituted (C~-C~-aryl radical, (C7-Cll)-aralXyl radical or heteroaryl radical, which carries 1 or 2 identical or different substituents from the series compxising hydroxyl, halogen, trifluoromethyl, (Cl-C6)-alkyl, (Cl-C6)-hydroxyalkyl, (Cl-C6)-alkoxy, (Cl-C6)-alkylcarbonyl and (Cl-C6)-alkoxycarbonyl, or F an unsubstituted ox substituted (C6-C12~-aryl radical or (C7-C11)-aralkyl radical, in which the aryl radical mentioned is, in particular, phenyl or naphthyl and which furthermore carries 1 or 2 identical or different substi-tuents from the series comprising hydroxyl, halogen, (Cl-C6)-alkyl, (Cl-C6)-alkoxy, carboxyl, trifluoromethyl, (C,-C6)-hydroxyalkyl, (C1~C6)-alkylcarbonyl and (C1-C6)-alkoxycarbonyl, or G a substituent of the formula -O~9 or -N(R9)2, in which R9 is hydrogen ox alk~l having in each case up to 6 carbon atoms, a (C6-C12)-aryl radical or a heteroaryl radical, which contains 1 or 2 identical or different substituents from the series comprising halogen, tri-fluoromethyl, (C1-C6)-alkyl, (Cl-C6)-alkoxy, amino, N-~Cl-C10)-alkylamino and di-N,N-(Cl-C10)-alkylamino.
_ ~7 ,~ ,3~
The inven-tion furthermore relates to the use of compounds of the :Eormula ~ and physiologically tolerated salts thereof for the preparation of a proline hydroxylasa-in-hibiting and lysine hydroxylase-inhibiting medicament.
Final.ly, the invention relates to the compounds of the formula I for use as medicaments.
In particular, the invention relates to the compounds of the formula I for use as fibrosuppressarlts and Lmmunosup-pressants and for inhibition of proline hydroxylase and lysine hydroxylase, and for influencing the metabolism of collagen and collagen-like substances and the biosyn-thesis of Clq.
The invention furthermore relates to a process for the preparation of compounds of the formula I.
The following Equation I applies to the preparation of 2,4-disubstituted pyridine N-oxide derivatives. However, in pri.nciple, it can also be used to illustrate the preparation of 2,5-disubstituted pyridine N-o~ide deriva-tives, and for mixed derivatives (esters/amides) ~ 2û ~ 5 ~1 Equat ion o Co~H C_o-R6 XlxEsterif ication\~ o R S C 9 2 H R ~ C - O - R V
V
Aminolysi~ /
/ Ox.idation ,~ C- O- R 6 C-N ( R7 ) R6 R ~ R 2 ~ N ( ~ 7 ) R 6 R S ~ C - O - R
RS li O
Oxidation ~
/ Aminolysis C-N ( R7 ) R6 R 1~ R 2 5/~N~\ C - N ( R 7 ) R 6 O
- 29 _ 2~ 5~
Substituted pyridine-2,4- and -2,5-dicarboxylic acids of the formula IV are obtained, for example, by oxidation from the corresponding dimethylpyridines VII or VIII or the corresponding methyl-2-hydroxymethylpyridines IX. The preparation of the dimethylpyridines VII and VIII in turn is described in R.J. Ife, J. Med. Chem. 32, 1970-1977 (1989) and the literature cited therein. The following Equation II gives an indication of this. On the basis of this equation, the substituted pyridine derivatives according to the invention are accessible to the expert.
A particular example is 2,5-dimethyl-3 r 4-dichloro-pyridine.
Equation II
~3 ;, -----------~ ',s~ ~ ? ` Qu~
o C L, 1~10 ~ /
O )~
hc~c~ C~3~
~3~C lh 1~ h2 olt X ~
- 30 - 2 ~5 ~ 5l~
Compounds of the formula VII are converted into compounds of the formula VIII with alcohols ROH and a base in dimethylfo.rmamide or dimethylacetamide at ~0 to 150~C.
Compounds of the type IX are prepared by reactions of VIII with acetic anhydride/ace-tic acid at 120C and subsequent reaction with NaOH/methanol at 25~C. ~he oxidation to give compound X with sodium permanganate in water at 70 to 100C can be carried out starting from VIII or IX. The dicarboxylic acids X can be either esterified and oxidized to give the N-oxides I according to the invention in accordance with Equation I, or - also in accordance with Equation I - converted into amides and oxidized.
The preparation of the compounds of type IV is described in the following literature references. This preparation is the introduction of the substituents R2, R4 and R5 into the ~,4- or 2,5~pyri.dine-dicarboxylic acid.
Starting with the compound of the formula IV, the amide VI can be prepared either directly from IV or via the ester V.
The reaction of V or VI to give the amides I or esters I
is carried out under conditions analogous to those in P 40 20 570.3-For this, an oxidizing agent, such as, for example, hydrogen peroxide or peracids, such as peracetic acid,perfluoroacetic acid, perbenzoic acid or metachloroper-benzoic acid, in solvents, such as chlorinated hydrocar-bons, such as, for example, methylene chloride, chloro-form, tri- or tetrachloroethylene, benzene or toluene, is added to the pyridine compounds to be oxidized, which can likewise be dissolved in the abovementioned solvents, and the mixture is stirred at a temperature of between -30 and +40C, preferably 0 and 25C, ~or between 30 minutes and 3 days~ The end of the reaction can be determined, _ 31 ~ 5~
for example, by means of thin layer chromatography.
Preferably, the compounds according co the invention can be prepared by employing the pyridine derivative and the oxidi~ing agent in equimolar ~nounts or with up to an approximately 5-fold excess o oxidiæing agen-t~
If appropriate, an excess of peracid can also be elimin-ated, for example, by passing gaseous ammonia into the reaction solution and separating off the resulting precipitate from the reaction solution by fil-tration.
If appropriate, the product can be worked up, for ex-ample, by extraction or by chromato~raphy, for example over silica gel. The product isolated can be recrystallized.
General instructions for this oxidation method are also described, for exampler in "E. Lingsberg, Pyridine and its Derivatives, Interscience Publishers, New York, 1961, Part 2, 93".
The oxidation with hydrogen peroxide is described, for example, in "E. Ochiai, J. Org. Chem. lB, 534 (1953)".
The conditions for an aminolysis of the ester I to give the amide I correspond to those used for the reaction of V to give VI.
The preparation and the aminolysis are otherwise reaction types which are known as such: However, compounds of the formula I prepared by the above reactions are novel.
The process conditions can be seen in detail in German Patent Applications P 38 26 471.4, 38 23 140.6, 39 24 093.2 and 40 01 002.3, and DE-A-37 03 959, 37 03 962 and 37 03 963.
32 ~ ) g~j3~
The compounds of the formula I according to the invention have useful pharmacological proper-ties and exhibit, in particular, activity as inhibitors of proline hydroxylase and lysine hydroxylase, and as a fibrosuppressant, immunosuppressant and antiatherosclerotic.
The antifibrotic action can be determined using the model of liver fibrosis induced by carbon tetrachloride. For this, rats are treated twice ~eekly with CCl,, (1 mlJkg) -dissolved in olive oil. The tes-t substance is adminis-tered daily, if appropriate even twice daily, perorallyor in~raperitoneally ~ dissolved in a sui~able tolerated solvent. The extent of the liver fibro~is is determined hi~tologically, and the amount of collagen in the liver is analysed by hydroxyproline determination - as de-scribed by Kivirikko et al. (Anal. Biochem. 19, ~49 etseq. (1967)). The fibrogenesis activity can be determined by radioimmunological assay of collagen fragments and procollagen peptidas in the serum. The compounds accord-ing to the invention are active in a concentration o~
1 - 100 mg/kg in this model.
The fibrogenesis activity can be determined by radioim-munological assay of the N~terminal propeptide of col-lagen type III or of the N- and C-terminal crosslinking domains of collagen type IV (7s-collagen or type IV
collagen-NC1) in the serum.
For this purpose, the hydroxypr~line, procollagen III
peptide, 7s-collagen and type IV collagen-NC concentra-tions wers measured in th~ liver of a) untreated rats (control) 0 b) rats to which carbon tetrachloride had been adminis-tered (CCl4 control) c) rats to which first CCl4 and then a compound accord-ing to the invention had been administered (this test method is described by Rouiller, C., experi-mental toxic injury of the liver; in The Liver, C. Rouiller, Vol. 2, 5. 335-476, New York, Academic Press, 1964).
Another model for evaluation of the antibiotic action is that of bleomycin-induced pulmonary fibrosis as described by Kelley et al. (j. Lab. Clin. Med. 96, 954, (1980)).
The model of the cotton-wool swab granuloma as described by Meier et al., Experimentia 6, 469 (1950) can be used to evaluate the action of the compounds according to the invention on granulation tissue.
The compounds of the formula I can be used as medicaments in the form of pharmaceutical preparations which comprise them, if appropriate together with tolerated pharmaceuti-cal excipients. The compounds can be used as medicines, for example in the form of pharmaceutical preparations which comprise these compounds as a mixture with a pharmaceutical, organic or inorganic excipient which is suitable for enteral, percutaneous or parenteral adminis-tration, such as, for example, water, gum Arabic, gela-tin, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, petroleum jelly and the like.
For this purpose, they can be administered orally in doses of 0.1 - 25 mg/kg/day, preferably 1 - 5 mg/kg/day, or parenterally in doses of 0.01 - 5 mg/kg/day, preferab-ly 0.01 - 2.5 mg/kg/day, in particular 0.5 -1.0 mg/kg/day. In serious cases, the dosage can also be increased. However, lower doses are also sufficient in many cases. These data relate to an adult weighing about 75 kg.
The invention furthermore relates to the use of the compounds according to the invention in the preparation of medicaments employed for the treatment and prophylaxis of the abovementioned metabolic disturbances.
3~ 5 ~I S ~
The invention furthermore relates to medicaments which comprise one or more compounds of the formula I according to the invention and/or physiologically tolerated salts thereof.
The medicaments are prepared by processes which are known per se and familiar to the expert. As medicaments, the pharmacologically acti~e compounds according to the invention (= active compound) are employed either as such or, preferably, in combination with suitable pharma-ceutical auxiliaries or excipients, in the form otable~s, coated tablets, capsules, suppo~itories, emulsions, suspensions or solutions, the active compound content being up to about 95 %, advantageously between lO
and 75 ~.
Suitable auxiliaries or excipients for the desired medicament formulation are, for example, in addition to solvents, gel forming agents, suppository bases, tablet auxiliaries and other active compound exc:ipientsl also antioxiflants, dispersing agents, emulsifiers, foam suppressants, flavor correctants, preservatives, solu-bilizing agents or dyestuffs.
The following examples are intended to illustrate the invention.
Example 1 5-Bromo-pyridine-1-oxide-2,4-dicarboxylic acid bis-~3-methoxypropyl)amide]
a) 5~Bromo-2,4-dimethylpyridine 150 ml of 65 % strength oleum are added dropwise to 28.9 ml of 2,4-dimethylpyridine, while cooling with ice and stirring, such that the temperature does not rise above 35C. When the solution has become homogenized, _ 35 h a ~ ~ 9 ~ ~
6.42 ml of bromine are slowly added dropwise. The mixture is stirred at 80C for 3~ hours. After cooling, it is allowed to drip carefully onto 1 kg of ice, and the resulting mixture is neutralized with solid Na2CO3 and extracted 3 times with 300 ml of ether each time. ~he organic layer is separated off and dried over magnesium sulfate. After remo~al of the sol~en~ by distillation in vacuol 34.6 g of a pale yellow oil wh:ich comprises the isomers S-bromo-2,4-dimethylpyridine and 3-bromo-2,4-dimethylpyridine are obtained. The isomers are separatedby column chromatography on silicon dioxide gel to give 10 g of S-bromo-2,4-dimethylpyridine as a colorless liquid (13.0 g of 3-bromo-2,4-dimethylpyridine).
Yield: 22 %.
b) 5-Bromo-pyridine-2,4-dicarboxylic *cid 4 g of 5-bromo-2,4-dimethylpyridine from Example 1 are heated to 70-80C in 200 ml of water and 2.4 g o KOH.
Half of 12.74 g of potassium permanganate is then intro-duced in portions. The solution is heated to the boiling point and the remainder of the potassium permanganate is added. The mixture .i9 s~irred at 70-80nC for 20 hours and then filtered hot with suction, and the precipitate is washed 4 times with 50 ml portions of hot water. The combined filtrates are concentrated to 100 ml in vacuo.
The solution is brought to pH 1 with concentrated hydro-chloric acid and is left to stand at 0C for 20 hours.
The crystalline solid is filtered off with suction and dried in vacuo at 100C. The yield is 2.9 g.
Melting point 261-263C.
c) 5-Bromo-pyridine-2,4-dicarboxylic acid bis-~3-methoxypropyl)amide]
2.46 g (10 mmol) of 5-bromo-pyridine-2,4-dicarboxylic acid are suspended in 70 ml of toluene and 0.2 ml of dimethylformamide, and 1.45 ml (20 mmol~ of thionyl - 36 ~
chloride are added. The reaction mixture is heated at 110C for 5 hours, during which a clear solution forms.
The solution is then allowed to cool to 0Cr and ~
solution of 2.05 ml ~20 mmol) of 3-methoxypropylamine and 2.8 ml of -triethylamine in 10 ml of tolllen~ is added dropwi 5 e.
The mixture is left to stand at 20~C for 12 hours and concentrated in ~acuo/ water is addedl the mixture is extracted with methylene chloride, and the organic phase is dried and freed from the solvent to give the subst~nce as a colorless oil, yield 2.2 g.
Empirical formula: C15H2~BrN3O4 (388.26 MS: m/e = 389 (M + H+) d) The above compound is dissolvad in 80 ml of methylene chloride, and 5 mg of meta-chloro perbenzoic acid are added in portions at 10C. After 2 hours, a further 5 g of peracid are added, the mixture i5 heated at 42C for 3 hours, a further 5 g of peracid are added, and the mixture is heated at 42C for 5 hours.
Excess peracid and 3-chlorobenzoic acid are precipitated by passing in ammonia gas ~nd are filtered off with suction. The solution is concentrated and the residue is chromatographed o~er silica gel using ethyl acetate/meth-anol 10:1 The title compound is obtained as colorless crystals. Melting point 94~.
Empirical formula: Cl5H22BrN304 (404.26) MS: m/e = 405 (M + H+) Example 2 Pyridine-1-oxide-2,4-dicarboxylic acid dimethyl ester 7.0 g (35.~ mmol) of pyridine-2,4-dicarboxylic acid dimethyl ester are dissol~ed in 200 ml of methylene chloride, and 6.2 g (36 mmol) of 3-chloroperbenzoic acid are added at 10C. Aftex ~ hours, a further 6.~ g of peracid are added, the mixture is allowed to stand overnight, a further 3.1 g of peracid are added, and the mixtura is heated at 40C for 5 hours (thin layer chroma-tography control).
Excess peracid and 3-chlorobenzoic acid are precipita-ted by passing in ammonia gas 3 times, and are filtered off.
The solution i5 concentrated and the residue is crystall-ized from toluene, 4.5 g.
Melting point 132C; R~ (SiO2, ethyl acetate) = 0.~9 Example 3 Pyridine-l-oxide-2-carboxylic acid methyl ester-4-car-hoxylic acid (2-benzyloxyethyl)amide and pyr:idine-1-oxide-2-carboxylic acid t~-benzyloxyalkyl)amide-4-car-boxylic acid methyl ester 3.1 g (15 mmol) of the title compound from Example 2 are ~0 heated at 100C in 50 ml of N,N-dimethylacetamide with 22.8 g (150 mmol) of 2-benzyloxyethylamine (prepared from 2-aminoethanol, sodium and benzyl chloride) for 1 hour.
The mixture i~ allowed to cool and is concentrated, water is added, the mixture is extracted with methylene chlor-ide and concentrated and the oily residue ~4.8 g) iscrys-tallized with ethyl acetate.
Melting point 76-78C (colorless crystals) Empirical formula: C17H1~N205 (330) MS: m/e = 331 (M + H+) The corresponding diamide was to be obtained after 10 hours at 140C.
- 38 - 2 ~ ~ 9 Example 4 4-Methoxy-pyridine-1-oxide-2~5-dicarbo~ylicacidbis-[(2-hydroxyethyl)~nide]
a) 2-Hydroxymethyl 4-methoxy-5-methyl-pyridine 5.4 g (35 mmol) of 4-methoxy-2,5-dimethyl-pyridine N-oxida (melting point 102-104C, diisopropyl ether;
prepared from 2,5-dimethyl-pyridine N oxide and sodium methylate in methanol) are dissolved in 30 ml of glacial acetic acid, and 40 ml of acetic anhydride are added dropwise at 80C.
The mixture is heated at 115C for 90 minutes and cooled to 80C, 75 ml of methanol are added dropwise, the mixture is concentrated, the residue i5 taken up in methanol, 200 ml of 1.5 N methanolic sodium hydroxide lS solution are added dropwise, water is added, the mixture is extracted with methylene chloride, dried and concen-trated and the residue is crystalli~ed with cyclohexane, yield: 4.4 g; melting point 92-94C.
b) 4-Methoxy pyridine-2,5-dicarboxylic acid 2.3 g (15 mmol) of the compound from 4a) are suspended in a solution of 1 g of XOH in 75 ml of watex, and 7.2 g (45 mmol) of KMnO4 are added in por~ions at 70C. Ths mixture is left at 80C for a further hour, the magnesi~n dioxide which has been filtered off with suction is washed with water, and the filtrate i5 concentrated and brought to pH 1 with hydrochloric acid;
Yield: 1.45 g; rnelting point 231C (decomposition).
c) 4-Methoxy-pyridine-1-oxide-2/5-dicarboxylic acid dimethyl ester - 39 ~
1.4 ~ of th~ compound from 4b) are heated at the boiling point in 150 ml of methanol and 2 g of sulfuric acid (98 % streng-th) for 15 hours. The mixture is allowed to cool, saturated ammonium chloride solution is added, while cooling, and the mixture is extracted with methyl-ene chloride and concentrated to give, analogously to Example 2 by reaction of the crude product with 3 chloro-perben~oic acid, 0.8 g of 4-methoxy-pyridine-2,5-dicar-boxylic acid dimethyl ester N~oxide, melting point 134-136C.
d) The title compound is obtained ~rom the above compound of Example 4c) by reaction with exces~ 2-aminoethanol, colorless crystals, melting point 124-127C ~from ethyl acetate).
lS The following compounds were to be obtained analogously from the compound of Example 4c) by reaction with the corresponding amines:
4-methoxy-pyridine 2,5-dicarboxylicacidbis-[(2-methoxy-ethyl)amide] N-oxide 4-methoxy-pyridin~-2,5-dicarboxylicacidbis-[(3-hydroxy-propyl)amide~ N-oxide 4-methoxy-pyridine-2,5-dicarboxylicacidbis-[(3-methoxy-propyl)amide~ N-oxide 4-methoxy-pyridine-2,5-dicarboxylic acid bis-[(2-benzyloxyethyl)amide] N-oxide Example 5 Pyridine-l-oxide-2,4-dicarboxylic acid bis-N,N'-[~-(4-methylbenzoyloxy)ethyl]amide a) Pyridine-2,4-dicarboxylic acid bis-N,N'-[2-~4-methylbenzoyloxy)ethyl]amide -- 4 0 _ h ~
b) 0.2 g of 4-N,N-dimethylaminopyridine and 0.8 ml (6 ~mol~ of triethylamine are added to 0.7 g (2.5 mmol) of pyridine-2,4-dicarboxylic acid bis-N,N'-(3-hydroxy-ethyl)amide in 100 ml of methylene chloride, and 0.6 ml (5 mmol) of 4 methylbenzoyl chloride are then added dropwise. After 1 hour, the mixture is concentrated and ~he residue is then taken up in water. After 1 hour, the mixture is extracted by shaking twice with water and the organic phase is concentrated. The crude product is chromatographed over silica ~el using ethyl acetate.
Colorless crystalline powder: melting point 165-166C
Empirical formula: C27H27N3O6 (489) MS: m/e = 490 (M + H+).
b) 0.31 ml of 30 percent strength H2Oz is added dropwise to a solution of 0.25 g of the above compound in 5 ml of 96 percent strength formic acid, and the mixture is heated at 80C ~or 4 hours. It is then evaporated in vacuo and the crystalline residue is stirred with hot methanol and filtered off with suct~on. 0.18 g of pyrid-ine-2,4-dicarboxylic acid N,N'-bis-[2-(4-methylbenzoyl-oxy)ethyl]amide is obtained as a colorless crystalline powder, melting point 186-188C.
MS: m/e = 506 (M+ ~ H+).
Example 6 Pyridine-1-oxide-2,4-dicarboxylic acid N,N'-bis-[~2-benzoyloxyethyl)amideJ
a) Pyridine-2,4-dicarboxylic acid bis-N,N'-[(2-benzoyloxyethyl)amide]
Analogously to Example Sa) Colorless needles, melting point 139-140C
Empirical formula: C2sHZ3N3o6 (461) MS: m/e = 462 IM+ + H+).
- 41 ~
b) 0.31 ml of 30 percent strength H2O2 is added dropwise to a solution of 0.46 g of pyridine-2,4-dicarboxylic acid N,N~-bis-[(2-benzoyloxy)ethyl]amide (Example 6a)) in 5 ml of 96 percent strength formic acid, and the mixture is heated at B0C for 4 hours, while stirring. After addi-tion of a further 0.2 ml of H2O2, the mixture is stirred at this temperature for a further 2 hours and then evaporated in vacuo, and the residue is purified by chromatography over silica gel using ethyl acetate as the eluent. 0.37 g of pyridine-1-oxide-2,4-dicarboxylic acid N,N-bis-[(2-benzoyloxyethyl)amide] is obtained as color-less crystals, melting point 159-160C (methanol), MS: m/e - 478 (Nt ~ H~).
Substituted pyridine N-oxides, processes for their preparation, and their use Compounds which inhibit the enzymes proline hydroxylase and lysine hydroxylase have the e~fect of a very select-ive inhibition of collagen biosynthesis by influencing the collagen-specific hydroxylation re~ctions. In the course therev, protein-bound pxoline or lysine is hydroxylated by the enzymes proline hydroxylase or, respectively, tysine hydroxylase. If this reaction is suppressed by inhibitors, a non-functional, hypohydroxyl-ated collagen molecule is formed, which can be released by cells into ~he extracellular space in only a small amount. The hypohydroxylated collagen moreover cannot be incorporated into the collagen matrix, and is very readily broken down proteolytically. As a consequence of these effects, the total amount of collagen deposited in the extracellular space is reduced.
Inhibitors of proline hydroxylase are therefore suitable substances in the therapy of diseases in which the deposition of collagen contributes decisively to the syndrome. These include, inter alia, fibroses of the lung, liver and skin (scleroderma), as well as atherosclerosis.
It is known that inhibition of proline hydroxylase by known inhibitors, such as ~ dipyridyl, leads to an inhibition of the Clq biosynthesis of macrophages (W. Muller et al., FEBS Lett. 90 (1978~, 218;
Immunobiology 155 (1978), 47). This results in a failure of the classical route of complement activation. Inhibit oxs of proline hydroxylase therefore also act as immuno-suppressants, for example in cases of immune complex diseases.
It is known that the enzyme proline hydroxylase is inhibited effectively by pyridin~-2,4- and rj -2,5-dicarboxylic acid (K. Majamaa et al., Eur. J.
Biochem. 13B (1984) 239-24$). Elowever, these compounds are active as inhibitors in the cell culture only in very high concen-trations (Tschank, G. et al., Biochem. J. 238 (1987) 625-633).
Pyridine-2,4- and -2,5-dicarboxylic acid diesters having 1-6 carbon atoms in the ester alkyl part are described in DE-A 34 32 094 as medicaments for inhibition of proline hydroxylase and lysine hydroxylaseO
These lower-alkylated diesters have the disadvantage, however, that they are split into the acids too quickly in the organism, and do not arrive at their action site in the cell in a sufficiently high concentration, and are therefore not particularly suitable for possible adminis-tration as medicaments.
DE-A 37 03 959, DE-A 37 03 962 and DE-A 37 03 963 de-scribe in general form mixed esters/amides, highe:r-alkyl-ated diesters and diamides of pyridine-2,4- and ~2,5-dicarboxylic acid which effectively inhibit collagen biosynthesis in an animal model.
2,4- and 2,5-disubstituted pyridine N-oxides are de-scribed in German Patent Application P ~0 20 570.3.
It has now been found that substituted pyridine N-oxides of the following formula I and the physiologically tolerated salts also effecti~ely inhibit lysine hydroxyl-ase and proline hydro~ylase.
The invention therefore relates to substituted pyridine N-oxides of the general formula I
_ 3 ~ 5 l~
R 4 J`-~Y, R ~
5 ~\ ~ (I) in which R1 and R3 or R4 are -C(O)-X-R6, in which X is O or -N(R7)- and 5 R5 and R7 are identical or different, and A are a branched or unbranched, aliphatic or cycloali-phatic (C1 C12)-alkyl radical or (C1-C1~3-alkenyl radi-cal or a (C1-C12)-alkynyl radical, which is unsubstituted or mono- or polysubstituted, preferably mono- or disubstituted, by halogen/ in par-ticular fluorine, chlorine or bromine, hydroxyl, cyano, carboxyl, (C1-C8)-alkoxy, (C1-C8)-alkoxycarbonyl, (C1-C8)-alkoxycarbonyloxy, (C1-C8)-alkoxy-(C1-C8)-alkoxycarbonyl-oxy, (C6-Cl2~-aryloxycarbonyloxy, (C7-Cll~-aralkyloxycar-bonyloxy, (C7-C11)-aralkylcarbonyloxy, cinnamoyl, cinna-moyloxy,(C8-C12)-arylcarbonyloxy,( C3 C8 ) - alkenylcarbonyl-oxy, (C3-C8)-alkynylcarbonyloxy, (C3-C8)-cycloalkylcarbon-yloxy, ~Cl-Cl2) alkoxy-(Cl-Cl2)-alkoxy, (Cl-Cl2)-alkoxy-amino, (Cl-Cl2)-alkoxy-N-(Cl-C6)-alkylamino, (Cl-cl2)-alkoxy-N,N-(C1-C6)-dialkylamino, carbamoyloxy, N-(Cl C8)-alkylcarbamoyloxy, N,N-di-(Cl-C8)-alkylcarbamoyl, N-(C3-C8)-cycloalkylcarbamoyl, N-(C8-C12)-arylamino, N-(C7-C11)-aralkylamino, N-alkyl-axalkylamino, N-alkyl-arylamino, (C3-C8)-cycloalkanoylamino, (C1-C8)-alkanoyl-amino, (C8-C12)-aroylamino, (C7-C11)-aralkanoylamino, (C1-C8)-alkanoyl-(C1-C8)-alkylamino,(C3-C8)-cycloalkanoyl-(cl-cs)-alkylamino~ (C8~cl2)-aroyl-(cl-c8)-alkylamino~
d, ~ 9 ~ l~
(C,-C~ aralkanoyl-(Cl-C8)-alkylamino, (Cl-C8)-alkylmercap~
to, (Cl-C8)-alkylsulfinyl, (Cl-Ca)-alkylsulfonyl, (Cl-Ca)-alkylcarbonyl, (C3-C8)-cycloalkylcarbonyl, nitro, tri-fluoromethyl, phenylmercapto, phenylsulfonyl, phenylsul-finyl,sulfamoyl,N~(Cl-C6)-alkylsulfamoyl,N,N-di-(C1-C6)-alkylsulfamoyl, (C1-C8)-alkyl-sulfonamido or a.rylsulfon-amido, in which the aryl and aralkyl radicals present in the above substituents can also he hetexocyclic in nature and/or, as is also the case for alkyl, a.re substituted by 1, 2, 3, 4 or 5 identical or different subs~ituentæ from the series comprising halogen, cyano, nitro, trifluoro-methyl, (Cl-C6)-alkyl, hydroxy, (Cl-C6)-hydroxyalkyl, (Cl-C6)-alkoxy, -O-[CH2-}xCyH(2frl-B)Fg~ -OCF2Cl, -O-CF2-CHFCl, trifluoromethyl, (C1-C6)-alkylmercapto, (Cl-C6)-alkylsul-finyl, (C1-C6)~alkylsulfonyl, (C1~C6)-alkylcarbonyl, (Cl-C6)-alkoxycarbonyl, carbamoyl, N~(Cl-C4)-alkylcar-bamoyl, N,N-di-(Cl-C4)-alkylcarbamoyl, (Cl-C6)-alkylcar-bonyloxy~ (C3 Ca)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, NR'-R", phenylmercapto, phenylsulfo:nyl, ~0 phenylsulfinyl, sulfamoyl, N-(C1-C4)-alkylsulfamoyl and N,N-di-(C1-C4)-alkylsulfamoyl, in particular by up to 3 of the abovemen~ioned identical or different substituents, and a CH2 group of the alkyl chain is optionally replaced by 0, S, SO, SO2 or NR', or by an unsubstituted or substituted (C6-Cl2)~aryl radical or heteroaryl radical which carries 1, 2, 3, 4 or 5 identi-cal or different substituents from the series comprising halogen, nitro, cyano, carboxyl, hydroxyl, trifluorometh-yl, (cl-c6)-hydroxyalkyl~ --[cH2~xc~H(2f+l8~F~ -OCF2Cl~
-OCF2-CHFCl, (C1 C6)-alkylmercapto, (C1-C6)-alkylsulfinyl, (cl-c6)-alkylsulfonyl~ (Cl-C8)-alkoxy, (Cl-Ca)-alkyl, (Cl-C6)-alkylcarbonyl, (C1-C6)~alkoxycarbonyl, carbamoyl, N-(Cl-C4)-alkylcarbamoyl, N,N-di-(Cl C4 ) -alkylcarbamoyl, (Cl-C6)-alkylcarbonyloxy, ~ C3-C8 ) -CyC1 oalkyl, phenyl, benzyl, phenoxy, benzyloxy, ~R~-R", phenylmercapto~
phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(Cl-C4)-alkylsulfamoyl, N,N-di-(C1-C4)-alkylsulfamoyl, 3 'j 9 '3 ~
(Cl-CD)-alkoxycarbQnyloxy, (Cl-C~)-alkoxy-(Cl-Ca)-alkoxy-carbonyloxyr (Ca-Ci2)~aryloxycarbonyloxy, (C7-Cll)-aralkyl-oxycarbonyloxy, (C7-C1l)-aralkylcarbonyloxy, cinnamoyl, cinnamoyloxy,(C6-C12)-arylcarbonyloxy,(C3-C~)-alkenylcar-S bonyloxy, (C3-C8)-alkynylcarbonyloxy, (C3-C8)-cycloalkyl-carbonyloxy, (Cl-C~2)-alkoxy-(C1-C12)-alkoxy, (Cl~cl2)~
alkoxy-amino, (cl-cl2)-alkoxy-N-(cl-c6)-alkylamino~
(cl-cl2)-alkoxy-N~N-(cl-c6)-dialkylamino~ carbamoyloxy, ~-(Cl-C8)-alkylcarbamoyloxy, N,N-d.i-(Cl-C~)-alkylcarbamoyl~
N-( C3-C~ ) -cyc.loalkylcarbamoyl, N-( C6-c12 )-arylamino r N-(C7-Cl1)-aralkylamino, N-alkyl-aralkylam.ino, N-alkyl-arylamino, (C3-C8)-cycloalkanoylamino, (C1-C8)-alkanoyl-amino, (C6-C12)-aroylamino, ( C7-C 11 )-aralkanoylamino, (Cl-C8) alkanoyl-(Cl-C8)-alkylamino,(C3-C8)-cycloalkanoyl-(C1-C8)-alkylamino, (C8-C12)-aroyl-(C1-C8)-alkylam:ino, (C7-Cll)-aralkanoyl-(Cl-C8)-alkylamino, (Cl~C8)-alkylmer-cap~o, (cl-c8)-alkylsulfinyl r ( Cl-C8 ) -alkylsulfonyl, (C1-C8)-alkylcarbonyl, (C3-C8)-cycloalkylcarbonyl, nitro, trifluoromethyl, phenylmercapto, phenylsulfonyl, phenyl~
sulfinyl, sulfamoyl, N-(C1-C6)-alkylsulfamoyl, N,N-di-(cl-c8)-alkylsulfamoyl, (Cl-C8)-alkyl-sulfonamido and arylsulfonamido, in which the aryl and aralkyl radicals present in the above substituents can also be heterocyc-lic in nature and/or, as is also the case for alkyl, can be substituted by 1,2,3,4 or 5 identical or different substituen~s from the series comprising halogen, cyano, nitro, trifluoromethyl, (C1-C6)-alkyl, hydroxyl, (C1-C6)-hydroxyalkyl and (C1-C6)-alkoxy, or by an unsubstituted or substituted (C6-C12)-aryloxy radical, (C7-C~ aralkyloxy radical or heteroaryloxy radical, which carries 1, 2, 3~ 4 or 5 identical or different substituents from the series comprising hydroxyl, halo-gen, cyano, nitro, trifluoromethyl, (Cl-C6)-alkyl, (C1-C6)-hydroxyalkyl, (C1-C6)-alkoxy, ~CH2~~xCfH(2fl1-s) -OCF2-CHFCl, (C1-C6)-alkylmercapto, (C1-C6)-alkylsulfinyl, (cl-c6)-alkylsulfonyl~ (cl-c6)-alkylcarbonyl~ (C1-C6)-alkoxycarbonyl, carbamoyl, N-(C1-C4) alkylcarbamoyl, N,N-di-( Cl-c4 )-alkylc:~arbamoyl, (Cl-C6)-alkylcarbonyloxy, (C3-Ca) cycloalkyl, carboxyl, phenyl, benzyl, phenoxy, benzyloxy, NF~'-R, phenylmercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(Cl-C4)-alkylsulfamoyl, N,N~
5 di.-(C1-C4)-alkylsulfamoyl, am.inoalkyl/ ~-(C1-C8)~alkyl-amino-(Cl-C 12 ) -alkyl and N-di-(Cl-C8)-alkylamin-(Cl-cl2)-alkyl, is optionally substituted by up to 3 of the abovementioned identical or di:E:ferent substituent~, and a C~z group of the alkyl chain is optionally replaced by lO 0, S, SO, SO2 or NR', or by a radical of the general formula II
O R8 (II~
in which R3 is an amino acid bonded via its acyl radica:L, a derivative of this amino acid or an alcohol-protect-ive ~roup, B are an unsubstituted or substituted (C8-C12)-aryl radical or ( C7 C11)-aralkyl radical or a heteroaryl radical, which is mono- or polysubstituted, preferably 20 mono- or disubstituted, by hydroxyl, halogan, cyano, carboxyl, amino, (Cl-C8)-alkyl, (Cl-C8)-alkoxy, (Cl-C8)-alkoxycarbonyl, tCl-C8)-alkylcar-bonyl, (C1-C8)-alkylcarbonyloxy, (Cl-C8)-alkylamino, di-( C1-C8) -alkylamino, ( C1-C6) -hydroxyalkyl, 25 -O-[CH2-]XCfH(2f.t1 ~,F~, -OCF2Cl, -OCF2-CHFCl, ca.rbamoyl, N-(Cl-C8)-alkylcarbamoyl, N,N-di-(C1-C8) al3cylcarbamoyl, (cl-c8)-alkylcarbonyloxy~ (C3-C8)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, aminoalkyl, N-(C1-C8)-alkyl-amino-(C1-C 12 ) alkyl or N,N-di-(C1-C8)-alkylamino-(C1-Cl2)-30 alkyl, (C1-C8)-alkoxycarbonyloxy, (C1-C8)-alkoxy-(C1-C8)-alkoxycarbonyloxy, (C8-C12)-aryloxycarbonyloxy, (C7-C11)-aralkyloxycarbonyloxy, (C7-C11)-aralkylcarbonyloxy, - 7 _ ~3 ~j ~
cinnamoyl, cinnamoyloxy, (c6-cl2)~arylcarbonyloxy, (C3 C8)-alkenylcarbonyloxy, (C3-C8)--alkynylcarbonyloxy, (C3-C8)-cycloalkylcarbonyloxy, (Cl-~l2)-alkoxy-(cl-c}2)-alkoxy, (cl-cl2)-alxoxy-aminol (C1-Cl2)-alkoxy-N-(C1-C6)-S alkylamino, (C1-Cl2)-alkoxy-N,N-(Cl C6)-dialkylamino, carbamoyloxy, N-(C~-CB)-alkylcarbamoyloxy, N,N-di-(Cl-C8)-alkylcarbamoyl, N-(C3-C8)~cycloalkylcarbamoyl, N-~C6-C12)-arylamino, N-( C7 Cll)-aralkylamino, N alkyl-aralkylamino, N-alkyl-arylamino, (C3-C8)-cycloalkanoyla~ino, (Cl-C6)-alkanoylamino, (C 6-C12)- aroylamino, ( C7-C~ aralkanoyl-amino, (C1-C8)-alkanoyl-( C1_CB ) -alkylamino, (c3-C8)-cyclo-alkanoyl-(Cl-Ca)-alkylamino, (C6-C12)-aroyl--(C1-C8)-alkyl-amino, (C7-Cll)-aralkanoyl-(Cl-C3)-alkylamino, (Cl-Ca)-alkylmercapto, (C1-C8)-alkylsulfinyl, (C1-C8)-alkylsul-fonyl, (C1-C8)-alkylcarbonyl, (C3-C8)-cycloalkylcarbonyl, nitro, trifluoromethyl, phenylmercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C6)-alkylsulfamoyl, N,N-di-(C1-C8)-alkylsulfamoyl, (Cl-Ca)-alXyl-sulfonamido or arylsulfonamido, C in the case where X = -N(R7)l are an unsubstituted or substituted (C1-C12~-alkoxy raclical, (C3-C8)-cycloalkoxy radical or (C6-C12)-aryloxy radical or a (C7-C11)-aralkyl-oxy radical, which is mono- or polysubstituted, preferab~
ly mono- or disubstituted, by halogen, trifluoromethyl, (Cl-C6)-alkoxy, hydroxyl, (C1-C6)-hydroxyalkyl, NR'R" or cyano, in which, in each case, R' and R" are identical or different and are hydrog2n, (c6-cl2)~aryl~ (cl-cs)~alkyl~ (C1-C8)~alkylcarbonyl, (C7-C11)-aralkylcarbonyl or (C6-C12)-arylcarbonyl or form a saturated heterocyclic ring, preferably a 5- or 6-membered ring, with the nitrogen, ~ 13.,~ A
and R2, R5 and R4 or R3, if R4 or R3 has not already been defined above, are identical or different and D are hydrogen, at least one radical R2, R5 and R4 or R3 being other than hydrogen, halogen, in particular fluorine, chlorine or bromine, cyano, nitro, krifluoro-methyl, (cl-C12)-alkyl, -o-[CH2-]yCyH(2t1-8)F8~ -OCF2Cl~
-O-CF2-C}IFCl,(C1-C8)-alkylmercapto,(C1-C8)-alkylsulfinyl, (C1-C8)-alkylsulfonyl,(C1-C8)-alkylcarbonyl~carbamoyl,N-10 ( Cl-C4 ) -alkylcarbamoyl, N,N-di-( Cl-C4 ) -alkylcarbamoyl~
(c3-c8)-cycloalkyl~ phanylmercap~o, phenylsulfonyl, phenylsulfinyl, (C1~C12)-alkoxycarbanoyl, (C1-C12)-alkyl-carbanoyloxy, amino, N-lCl-C1O)-alkylamino, di-N,N-(Cl-C10)-alkylamino, N,N-(C3-C8)-alkanediylamino, such as, for example, pyrrolidino, piperidino or their hetero-cyclic derivatives morpholino and thiomorpholîno, N-( C6-C12 ) - arylamino, N-(C6-Cl2) aryl-N (C1-CIO)-alkylamino, N-(C7-C11)-aralkylamino, N-( C7 Cll ) -aralkyl-N-(C1-C1O)~alkyl-amino, (Cl-Cl2)-alkanoylamino, (C3-C6)-cycloalkanoylamino-( Cl-C 12 ) - hydroxyalkanoylamino, (C1-c8)-alkoxy-(cl-cl2) alkanoylamino, (C6-Cl2)-arylcarbonylamino, (C7-Cll)-aralk-ylcarbonylamino, (Cl-C8)-alkoxycarbonyloxy, (Cl-C8)-alkoxy-(cl-c8)-alkoxycarbonyloxy, (C6-Cl2)-aryloxycarbonyloxy, (C7-Cll)-aralkyloxycarbonyloxy, (C7-Cll)-aralkylcarbonyloxy, (C~-C12)-arylcarbonyloxy, (C3-C8)-alkenylcarbonyloxy, (C3-C8)-alkynylcarbonyloxy,(C3-C8)-cycloalkylcarbonyloxy, (C1-C12)-alkoxy-(C1-C12)-alkoxy, (C1-C12)-alkoxy-amino, ~Cl-cl2)-alkoxy-N-(cl-c6)-alkylamino~ (Cl-Cl2)-alkoxy-N,N-(Cl-C6)-dialkylamino, carbamoyloxy, N-(C1~Ca)-alkylcar-bamoyloxy, N,N-di-(C1-C8)-alkylcarbamoylox~, N-(C3-C8)-cycloalkylcarbamoyloxy, NR'R", (Cl-C8)-alkylmercapto, (Cl-C8)-alkylsulfinyl, (cl-c8)-alkylsulfonyl~ (Cl-C8)-alkylcarbonyl, (C3-C8)-cycloalkylcarbonyl, sulfamoyl, N-(Cl-C6)-alkylsulfamoyl, N,N-di-(Cl-C6)-alkylsulfamoyl, (C1-C8)-alkylsulfonamido or arylsulfonamido, in which the aryl and aralkyl radicals present in the above 9 ~ 5 ~
substituents can also be hete.rocyclic in nature and/or are substit~lted, as is also the case for alkyl, with 1, 2, 3, 4 or 5 identical or different substituents from the series comprising halogen, cyanor nitro, trifluoromethyl, (C,-C6)-alkyl, hydroxyl, (C1-C6)-hydroxyalkyl, (C1-C6)-alkoxy~ --[CH2-~CfH(2f+~8~F~ -OCF2Cl, -O-CF2-CHFCl, tri-fluoromethyl, (C~-C6)-alkylmercapto, (C~-C6)-alkylsulfinyl, (C~-C6)-alkylsulfonyl, (C~-C6)-alkylcarbonyl, ~Cl-C6)-alkoxycarbonyl, carbamoyl, N-( Cl-c4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (Cl-C6) alkylcarbonyloxy, (C3-C8)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, NR'-R", phenylmercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(Cl-C4)-alkylsulfamoyl and N,N-di-(C~-C4)-alkylsulfamoyl, in particular by up to 3 of the abovemen-tioned identical or different substituents, and a CH2group of ~he alkyl chain is optionally replaced by O~ S, SO, SO2 or NR', or E are an alkyl, alkenyl or alkynyl radical having up to 9 carbon atoms~ which i5 optionally substitu~ed by 1, 2, 3, 4 or S identical or dif~erent substituents from the series comprising hydroxyl, halogen, cyano, nitro, trifluoromethyl, ~C1-C6)-hydroxyalkyl, (C1-C6)-alkoxy, [CH2~]xcfH(2ftl-B)Fs~ -OCF2CHFCl, (C1-C6)-alkylmercapto, (Cl-C6)-alkylsulfinyl, (C~-C6)-alkylsulfonyl, (Cl C6)-alkylcarbonyl, (C1 C6)-alkoxycarbonyl, carbamoyl, N-(Cl-C4)-alkylcarbamoyl, N,N-di-(Cl-C4)-alkylcarbamoyl, (C1~C6)-alkylcarbonyloxy, (C3-C8)-cycloalkyl, carboxyl/
phenyl, benzyl, phenoxy, benzyloxy, phenylmercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C4~-alkylsulfamoyl, N,N-di-(C1-C4)-alXylsulfamoyl, amino, N-(C1-C10)-alkylamino, di-N,N-(C1 C10)-alkylamino, N,N-(C3-C8)-alkanediylamino, such as, for example, pyrroli-dino, piperidino or their het~rocyclic derivatives morpholino and thiomorpholino, N-(C6 Cl2)-arylamino, - lO ~ J~
N-(C~-C~2)-aryl-N-(Cl-C~O)-alkyl~nino, N-(C7-Cll)-aralkyl-amino~ N-(c7-cll)-aralkyl-N-(cl-c~ alkylamino~ (C~-Clz)-alkanoylamino, (C3-C8~-cyclo-alkanoylamino, (Cl-cl2)-hydrQxyalkanoylamino, (C~-C8)-alkoxy-(C,-C~2)-alkanoyl-amino, (C6-C12)-arylcarbonylamino and (C7-C11)-aralkyl-carbonylamino, in particular by up -to 3 of the above-mentioned identical or different substituents, and a CH2 group of the alkyl chain is optionally replaced by 0, S, SO, SO2 or NR', or by an unsubstituted or substituted (C6~C12)-aryl radical, tC7-C~l)-aralkyl radical or heteroaryl radical, which carries 1, 2, 3, 4 or 5 identical or different substitu~
ents from the series comprising hydroxyl, halogen, cyano, nitro, trifluoromethyl, (C1-C6)-hydroxyalkyl, (C1-C8)-alkyl r ( Cl-C6 ) -alkoxy, [CH2~]xc~H~2f+l-8)F~ -OCF2C~IFCl, (Cl-C6)-alkylmercapto, (Cl-C6)-alkylsulfinyl, (Cl-C6)-alkylsulfonyl, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxycar~
bonyl,carbamoyl,N-(C1-C4)-alkylcarbamoyl,N,N-di (C1--C4)-~0 alkylcarbamoyl, (C1-C6)-alkylcarbonyloxy, (C3-C8)-cyclo-alkyl, carboxyl, phenyl, benzyl, phenoxy, benzyloxy, phenylmexcapto, phenylsulfonyl, phenylsul~inyl, sul-famoyl, N-(C1-C4)-alkylsulfamoyl, amino, N-(C1~C10)-alkyl-amino, di-N,N-(Cl-C10)-alkylamino, N,~-~C3-C8)-alkanediyl-am.ino, such as, for example, pyrrolidino, piperidino ortheir heterocyclic derivatives morpholino and thiomor-pholino, N-(C6-C12)-arylamino, N-(C6-Cl2)-aryl-N-(C1-ClO)-alkylamino, N-(C7-C~ aralkylamino, N-(C7-C~ aralkyl-N-(C1-C1O)-alkylamino, (Cl-C12)-alkanoylamino~ ( C3 -C8)-cyclo-alkanoylamino, (C1-Cl2)-hydroxyalkanoylamino, (Cl-C8)-alkoxy-(Cl-Cl2)-alkanoylamino, (C6-Cl2)-arylcarbonylamino and (C7-C~1)-aralkylcarbonylamino, in particular by up to 3 of the abovementioned identical or different substitu-ents, and a CH2 group of the alkyl chain is optionally replaced by 0, S, SO, SO2 or NR', or F denote a substituted or unsubstituted (c6-cl2)-ar radical, ~C7-C~ aralkyl radical or heteroaryl radical, in which the aryl and heteroaryl radical mentioned is, .in particular, phenyl, naphthyl, thienyl, furyl, pyrrolyl or pyridine, and which furthermore carries in the aryl part 1, 2, 3, 4 or S iden~ical or different substituents from the series comprising hydrox-yl, halogen, cyano, nitro, tC1--C8)-alkyl, (C1-Cb)-alJcoxy, carboxyl, trifluoromethyl, (C1-C63-hydroxyalXyl, --[CH2~]xC~H(2f~ 8)F8/ -OCF2Cl, -OCF2CHFCl, (C~-C6)- lkylmer-capto, (cl-c6)-alkylsulfonyl~ (C1-c6)-alkYlsulfinyl~
(C1-C6)-alkylcarbonyl, (C1-C6)-alkoxycarbonyl, carbamoyl, N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (C1-C6)-alkylcarbonyloxy, (C3-Ca) cycloalkyl r phe:nyl, benzyl, phenoxy, benzyloxy, amino, N-(Cl-CIo) alkylamino, di-N,N-(C1-C1O)-alkylamino, N,N-( C3_CB )-alkanediylamino, such as, for example, pyrrolidino, piperidino, morpho-lino, thiomorpholino, (cl-clo)-alkanoylaminol (C6-C12)-arylcarbonylamino, (C7-C11)-aralkylcarbonylclmino, phenyl-mercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C4)-alkylsulfamoylorN,N-di-(C1-C4)-alkylsulfamoyl,in particular up to 3 of the abovementioned identical or different substituents, and in which a CH2 group of the aryl chain is optionally replaced by O, S, SO, SO2 or NR', or G are a substituent of the formulae -OR9 or ~M(R9)2l in which R9 is hydrogen, alkyl, alkenyl or alkynyl, in each case having up to 9 carbon atoms, a (C6-Cl2)-aryl radical or a heteroaryl radical, which carries in the aryl part 1, 2, 3, 4 or 5 identical or different substituents from the series comprising hydrox-yl, halogen, cyano, nitro, carboxyl, (C1-C6)-alkyl, (Cl-C6)-alkoxy, trifluoromethyl, (C~-C6)-hydroxyal}cyl, --[CH2-~XCfH(2f+1-B~F8~ -OCF2Cl, -OCF2CHFCl, (Cl C6)-alkylmer-1 ~ 2 i~
capto, ~C1-C~)-alkylsulfonyl, tCl-C8)-alkylsulfinyl, (Cl-C6)-alkylcarbonyl, (Cl-C~)-alkoxycarbonyl, carbamoyl, N-(C1-C4)-alkylcarbamoyl, N,N-di-( Cl-c4 )-alkylcarbamoyl, (Cl-C6)-alkylcarbonyloxy, ( C3-C~ ) -cycloalkyl, phenyl r benzyl, phenoxy, benzyloxy, amino, N-(Cl-C10)-alkylamino, di-N,N-(Cl-C10)-alkylamino, N,N-(C3-Ca)-alkanediylam.ino, such as, for example, pyrrolidino, piperi.dino, morpho-lino, thiomorpholino, (C1-C10)-alkanoylaTn.ino, (C5-C12)-arylcarbonylamino, (C7-C11~-aralkylcarbonylamino, phenyl-mercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C4)-alkylsulfamoylorN,N-di-(C1-C4) alkylsulfamoyl,in particular up to 3 of the abovemen~ioned identical or different substituents, and in which a CH2 group of ~he aryl chain is optionally replaced by O, S, SO, SO2 or NR', and n = 0 or 1, f = 1 to 8, preferably 1 to 5, g = 0.1 to (2f + 1) and x is 0, 1, 2 or 3, preferably 0 or 1, plus all derivatives which carry a corresponding protect-ive group in their amino or hydroxyl groups, and the physiologically active salts.
~ryl, aryloxy, heteroaryl and heteroaryloxy compounds are understood as meaning, in particular, phenyl and naphthyl rings and unsubstituted 5- and 6-memhered heteroaromatic rings having 1 ,2 or 3 nitrogen and/or oxygen and/or sulfur atoms, such as pyridyl, pyridazyl, pyrimidyl, pyrazyl, imidazolyl, triazolyl, thienyl, oxazolyl and thiazolyl derivatives, and benzo-fused derivatives thereof. The radical (C7-C~ aralkyloxy is preferably understood as meaning a substituted phenylalkyloxy - 13 ~ tr~9 5i radical of the formula III
~10 Rl I
~'' -o-lCH2~ Rl2 (III) R 4 Rl3 i hich R10 R11 R12 ~13 and Rl4 are identical or dif-erent and are hydrogen, halogen, cyano, nitro, txi-fluoromethyl, (C1-C6)-alkyl, (C1~C6)-alkoxy, -~[CH2~]xCfH~2~ B)F8r -OCFzCl, -OCF2CHFCl, (C1~C6)-alkylmer-capto, (~ 6)-alkylsulfinyl~ ~Cl-C6)~alkylsulfonyl, (C1-C6) alkylcarbonyl, (Cl-C6)-alkoxycarbonyl, carbamoyl, N-(C1-C4)-alkylcarbamoyl~ N,N-di~(C1-C4)-alkylcarbamoyl, (Cl-C6)-alkylcarbonyloxy, (C3-C8)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, NR'R~, such as amino~ anilino or N-methylanilino/ phenylmercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C4)-alkylsulfamoyl or N,N di-(C1-C4~-alkylsulfamoyl, or two adjacent substitu-ents togethex are a -[CH2-]n or ~C~=C~-CH=C~- chain, in which a CH2 group of the chain is optionally replaced by O, S, SO, SO2 or NR', Y is 1, 2, 3 or 4, preferably 0 or 1, and the other substituents R10, R1lr R12, R13 and R14 are as defined aboYe.
Of the amino acids mentioned, the naturally occurring ~-amino acids are particularly preferred.
Amino-protective groups are understood as meaning, in particular, tho~e groups which are described in R. Geiger and W. Xonig "The Peptides" Volume 3, ~Protection of Functional Groups in Peptide Synthesis~, E.G. Gross, J. Meienhofer Edit, Academic Press, New York (1981), in particular pages 7 - 46.
- 14 _ 2~5~
Such groups are likewise described in A. Hubbuch, Schutzgruppen in der Peptidsynthese [Protective Groups in Peptide Synthesis], Kontakte 3/79, pages .L4~23.
The following amino-protective groups are pa.rticularly preferred:
acetamidomethyl, l-adamantyloxycarbonyl, l-(l-adamantyl~ me-thyl-ethoxycarbonyl, allyloxycarbonyl, tert-butyloxycarbonyl, 1-(4-biphenylyl)-1-methyl-ethoxycarbonyl, dicyclohexylcarbodiimide, ~ dimethyl-3,5-dimethoxybenzyloxycarbonyl, 4-dihydroxyborylbenzyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, l-hydroxybenzotriazole, 3-hydroxy-4-oxo-3,4-dihydro-1,2,3 benzot.riazine, isobornyloxycarbonyl, l-methyl~cyclobutyloxycarbonyl, 4-methoxybenzyloxycarbonyl, methylsulfonylethyloxycarbonyl, 4-pyridylmethyloxycarbonyl, 2,2,2-trichloro-tert-butyloxycarbonyl, benzyloxycarbonyl, halogen-substitu-ted benæyloxycarbonyl, 4-nitro-benzyloxycarbonyl, 2-phosphonoethyloxycarbonyl, phenylsulfonylethoxycarbonyl, toluenesulfonylethoxycarbonyl, 2,3,5-trimethyl-4-methoxy-phenylsulfonyl and benzotriazol-1-yl-oxy-tris(dimethylamino~phosphonium hexafluorophosphate.
Preferred compounds of the formula I in which the amino groups are protected are those in which the protected amino groups are part of this amino acid Ra.
- 15 ~
Poss.ible alcohol-protec-tive groups are, in particular, substituted or unsubst.ituted methyl ethers, ethyl ethers, ben2yl ethers, silyl ethers, esters, carbonates or sulfonates.
These include the following compounds:
As substituted methyl ethers:
me~hoxymethyl, methylthiomethyl, t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl, benzyloxymethyl, p-methoxybenzyloxymethyl, (4-methoxyphenoxy)-methyl, guaiacolmethyl, t-butoxymethyl, 4-pentenyloxymethyl, siloxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloro-ethoxymethyl, bis-(2-chloroethoxy)methyl, 2-(trLmethyl-silyl)ethoxymethyl,tetrahydropyranyl,3-bromotetrahydro-pyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl, 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl-S,S-dioxo, 1-[2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl, 1,4-dioxan-2-yl, tetrahydrofuranyl and ~etrahydrothiofuranyl.
As substituted ethyl ethers:
1-ethoxyethyl, 1-~2-chloroethoxy)athyl, 1 methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl,2,2,2-trichloroethyl r 2-trimeth-ylsilylethyl, 2-(phenylselenyl)ethyl, t butyl, allyl J p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl and benzyl.
As substituted benzyl ethers:
p-methoxy.benzyl, 3,4-dimethoxyben2yl, o-nitrobenzyl, p-nitrobenzyl, p-halogenobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2- and 4-picolyl, 3-methyl-2-picolyl-N-oxido, diphenylmethyl, p,p'-dinitrobenzohy-dryl, triphenylmethyl, ~-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(-p-methoxyphenyl)phenyl-methyl, tri(p-methoxyphenyl)methyl, 4-(4'-bromophenacyl-oxy)phenyldiphenylmethyl, 4,4',4"'tris(4,5-dichloro~
- 16 - ~J ~ Ll phthalimidophenyl)methyl, 4,4',4"-tristlevulinooxyphen-yl)methyl, 4,4',4'l-tris(benzoyloxyphenyl)methyl, 3-(imidazol-1,4' methyl)bis(4',4"-dLmethoxyphenyl)methyl, 1,1-bis-(4~methoxyphenyl)-1~-pyrenylmethyl, 9-anthryl, 9 (9-phenyl)xanthenyl~ 9-(9-phenyl-lO-oxo)anthryl.
As silyl ethers:
trimethylsilyl, triethylsilyl, triisopropylsilyl, dimeth-ylisopropylsilyl, diethylisopropylsilyl, dimethylthexyl-silyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triben~ylsilyl, tri-p-xylylsilyl~ triphenylsilyl, diphen-ylmethylsilyl and t-butylmethoxyphenylsilyl.
As esters:
formates, benzoylformates, acetates, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyaceta~e, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, p-P-phenylacetate, 3~phenylpro-pionate, 4 oxopentanoate ~levulinate), 4,4-(ethylen~3di-thio)pentanoate, pivaloate, ad~mantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate and 2,4,6-trimethylbenzoate (mes.itoate).
As carbonates:methyl, 9-~luorenylmethyl, ethyl, 2,2,2-tri.chloroethyl, 2-(trimethylsilyl)ethyl, 2-~phenylsulfonyl)ethyl, 2-(triphenylphosphonio)ethyl, isobutyl, vinyl, allyl, p-nitrophenyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenz-yl, o-nitrobenzyl, p-nitrobenzyl, S-ben~yl thiocarbon-ates, 4-ethoxy-1-naphthyl and methyl dithiocarbonates.
Further esters:
2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis-(l,l-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinate, (E)-2-methyl-2-butenoate (tigloate), o-(methoxycarbonyl)benzoa~el p-P-benzoate, ~-naphthoate, nitrate, alkyl N,N,N',N~-tetramethylphos-- 17 - 2 ~ 2~
phorodiamidate, N-phenylcarbamate, bora-tes, dime-thylphos-phinothioy:l and 2,4-dinitrophenylsulfenate.
As sulfonates:
sulfates, me-thanesulfonate ~mesylate), benzylsulfonate and tosylates.
The following protective groups are particularly preferred:
(Cl-C6~-alkanoyl, (Cl-C~)-alkylcarbamoyl, di~(Cl-C8)-alkyl-carbamoyl, N-(C3-C8)-cycloalkylcarbamoyl, (C1-C6)-alko~y-carbonyl, ( C6-cl2 ~ aryloxycarbonyl, ( C7-cll ) -aralkyloxycar-bonyl, in particular benzyloxycarbonyl, (C6-C12)-arylcar-bonyl, (C7-C11)-aralkylcarbonyl, (C1-C6)-alkyl, (C1-C6)-alkoxy-(C1-C6)-alkyl, carbamoyl-(Cl-C6)-alkyl esters, (C1-C10)-acyloxy-(Cl-C6)-alkyl, preferably (Cl-C10)-alkan-oyloxy-( Cl-C6 ) -alkyl, ben~yloxy-( Cl-C6 ) -alkyl, benzyloxy-carbonyloxy-(Cl-C6)~alkyl, (C1-C6)-alkoxycarbonyloxy-(Cl-C6)-alkyl, amino acid esters and tetrahydropyranyl.
Preferred compounds of the formula I are those in which Rl and R3 or ~4 are -C(O)-X-R6, in which X is -N(R7)~.
Compounds of the formula I which are furthermore pre-ferred are those in which R6 is hydrogen or methyl and R7 has the abovementioned meaning, 5 R~ and R7 are.hydrogen and/or methyl, if at least one group R1, R3 or R4 is a radical -C(o)-N(R7) R6, in which R5 and/or R7 have the abovementioned meaning.
If R5 or R7 is not hydrogen or methyl according to the above preferred embodiment, the following compounds are preferred, in which the radicals 2,)(~5~1 - 18 ~
~ are a branched or unbranched (cl-cl~)-alkyl radical, which is unsubstituted or mono- or polysubstituted by halogen, in particular fluorine, chlorinel bromine, hydroxyl, cyano, carboxyl, (Cl-C4)-alkoxy, (cl-c4~-alk carboxyl, (C1-C~)-alkoxycarbonyloxy, (Cl-c8)-alX
(Cl-C8)-alkoxycarbonyloxy, (C6-Cl2)-aryloxycarbonyloxy, (C7-Cl1)-aralkyloxycarbonyloxy, (C7-C~ aralkylcarbonyloxy, ( C7 -Cll ) -arylcarbonyloxy, (C3-C8)-cycloalkylcarbonyloxy, (C1-C12)-alkoxy-(C1-C12)-alkoxy, carbamoyloxy, N-(C1-C8)-alkylcarbamoyloxy, N,N-di-(Cl-C8)-alkylcarbamoyl, N-( C3 -C 8 ~ -CyC loalkylcarbamoyll N-( C7~C 11 )-aralkylcarbamoyloxy or N-~C6~C12)-arylcarbamoyloxy, in wh.ich the aryl and aralkyl radicals present in the above substituents can also be heterocyclic in nature, and/or, as is also the case for alkyl, are substituted by 1 or 2 identical or different substituents from the series comprising halo-gen, trifluoromethyl, hydroxyl, (C1-C3)-alkyl, (C1--C3)-hydroxyalkyl, (C1-C9)-alkoxy, -O [CH2-]xcfH(2f~l-B)F8l -OCF2Cl~
-O-CF2-CHFC1, (C1-C3)-alkoxycarbonyl, carhamoyl, (C1-C5)-alkylcarbonyloxy, (C3-C8)~cycloalkyl, phenyl, benzyl, phenoxy, benÆyloxy, or by an unsubstituted or substituted (C6-C12)-aryl radical or heteroaryl radical, which carries 1 or 2 identical or different substituents from the series comprising halo-gen, nitro, cy~no, carboxyl, hydroxyl, trifluoromet:hyl,(Cl-C3)-hydroxyalkyl, (Cl-C3)-alkoxycarbonyl, carbamoyl, NR'R", N-~Cl-C4) alkylcarbamoyl, N,N-di-(Cl-C4)-alkylcar-bamoyl, (Cl-C8)-alkoxy-(Cl-C8) alkyl, (Cl-C3)-alkylcarbon-yloxy, aminoalkyl and N-(C1-C4)-alkylamino-~C1-C6) alkyl, in which R~ and R~ are identical or differen~ and are hydrogen, (C6-Cl2)-aryl or (C1-C4)-alkyl, or by an unsubstituted or substituted (C5-C10)-aryloxy radical or (C7-C11)-aralkyloxy radical, which carries 1 or 2 identi.cal or different substituents from the series comprising hydroxyl, halogen, trifluoromethyl, - 19 ~ 5~
( C l-C3 ) -alkyl, ~Cl-C3 )-hydroxyalkyl, (Cl-C3)-alkoxy, (Cl-C3)-alkylmercapto, (Cl-C3)-alkylsulfinyl, ( alkylsulfonyl, ~C1-C3)-alkylcarbonyl, (C1-C3)-alkoxycar-bonyl,carbamoyl,N-(C1-C4)-alkylcarbamoyl,N,N~di-tCl-C4)-alkylcarbamoyl/ (Cl-C3)-alkylcarhonyloxy and NR'R", in which R' and R~ are identical or different and are hydrogen, (C6-ClO)-aryl or (Cl-C,,)-alkyl~ or by a radical of the formula II
o Ra (II) in which R8 iS an amino acid bonded via its ~cyl radical, or is a derivative thereof, B denote a (C~-Cl2)-aryl or (c7-cll)-aralkyl radical~
preferahly phenyl~ benzyl or phene~hyl, which are unsub-stituted or monosubstitu~ed by halogen, cyano, carboxyl,hydroxyl, ~Cl-C8)-alkyl, (Cl-C8)-alkoxy, (C1-C8)-alkylcar-bonyl, (Cl-C4)-alkylcarbonyloxy, (Cl-C4)-alkoxycarbonyl, (Cl-C4)-hydroxyalkyl, amino, (Cl-C5~-alkylamino, di-1Cl-Cs)-alkylamino, (Cl-C5)-alkanoylamino, carbamoyl, N-(Cl-C4)-alkylcarbamoyl, N,N-di-(Cl-C4)-alkylcarbamoyl, carbamoyl, N-(Cl-C4)-alkylcarbamoyloxy or N,N-di-(Cl-C4)-alkylcarbamoyloxy or C are an unsubstituted (C1-C6)-alkoxy radical, (C3-C8)-cycloalkoxy radical, (C6-Cl2)-aryloxy radical or (C7-Cll~-aralkyloxy radical.
Particularly preferred compounds of the formula I are those in which R6 and R7, if these are not hydrogen or methyl, as described above, are A an unbranched (Cl-Cl2)-alkyl radical, which is unsub-stituted or monosubstituted by 2f~
hydroxyl, halogen, (C1-C8)-alkoxy r (C1-C~)-alkoxycarbonyl, (Cl-C8)-alkoxycarbonyloxy, (C~-C8)-alkoacy-(Cl-C8)-alkoxy-carbonyloxy, (C6-C12)-aryloxycarbonyloxy, (C7-C~ aralkyl-oxycarbonyloxy, (C7-Cll)-aralkylcarbonyloxy, (C6-cl2)-S arylcarbonyloxy, (C3-C8)-cycloalkylcarbonyloxy, (Cl-C,2)-alkoxy-(Cl-Cl2~-alkos~y, (Cl-Cl2)-alkoxy-amino, (Cl-Cl2~-alkoxy-N-(Cl-C6)-alkylamino, (Cl-Cl2) alkoxy-N,N-(Cl-C6~-dialkyl~mino, N,N-di-(C1-C8)-alkylcarbamoyl, N-( C3-C~ ) -cycloalkylcarbamoyl, N-(C7-Cll)-aralkylcarbonyloxy, N-10 (C8-Cl2)-arylcarbanoyloxy, (Cl-C5)-allcanoylamino, (C3-C6)-cycloalkanoylamino,(C6-C12)-aroylaminoor(C7-Cll)-aralkan-oylamino, in which alkyl, aryl, aryloxy, aralkyl or aralkyloxy in turn are substituted by hydroxyl, halogen, in particular fluorine, (Cl-C3)-alkyl or (Cl-C3)-al~oxy, or by a phenyl radical which is unsukstituted or monosubstitut-ed by a hydroxyl group, ~ phenoxy or benæyloxy radical which is unsubstituted or subskitu~ed by hydroxyl, halogen or (Cl-C4)-alkoxy/ or by a radical o:E the formula II
o Ra (II) in which Ra is an amino acid bonded via its acyl radical, or its derivative subs~ituted on the ~mino group, or B are a (C6-Cl2)-aryl or ~C7-C11)-aralkyl radical, preferably phenyl~ benzyl or phenethyl, which is unsub-stituted or monosubstituted by hydroxyl.
In respect of the substituents R2, Rs and R4 or R3, if R3 or R4 is not already defined as above, compounds in which not more than two of the three radicals are pre~erably other than hydrogen, particularly preferably not more than one of the radicals is other than hydrogen, are preferred.
2 1 f d ~ ~? ~
-Compounds which are furthermore preferred are those in which, independently of one another, R2, Rs and R4 or R3 are other than hydrogen if these are directly adjacent to not more than one other substi~.u4nt R1 and R3 or R4.
S R2, R5 and R4 or R3, lf R4 and R3 are not already defined above and are not to be hydrogen, are preferably D halogen, in particular fluorine, chlorine or brom-ine, cyano, nitro, trifluoromethyl, tC1-C12)-alkyl, --[CH~-]xC~H(2ft1-8)Fg~ -OCF2Cl, -O-CF2-CHFCl, (Cl-C8)-alkyl-carbonyl, carbamoyl, N-(Cl-C4)-alkylcarbamoyl, N,N-dl-(Cl-c4?-alkylcarbamoyl~( C3-CB ) -cycloalkyl~(C1-C12)-alkoxy-carbonyl, ~Cl-Cl2)-alkylcarbonyloxy, amino, N-(C1-Clo)-alkylamino, di-N,N-(C1-C10)-alkylamino or NIN ( C3-~C~ ) -alkanediylamino, such as, for example/ pyrrolidino, piperidino or their heterocyclic derivatives morpholino and thiomorpholino, N-(C6-Cl2)-arylamino, N-(C6-Cl2)~-aryl-N-(C1-C8)-alkylamino, N-(C7-C11) aralkylamino; N-(C7-C11)-aralkyl-N-~Cl-C10)-alkylamino, (C6-Cl2~-arylcarbonylamino, (C7-Cll)-aralkylcarbonylamino, (Cl-C6)-alkoxycarbonyloxy, (C6-C12)-aryloxycarbonyloxy, (C7-Cl1)-aralkylcarbonyloxy, (C6-Cl2)-arylcarbonyloxy, (C3-C8)-alkenylcarbonyloxy, (C3-Ca)-cycloalkylcarbonyloxy, (Cl-Cl2)-alkoxy-(cl~cl2) alkoxy, (Cl-Cl2)-alkoxy-amino, (C1-Cl2)-alkoxy-N-(C1-C6) alkylamino, ( Cl-Cl2 ) -alkoxy-N,N-( Cl-C6 ) -dialkylamino, carbamoyloxy, N-(Cl-C6)-alkylcarbamoyloxy, N,N-di-(Cl-Ca)-alkylcarbamoyloxy, N-(C3-C8~-cycloalkylcarbamoyloxy, NR'R", (Cl-C8)-alkylmercapto, (Cl-C6)-alkylsulfinyl, (C1-C8)-alkylsulfonyl, (C1-C8~-alkylcarbonyl or (C3-C8)-cycloalkylcarbvnyl, in which the aryl and aralkyl radi-cals present in the above substituents can also be heterocyclic in nature and/or, as is also the case for alkyl, are substituted by 1, 2 or 3 identical or dif-ferent substituents from the series comprising halogen, trifluoromethyl, (Cl-C6)-alkyl, hydroxyl, (Cl-C6)-hydro~y-alkyl, (C1-C6)-alkoxy, -o-[cH2-]xcfH(2f~l-6)FBl (C3_CB)_CYC1O_ alkyl, phenyl, benzyl, phenoxy, benzyloxy, NR'R", r~ S ~9 ~ ~
phenylmercapto, phenylsulfonyl, phenylsulfinyl, sul-famoyl, N-(Cl-C4)-alkylsulfamoyl or N,N-di-(C~-C4)-alkylsulfamoyl, or E an alkyl or alkenyl radical having up to 5 carbon atoms, which is optionally substituted by l, 2 or 3 identical or different substi.~uents from the series comprising hydroxyl, halogen, cyano, nitro, trifluoro-methyl, (cl-c6)-hydroxyal]cyl~ (cl-c6)-alkoxy~
10 ,[cH2-]xc~H(2f~l-8~F8r -OCF2-CHFCl, (C~-C6)--alkylcar}:)onyl, (Cl-C6)-alkoxycarbonyl, carbamoyl, N-(C1~C4)-alkylcar-bamoyl, N,N-di-(C1-C~)-alkylcarbamoyl, (Cl-C6)-zlkylcar-bonyloxy, (C3-C8)-cycloalkyl, carboxyl, phenyl, benzyl, phenoxy, benzyloxy, amino, N~(C1-C6)-alkylamino, di-N,N-(C1-C6)-alkylamino or N,N-(C3-C8)-alkanediylamino, such as, for example, pyrrolidino or piperidino, N-(C6-C12)-aryl-amino, N-(C6-C1z)-aryl-:N-(Cl-C6~-alkylamino, N-(C7-~
aralkylamino, N~( C7-C~ )-aralkyl-N-(Cl-C10)-alkylamino, (C~-C6)-alkanoylamino, (C1-C8)-alkoxy-(C1-C6)-alkanoylamino, (C6-C12)-arylcarbonylamino and (C7-C1~)-aralkylcarbonyl-amino, or by an unsubstituted or substituted (C6-C~z)-a.ryl radical, ( C7-C~ ) -aralkyl radical or heteroaryl radical, which ~5 carries 1, 2 or 3 identical or different substituents from the series comprising hydroxyl, halogen, cyano, nitro, trifluoromethyl, (C1-C6)-hydro~yalkyl, (C~-C6)-alkoxy, (cl-c6)-alkoxy~ [cH2-]xcfHt2~+l-8)F8~ (C1-C6) alky bonyl, (C~-C6)-alkoxycarbonyl, carbamoyl, N-( C~-C4 )-alkyl-carbamoyl, N,N-di-(Cl-C4)-alkylcarbamoyl, (Cl-C6)-alky.lcar-bonyloxy, (C3-C8)-cycloalkyl, carboxyl, phenyl, benzyl, phenoxy, benzyloxy, amino, N-(C1-C6)-alkylamino, di N,N-(Cl-C6)-alkylamino or N,N-(C3-C8)-alXanediylamino, such as, for example, pyrrolidino or piperidino, N-(C6~C12)-aryl-35 amino, N-(C6-C12)-aryl-N-(C1-C6)-alkylamino, N-~C7-C11)-~ 3 aralkylamino, N-~C7-C~ aralXyl-N-~C1-C10)-alkylamino, (Cl-C6)-alkanoylamino, (c3-c3)-cycloalkanoylamino~ (Cl-C6)-hydroxyalXanoylamino, (Cl-C6)-alko~y-(Cl C~)-alkanoylamino, (Cg-Cl2)-arylcarbonylamino and (C7-C11)-aralkylcarbonyl-amino, or F an unsubstituted or substituted (C6-Cl2~-aryl radi-cal, (C7-C1l)-aralkyl radical or het~roaryl radical, in which the aryl and heteroaryl radical mentioned is, in particular, phenyl, naphthyl, thienyl, furyl, pyrrolyl or pyridine, and which furthermore carries 1, 2 or 3 identi-cal or differsnt substituents from the series comprising hydroxyl, halogen, cyano, nitro, (Cl-C6)-alkyl, (Cl-C6)-alkoxy, carboxyl, trifluoromethyl, (C1-C6)-hydroxyalkyl, --~CH2-]xCfH~2~+1-g)F6~ (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxy-carbonyl, carbamoyl, N-(C}-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarhamoyl, (C1-Cg)-alkylcarbonyloxy, (C3-C~)~
cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, amino, N-(C1-C10)-alkylamino, di-N,N-(C1-C10)-alkylamino or N,N-(C3-C3)-alkanediylamino, such as, for example, pyrrolidino or piperidino, (C1-C10)-alkanoylamino, (C6~C1z)-aryl-carbonylamino and (C7-Cll)-aralkylcarbonylamino, or G a substituent of the formula -OR9 or -N(R9)2, in which R9 is hydrogen, alkyl or alkenyl having in each case up to 6 carbon atoms, a (C6-C12)-aryl radical or a heteroaryl radical, which carries 1, 2 or 3 identical or different substituents from the series comprising halogen, hydrox-yl, cyano, nitro, carboxyl, trifluoromethyl, (C1-C6)-alkyl, (C1-C6)-hydroxyalkyl, (Cl-C6)-alkoxy, --[CH2-]xCfH(2f+1-g)F6/ (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxy-carbonyl, carbamoyl, N-(Cl-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (C1-C6) alkylcarbonyloxy, (C3-C6)-5 1~
cycloalkyl, phenyl, ben~yl, phenoxy, benzyloxy, amino, N-(Cl-C~ alkylamino, di-N,N-(Cl-C10)-alkylamino or N,N-(C3-C8)~alkanediylamino r such as, ~or example, pyrrolidino or piperidino, (Cl-C10)-alkanoylamino, (C6-Cl2~-aryl-carbonylamino and (C7-C11)-aralkylcar~onylamino.
Of these, compounds of the formula I which are preferred are those in which R2, R5 and R4 or R3, if R4 and R3 are not already defined above and are not to be hydrogen, are D halogen, in particular flllorine, chlorine or brom-ine, trifluoromethyl, (C1-C12)-alkyl, -O-[CH2-3xC~H~2~+l-~)F8 -OCF2Cl, -O-CF2-CHFCl, (Cl-C8)-alkylcarbonyl, ~ C3 C8)~
cycloalkyl, amino, N-(Cl-C1O)-alkylamino, di-N,N-(C1-C,o)-alkylamino,N-~C6-Cl2)-arylamino,N-(C6-Cl2)-aryl-N-(Cl~Ca)~
alkylamino, N-( C7-cll)-aralkylamino or N-( C7-cll )-aralkyl-N-(C~-C1O)~alkylamino, in which the aryl and aralkyl radicals present in the above substituents can also be heterocyclic in nature and/or, as is also the case -for alkyl, can be substituted by 1 or 2 identical or dif-ferent substituents from the series comprising halogen,trifluoromethyl, (C1-C6)-alkyl, hydroxyll (C1-C6)-hydroxy-alkyl, (C1-C6)-alkoxy, -O [CH2-~XC~H(2~18,F~ and NR -R, or E an alkyl or alkenyl radical having up to 5 carbon atoms, which is optionally substituted by 1 or 2 identi-cal or different substituents from the series comprisinghydroxyl, halogen, trifluoromethyl, tCl-C6)-hydroxyalkyl, (Cl-C6)-alkoxy, (C1-C6)-alkylcarbonyl, (Cl-C6)-alkoxycar-bonyl, ~C1-C6)-alkylcarbonyloxy, phenyl~ benzyl, phenoxy, benzyloxy, amino, N-~Cl C5)-alkylamino and di-N,N-(C~-C6)-alkylamino, or by an unsubstituted or substituted (C6-C12)-aryl radical, (C7-Cll)-aralkyl radical or heteroa.ryl radical, which carries 1 or 2 identical or different substituents from _ ~5 _ ~~
the series comprising hydroxyl, halogen, trifluoromethyl, (Cl-C6)-alkyl, (Cl-C6)-hydroxyalkyl, (Cl-C6)-alkoxy, --[CH2-]xCfH~2f~l-8)F~ (C1-C6)-alkylcarbonyl, (Cl-C6)-alkoxy-carbonyl, phenyl, benzyl, phenoxyl ben~yloxy, amino, N-(Cl-C6)-alkylamino, di-N,N-(C1 C6)-alkyl~lino or N,N-(C3-C~)-alkanediylamino, such as, for example, pyrrolidino or piperidi.no, or F an unsubstituted or substituted ~C6-Cl2)-aryl radi-cal, ( C7 C11)-aralkyl radical or hetero ryl radical, in which the aryl and heteroaryl radical mentioned is, in par~.icular, phenylr naphthyl, th.ienyl, furyl~ pyrrolyl or pyridine, and which fur~hermore carries 1, 2 or 3 identi-cal or different substituents from the series comprising hydroxyl, halogen, (Cl C6)-alkyl, (C1-C6~-alkoxy, carbo~yl, trifluoromethyl, (Cl -C8 )-hydroxyalkyl, --[CH2 ]XCfH(2f+1~,Fg, (Cl-C63-alkylcarbonyl, (Cl-C6)-alkoxycarbonyl, amino, N-(C~-C10)-alkylamino and di-N,N-(Cl-C10)-alkylamino, or G a substituent of the formula -oR9 or -N(R~)2, in which R9 is hydrogen or alkyl having in each case up ~o 6 carbon atoms, a (C6-Cl2)-aryl radical or a heteroaryl radical, which contains 1 or 2 identical or different substituents from the series comprising halogen, tri-fluoromethyl, (Cl-C6)-alkyl, (Cl-C6)-alkoxy, -O-~CH2-]xCfH(2f+~8~F~, amino, N-(C,-C10)-alkylamino and di-N,N-(Cl-C10)-alkylamino.
Particularly preferred compounds of the formula I are those in which R2, R5 and R4 or R3, if R4 and R3 are not already defined above and are not to be hydrogen, are D halogen~ in particular fluorine, chlorine or brom-ine, trifluoromethyl, (Cl-Cl2)-alkyl/ --[CH2-]xCfH(2f~l-g)Fg~
-- 2 6 ~ h ~ ) r3 9 ~
-OCF2Cl, -O CF2~CHFCl, (Cl-C~)-alkylcarbonyl, (C3-C8)-cycloalkyl, amino, N-(Cl C10)-alkylamino, di-N,N-(Cl-Clo)-alkylamino~N-(c6-cl2)-arylamino~N-(c6-cl2)~aryl-N-(cl-c~)-alkylamino, N-(C7-Cl,)-aralkylamino or N (C7--Cl1)-aralkyl-N-(C1-C10)-alkylamino, or:
E an alkyl or alkenyl radical having up to 5 carbon atoms, which is optionally substituted by 1 or 2 identi-cal or different substituents from the series comprising hydroxyl, halogen, trifluoromethyl, (Cl-C6)-alkoxy, 10 (Cl-C6)-alkylcarbonyl, (Cl-C6)-alkoxycarbonyl, (Cl-C6)-alkylcarbonyloxy, phenyl, phenoxy, benzyloxy, amino, N-(Cl-C6)-alkylamino and di-N,N-(Cl-Cs)-alkylamino/ or by an unsubstituted or &ubstituted (C~-C~-aryl radical, (C7-Cll)-aralXyl radical or heteroaryl radical, which carries 1 or 2 identical or different substituents from the series compxising hydroxyl, halogen, trifluoromethyl, (Cl-C6)-alkyl, (Cl-C6)-hydroxyalkyl, (Cl-C6)-alkoxy, (Cl-C6)-alkylcarbonyl and (Cl-C6)-alkoxycarbonyl, or F an unsubstituted ox substituted (C6-C12~-aryl radical or (C7-C11)-aralkyl radical, in which the aryl radical mentioned is, in particular, phenyl or naphthyl and which furthermore carries 1 or 2 identical or different substi-tuents from the series comprising hydroxyl, halogen, (Cl-C6)-alkyl, (Cl-C6)-alkoxy, carboxyl, trifluoromethyl, (C,-C6)-hydroxyalkyl, (C1~C6)-alkylcarbonyl and (C1-C6)-alkoxycarbonyl, or G a substituent of the formula -O~9 or -N(R9)2, in which R9 is hydrogen ox alk~l having in each case up to 6 carbon atoms, a (C6-C12)-aryl radical or a heteroaryl radical, which contains 1 or 2 identical or different substituents from the series comprising halogen, tri-fluoromethyl, (C1-C6)-alkyl, (Cl-C6)-alkoxy, amino, N-~Cl-C10)-alkylamino and di-N,N-(Cl-C10)-alkylamino.
_ ~7 ,~ ,3~
The inven-tion furthermore relates to the use of compounds of the :Eormula ~ and physiologically tolerated salts thereof for the preparation of a proline hydroxylasa-in-hibiting and lysine hydroxylase-inhibiting medicament.
Final.ly, the invention relates to the compounds of the formula I for use as medicaments.
In particular, the invention relates to the compounds of the formula I for use as fibrosuppressarlts and Lmmunosup-pressants and for inhibition of proline hydroxylase and lysine hydroxylase, and for influencing the metabolism of collagen and collagen-like substances and the biosyn-thesis of Clq.
The invention furthermore relates to a process for the preparation of compounds of the formula I.
The following Equation I applies to the preparation of 2,4-disubstituted pyridine N-oxide derivatives. However, in pri.nciple, it can also be used to illustrate the preparation of 2,5-disubstituted pyridine N-o~ide deriva-tives, and for mixed derivatives (esters/amides) ~ 2û ~ 5 ~1 Equat ion o Co~H C_o-R6 XlxEsterif ication\~ o R S C 9 2 H R ~ C - O - R V
V
Aminolysi~ /
/ Ox.idation ,~ C- O- R 6 C-N ( R7 ) R6 R ~ R 2 ~ N ( ~ 7 ) R 6 R S ~ C - O - R
RS li O
Oxidation ~
/ Aminolysis C-N ( R7 ) R6 R 1~ R 2 5/~N~\ C - N ( R 7 ) R 6 O
- 29 _ 2~ 5~
Substituted pyridine-2,4- and -2,5-dicarboxylic acids of the formula IV are obtained, for example, by oxidation from the corresponding dimethylpyridines VII or VIII or the corresponding methyl-2-hydroxymethylpyridines IX. The preparation of the dimethylpyridines VII and VIII in turn is described in R.J. Ife, J. Med. Chem. 32, 1970-1977 (1989) and the literature cited therein. The following Equation II gives an indication of this. On the basis of this equation, the substituted pyridine derivatives according to the invention are accessible to the expert.
A particular example is 2,5-dimethyl-3 r 4-dichloro-pyridine.
Equation II
~3 ;, -----------~ ',s~ ~ ? ` Qu~
o C L, 1~10 ~ /
O )~
hc~c~ C~3~
~3~C lh 1~ h2 olt X ~
- 30 - 2 ~5 ~ 5l~
Compounds of the formula VII are converted into compounds of the formula VIII with alcohols ROH and a base in dimethylfo.rmamide or dimethylacetamide at ~0 to 150~C.
Compounds of the type IX are prepared by reactions of VIII with acetic anhydride/ace-tic acid at 120C and subsequent reaction with NaOH/methanol at 25~C. ~he oxidation to give compound X with sodium permanganate in water at 70 to 100C can be carried out starting from VIII or IX. The dicarboxylic acids X can be either esterified and oxidized to give the N-oxides I according to the invention in accordance with Equation I, or - also in accordance with Equation I - converted into amides and oxidized.
The preparation of the compounds of type IV is described in the following literature references. This preparation is the introduction of the substituents R2, R4 and R5 into the ~,4- or 2,5~pyri.dine-dicarboxylic acid.
Starting with the compound of the formula IV, the amide VI can be prepared either directly from IV or via the ester V.
The reaction of V or VI to give the amides I or esters I
is carried out under conditions analogous to those in P 40 20 570.3-For this, an oxidizing agent, such as, for example, hydrogen peroxide or peracids, such as peracetic acid,perfluoroacetic acid, perbenzoic acid or metachloroper-benzoic acid, in solvents, such as chlorinated hydrocar-bons, such as, for example, methylene chloride, chloro-form, tri- or tetrachloroethylene, benzene or toluene, is added to the pyridine compounds to be oxidized, which can likewise be dissolved in the abovementioned solvents, and the mixture is stirred at a temperature of between -30 and +40C, preferably 0 and 25C, ~or between 30 minutes and 3 days~ The end of the reaction can be determined, _ 31 ~ 5~
for example, by means of thin layer chromatography.
Preferably, the compounds according co the invention can be prepared by employing the pyridine derivative and the oxidi~ing agent in equimolar ~nounts or with up to an approximately 5-fold excess o oxidiæing agen-t~
If appropriate, an excess of peracid can also be elimin-ated, for example, by passing gaseous ammonia into the reaction solution and separating off the resulting precipitate from the reaction solution by fil-tration.
If appropriate, the product can be worked up, for ex-ample, by extraction or by chromato~raphy, for example over silica gel. The product isolated can be recrystallized.
General instructions for this oxidation method are also described, for exampler in "E. Lingsberg, Pyridine and its Derivatives, Interscience Publishers, New York, 1961, Part 2, 93".
The oxidation with hydrogen peroxide is described, for example, in "E. Ochiai, J. Org. Chem. lB, 534 (1953)".
The conditions for an aminolysis of the ester I to give the amide I correspond to those used for the reaction of V to give VI.
The preparation and the aminolysis are otherwise reaction types which are known as such: However, compounds of the formula I prepared by the above reactions are novel.
The process conditions can be seen in detail in German Patent Applications P 38 26 471.4, 38 23 140.6, 39 24 093.2 and 40 01 002.3, and DE-A-37 03 959, 37 03 962 and 37 03 963.
32 ~ ) g~j3~
The compounds of the formula I according to the invention have useful pharmacological proper-ties and exhibit, in particular, activity as inhibitors of proline hydroxylase and lysine hydroxylase, and as a fibrosuppressant, immunosuppressant and antiatherosclerotic.
The antifibrotic action can be determined using the model of liver fibrosis induced by carbon tetrachloride. For this, rats are treated twice ~eekly with CCl,, (1 mlJkg) -dissolved in olive oil. The tes-t substance is adminis-tered daily, if appropriate even twice daily, perorallyor in~raperitoneally ~ dissolved in a sui~able tolerated solvent. The extent of the liver fibro~is is determined hi~tologically, and the amount of collagen in the liver is analysed by hydroxyproline determination - as de-scribed by Kivirikko et al. (Anal. Biochem. 19, ~49 etseq. (1967)). The fibrogenesis activity can be determined by radioimmunological assay of collagen fragments and procollagen peptidas in the serum. The compounds accord-ing to the invention are active in a concentration o~
1 - 100 mg/kg in this model.
The fibrogenesis activity can be determined by radioim-munological assay of the N~terminal propeptide of col-lagen type III or of the N- and C-terminal crosslinking domains of collagen type IV (7s-collagen or type IV
collagen-NC1) in the serum.
For this purpose, the hydroxypr~line, procollagen III
peptide, 7s-collagen and type IV collagen-NC concentra-tions wers measured in th~ liver of a) untreated rats (control) 0 b) rats to which carbon tetrachloride had been adminis-tered (CCl4 control) c) rats to which first CCl4 and then a compound accord-ing to the invention had been administered (this test method is described by Rouiller, C., experi-mental toxic injury of the liver; in The Liver, C. Rouiller, Vol. 2, 5. 335-476, New York, Academic Press, 1964).
Another model for evaluation of the antibiotic action is that of bleomycin-induced pulmonary fibrosis as described by Kelley et al. (j. Lab. Clin. Med. 96, 954, (1980)).
The model of the cotton-wool swab granuloma as described by Meier et al., Experimentia 6, 469 (1950) can be used to evaluate the action of the compounds according to the invention on granulation tissue.
The compounds of the formula I can be used as medicaments in the form of pharmaceutical preparations which comprise them, if appropriate together with tolerated pharmaceuti-cal excipients. The compounds can be used as medicines, for example in the form of pharmaceutical preparations which comprise these compounds as a mixture with a pharmaceutical, organic or inorganic excipient which is suitable for enteral, percutaneous or parenteral adminis-tration, such as, for example, water, gum Arabic, gela-tin, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, petroleum jelly and the like.
For this purpose, they can be administered orally in doses of 0.1 - 25 mg/kg/day, preferably 1 - 5 mg/kg/day, or parenterally in doses of 0.01 - 5 mg/kg/day, preferab-ly 0.01 - 2.5 mg/kg/day, in particular 0.5 -1.0 mg/kg/day. In serious cases, the dosage can also be increased. However, lower doses are also sufficient in many cases. These data relate to an adult weighing about 75 kg.
The invention furthermore relates to the use of the compounds according to the invention in the preparation of medicaments employed for the treatment and prophylaxis of the abovementioned metabolic disturbances.
3~ 5 ~I S ~
The invention furthermore relates to medicaments which comprise one or more compounds of the formula I according to the invention and/or physiologically tolerated salts thereof.
The medicaments are prepared by processes which are known per se and familiar to the expert. As medicaments, the pharmacologically acti~e compounds according to the invention (= active compound) are employed either as such or, preferably, in combination with suitable pharma-ceutical auxiliaries or excipients, in the form otable~s, coated tablets, capsules, suppo~itories, emulsions, suspensions or solutions, the active compound content being up to about 95 %, advantageously between lO
and 75 ~.
Suitable auxiliaries or excipients for the desired medicament formulation are, for example, in addition to solvents, gel forming agents, suppository bases, tablet auxiliaries and other active compound exc:ipientsl also antioxiflants, dispersing agents, emulsifiers, foam suppressants, flavor correctants, preservatives, solu-bilizing agents or dyestuffs.
The following examples are intended to illustrate the invention.
Example 1 5-Bromo-pyridine-1-oxide-2,4-dicarboxylic acid bis-~3-methoxypropyl)amide]
a) 5~Bromo-2,4-dimethylpyridine 150 ml of 65 % strength oleum are added dropwise to 28.9 ml of 2,4-dimethylpyridine, while cooling with ice and stirring, such that the temperature does not rise above 35C. When the solution has become homogenized, _ 35 h a ~ ~ 9 ~ ~
6.42 ml of bromine are slowly added dropwise. The mixture is stirred at 80C for 3~ hours. After cooling, it is allowed to drip carefully onto 1 kg of ice, and the resulting mixture is neutralized with solid Na2CO3 and extracted 3 times with 300 ml of ether each time. ~he organic layer is separated off and dried over magnesium sulfate. After remo~al of the sol~en~ by distillation in vacuol 34.6 g of a pale yellow oil wh:ich comprises the isomers S-bromo-2,4-dimethylpyridine and 3-bromo-2,4-dimethylpyridine are obtained. The isomers are separatedby column chromatography on silicon dioxide gel to give 10 g of S-bromo-2,4-dimethylpyridine as a colorless liquid (13.0 g of 3-bromo-2,4-dimethylpyridine).
Yield: 22 %.
b) 5-Bromo-pyridine-2,4-dicarboxylic *cid 4 g of 5-bromo-2,4-dimethylpyridine from Example 1 are heated to 70-80C in 200 ml of water and 2.4 g o KOH.
Half of 12.74 g of potassium permanganate is then intro-duced in portions. The solution is heated to the boiling point and the remainder of the potassium permanganate is added. The mixture .i9 s~irred at 70-80nC for 20 hours and then filtered hot with suction, and the precipitate is washed 4 times with 50 ml portions of hot water. The combined filtrates are concentrated to 100 ml in vacuo.
The solution is brought to pH 1 with concentrated hydro-chloric acid and is left to stand at 0C for 20 hours.
The crystalline solid is filtered off with suction and dried in vacuo at 100C. The yield is 2.9 g.
Melting point 261-263C.
c) 5-Bromo-pyridine-2,4-dicarboxylic acid bis-~3-methoxypropyl)amide]
2.46 g (10 mmol) of 5-bromo-pyridine-2,4-dicarboxylic acid are suspended in 70 ml of toluene and 0.2 ml of dimethylformamide, and 1.45 ml (20 mmol~ of thionyl - 36 ~
chloride are added. The reaction mixture is heated at 110C for 5 hours, during which a clear solution forms.
The solution is then allowed to cool to 0Cr and ~
solution of 2.05 ml ~20 mmol) of 3-methoxypropylamine and 2.8 ml of -triethylamine in 10 ml of tolllen~ is added dropwi 5 e.
The mixture is left to stand at 20~C for 12 hours and concentrated in ~acuo/ water is addedl the mixture is extracted with methylene chloride, and the organic phase is dried and freed from the solvent to give the subst~nce as a colorless oil, yield 2.2 g.
Empirical formula: C15H2~BrN3O4 (388.26 MS: m/e = 389 (M + H+) d) The above compound is dissolvad in 80 ml of methylene chloride, and 5 mg of meta-chloro perbenzoic acid are added in portions at 10C. After 2 hours, a further 5 g of peracid are added, the mixture i5 heated at 42C for 3 hours, a further 5 g of peracid are added, and the mixture is heated at 42C for 5 hours.
Excess peracid and 3-chlorobenzoic acid are precipitated by passing in ammonia gas ~nd are filtered off with suction. The solution is concentrated and the residue is chromatographed o~er silica gel using ethyl acetate/meth-anol 10:1 The title compound is obtained as colorless crystals. Melting point 94~.
Empirical formula: Cl5H22BrN304 (404.26) MS: m/e = 405 (M + H+) Example 2 Pyridine-1-oxide-2,4-dicarboxylic acid dimethyl ester 7.0 g (35.~ mmol) of pyridine-2,4-dicarboxylic acid dimethyl ester are dissol~ed in 200 ml of methylene chloride, and 6.2 g (36 mmol) of 3-chloroperbenzoic acid are added at 10C. Aftex ~ hours, a further 6.~ g of peracid are added, the mixture is allowed to stand overnight, a further 3.1 g of peracid are added, and the mixtura is heated at 40C for 5 hours (thin layer chroma-tography control).
Excess peracid and 3-chlorobenzoic acid are precipita-ted by passing in ammonia gas 3 times, and are filtered off.
The solution i5 concentrated and the residue is crystall-ized from toluene, 4.5 g.
Melting point 132C; R~ (SiO2, ethyl acetate) = 0.~9 Example 3 Pyridine-l-oxide-2-carboxylic acid methyl ester-4-car-hoxylic acid (2-benzyloxyethyl)amide and pyr:idine-1-oxide-2-carboxylic acid t~-benzyloxyalkyl)amide-4-car-boxylic acid methyl ester 3.1 g (15 mmol) of the title compound from Example 2 are ~0 heated at 100C in 50 ml of N,N-dimethylacetamide with 22.8 g (150 mmol) of 2-benzyloxyethylamine (prepared from 2-aminoethanol, sodium and benzyl chloride) for 1 hour.
The mixture i~ allowed to cool and is concentrated, water is added, the mixture is extracted with methylene chlor-ide and concentrated and the oily residue ~4.8 g) iscrys-tallized with ethyl acetate.
Melting point 76-78C (colorless crystals) Empirical formula: C17H1~N205 (330) MS: m/e = 331 (M + H+) The corresponding diamide was to be obtained after 10 hours at 140C.
- 38 - 2 ~ ~ 9 Example 4 4-Methoxy-pyridine-1-oxide-2~5-dicarbo~ylicacidbis-[(2-hydroxyethyl)~nide]
a) 2-Hydroxymethyl 4-methoxy-5-methyl-pyridine 5.4 g (35 mmol) of 4-methoxy-2,5-dimethyl-pyridine N-oxida (melting point 102-104C, diisopropyl ether;
prepared from 2,5-dimethyl-pyridine N oxide and sodium methylate in methanol) are dissolved in 30 ml of glacial acetic acid, and 40 ml of acetic anhydride are added dropwise at 80C.
The mixture is heated at 115C for 90 minutes and cooled to 80C, 75 ml of methanol are added dropwise, the mixture is concentrated, the residue i5 taken up in methanol, 200 ml of 1.5 N methanolic sodium hydroxide lS solution are added dropwise, water is added, the mixture is extracted with methylene chloride, dried and concen-trated and the residue is crystalli~ed with cyclohexane, yield: 4.4 g; melting point 92-94C.
b) 4-Methoxy pyridine-2,5-dicarboxylic acid 2.3 g (15 mmol) of the compound from 4a) are suspended in a solution of 1 g of XOH in 75 ml of watex, and 7.2 g (45 mmol) of KMnO4 are added in por~ions at 70C. Ths mixture is left at 80C for a further hour, the magnesi~n dioxide which has been filtered off with suction is washed with water, and the filtrate i5 concentrated and brought to pH 1 with hydrochloric acid;
Yield: 1.45 g; rnelting point 231C (decomposition).
c) 4-Methoxy-pyridine-1-oxide-2/5-dicarboxylic acid dimethyl ester - 39 ~
1.4 ~ of th~ compound from 4b) are heated at the boiling point in 150 ml of methanol and 2 g of sulfuric acid (98 % streng-th) for 15 hours. The mixture is allowed to cool, saturated ammonium chloride solution is added, while cooling, and the mixture is extracted with methyl-ene chloride and concentrated to give, analogously to Example 2 by reaction of the crude product with 3 chloro-perben~oic acid, 0.8 g of 4-methoxy-pyridine-2,5-dicar-boxylic acid dimethyl ester N~oxide, melting point 134-136C.
d) The title compound is obtained ~rom the above compound of Example 4c) by reaction with exces~ 2-aminoethanol, colorless crystals, melting point 124-127C ~from ethyl acetate).
lS The following compounds were to be obtained analogously from the compound of Example 4c) by reaction with the corresponding amines:
4-methoxy-pyridine 2,5-dicarboxylicacidbis-[(2-methoxy-ethyl)amide] N-oxide 4-methoxy-pyridin~-2,5-dicarboxylicacidbis-[(3-hydroxy-propyl)amide~ N-oxide 4-methoxy-pyridine-2,5-dicarboxylicacidbis-[(3-methoxy-propyl)amide~ N-oxide 4-methoxy-pyridine-2,5-dicarboxylic acid bis-[(2-benzyloxyethyl)amide] N-oxide Example 5 Pyridine-l-oxide-2,4-dicarboxylic acid bis-N,N'-[~-(4-methylbenzoyloxy)ethyl]amide a) Pyridine-2,4-dicarboxylic acid bis-N,N'-[2-~4-methylbenzoyloxy)ethyl]amide -- 4 0 _ h ~
b) 0.2 g of 4-N,N-dimethylaminopyridine and 0.8 ml (6 ~mol~ of triethylamine are added to 0.7 g (2.5 mmol) of pyridine-2,4-dicarboxylic acid bis-N,N'-(3-hydroxy-ethyl)amide in 100 ml of methylene chloride, and 0.6 ml (5 mmol) of 4 methylbenzoyl chloride are then added dropwise. After 1 hour, the mixture is concentrated and ~he residue is then taken up in water. After 1 hour, the mixture is extracted by shaking twice with water and the organic phase is concentrated. The crude product is chromatographed over silica ~el using ethyl acetate.
Colorless crystalline powder: melting point 165-166C
Empirical formula: C27H27N3O6 (489) MS: m/e = 490 (M + H+).
b) 0.31 ml of 30 percent strength H2Oz is added dropwise to a solution of 0.25 g of the above compound in 5 ml of 96 percent strength formic acid, and the mixture is heated at 80C ~or 4 hours. It is then evaporated in vacuo and the crystalline residue is stirred with hot methanol and filtered off with suct~on. 0.18 g of pyrid-ine-2,4-dicarboxylic acid N,N'-bis-[2-(4-methylbenzoyl-oxy)ethyl]amide is obtained as a colorless crystalline powder, melting point 186-188C.
MS: m/e = 506 (M+ ~ H+).
Example 6 Pyridine-1-oxide-2,4-dicarboxylic acid N,N'-bis-[~2-benzoyloxyethyl)amideJ
a) Pyridine-2,4-dicarboxylic acid bis-N,N'-[(2-benzoyloxyethyl)amide]
Analogously to Example Sa) Colorless needles, melting point 139-140C
Empirical formula: C2sHZ3N3o6 (461) MS: m/e = 462 IM+ + H+).
- 41 ~
b) 0.31 ml of 30 percent strength H2O2 is added dropwise to a solution of 0.46 g of pyridine-2,4-dicarboxylic acid N,N~-bis-[(2-benzoyloxy)ethyl]amide (Example 6a)) in 5 ml of 96 percent strength formic acid, and the mixture is heated at B0C for 4 hours, while stirring. After addi-tion of a further 0.2 ml of H2O2, the mixture is stirred at this temperature for a further 2 hours and then evaporated in vacuo, and the residue is purified by chromatography over silica gel using ethyl acetate as the eluent. 0.37 g of pyridine-1-oxide-2,4-dicarboxylic acid N,N-bis-[(2-benzoyloxyethyl)amide] is obtained as color-less crystals, melting point 159-160C (methanol), MS: m/e - 478 (Nt ~ H~).
Claims (14)
1. A substituted pyridine N-oxide of the formula I
(I) in which R1 and R3 or R4 are -C(O)-X-R6, in which X is O or N(R7)- and R5 and R7 are identical or different, and A are a branched or unbranched, aliphatic or cycloali-phatic (C1-C12)-alkyl radical or (C1-C12)-alkenyl radi-cal or a (C1-C12)-alkynyl radical, which is unsubstituted or mono- or polysubstituted, preferably mono- or disubstituted, by halogen, in par-ticular fluorine, chlorine or bromine, hydroxyl, cyano, carboxyl, (C1-C8)-alkoxy, (C1-C8)-alkoxycarbonyl, (C1-C8)-alkoxycarbonyloxy, (C1-C6)-alkoxy-(C1-C8)-alkoxycarbonyl-oxy, (C6-C12)-aryloxycarbonyloxy, (C7-C11)-aralkyloxycar-bonyloxy, (C7-C11)-aralkylcarbonyloxy, cinnamoyl, cinna-moyloxy,(C6-C12)-arylcarbonyloxy,(C3-C8)-alkenylcarbonyl-oxy, (C3-C6)-alkynylcarbonyloxy, (C3-C8)-cycloalkylcarbon-yloxy, (C1-C12)-alkoxy-(C1-C12)-alkoxy, (C1-C12)-alkoxy-amino, (C1-C12)-alkoxy-N-(C1-C6)-alkylamino, (C1-C12)-alkoxy-N,N-(C1-C6)-dialkylamino, carbamoyloxy, N-(C1-C8)-alkylcarbamoyloxy, N,N-di-(C1-C8)-alkylcarbamoyl, N-(C3-C8)-cycloalkylcarbamoyl, N-(C6-C12)-arylamino, N-(C7-C11)-aralkylamino, N-alkyl-aralkylamino, N-alkyl-arylamino, (C3-C8)-cycloalkanoylamino, (C1-C8)-alkanoyl-amino, (C6-C12)-aroylamino, (C7-C11)-aralkanoylamino, (C1-C8)-alkanoyl-(C1-C8)-alkylamino,(C3-C8)-cycloalkanoyl-(C1-C8)-alkylamino, (C6-C12)-aroyl-(C1-C8)-alkylamino, (C7-C11)-aralkanoyl-(C1-C8)-alkylamino, (C1-C8)-alkylmercap-to, (C1-C8)-alkylsulfinyl, (C1-C8)-alkylsulfonyl, (C1-C8)-alkylcarbonyl, (C3-C8)-cycloalkylcarbonyl, nitro, tri-fluoromethyl, phenylmercapto, phenylsulfonyl, phenylsul-finyl, sulfamoyl, N-(C1-C6)-alkylsulfamoyl, N,N-di-(C1-C6)-alkylsulfamoyl, (C1-C8)-alkyl-sulfonamido or arylsulfon-amido, in which the aryl and aralkyl radicals present in the above substituents can also be heterocyclic in nature and/or, as is also the case for alkyl, are substituted by 1, 2, 3, 4 or 5 identical or different substituents from the series comprising halogen, cyano, nitro, trifluoro-methyl, (C1-C5)-alkyl, hydroxy, (C1-C6)-hydroxyalkyl, (C1-C6)-alkoxy, -O-[CH2-]xCfH(2f+1-g)Fg, -OCF2Cl, -O-CF2-CHFCl, trifluoromethyl, (C1-C6)-alkylmercapto, (C1-C6)-alkylsul-finyl, (C1-C6)-alkylsulfonyl, (C1-C6)-alkylcarbonyl-(C1-C6)-alkoxycarbonyl, carbamoyl, N-(C1-C4)-alkylcar-bamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (C1-C6)-alkylcar-bonyloxy, (C3-C8)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, NR'-R", phenylmercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C4)-alkylsulfamoyl and N,N-di-(C1-C4)-alkylsulfamoyl, in particular by up to 3 of the abovementioned identical or different substituents, and a CH2 group of the alkyl chain is optionally replaced by O, S, SO, SO2 or NR', or by an unsubstituted or substituted (C6-C12)-aryl radical or heteroaryl radical which carries 1, 2, 3, 4 or 5 identi-cal or different substituents from the series comprising halogen, nitro, cyano, carboxyl, hydroxyl, trifluorometh-yl, (C1-C6)-hydroxyalkyl, -O-[CH2]xCfH(2f+1-g)Fg, -OCF2Cl, -OCF2-CHFCl, (C1-C6)-alkylmercapto, (C1-C6)-alkylsulfinyl, (C1-C6)-alkylsulfonyl, (C1-C8)-alkoxy, (C1-C8)-alkyl, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxycarbonyl, carbamoyl, N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (C1-C6)-alkylcarbonyloxy, (C3-C8)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, NR'-R", phenylmercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C4)-alkylsulfamoyl, N,N-di-(C1-C4)-alkylsulfamoyl, (C1-C6)-alkoxycarbonyloxy, (C1-C8)-alkoxy-(C1-C8)-alkoxy-carbonyloxy, (C6-C12)-aryloxycarbonyloxy, (C7-C11)-aralkyl-oxycarbonyloxy, (C7-C11)-aralkylcarbonyloxy, cinnamoyl, cinnamoyloxy, (C6-Cl2)-arylcarbonyloxy,(C3-C8)-alkenylcar-bonyloxy, (C3-C8)-alkynylcarbonyloxy, (C3-C8)-cycloalkyl-carbonyloxy, (C1-C12)-alkoxy-(C1-C12)-alkoxy, (C1-C12)-alkoxy-amino, (C1-C12)-alkoxy-N-(C1-C6)-alkylamino, (C1-C12)-alkoxy-N,N-(C1-C6)-dialkylamino, carbamoyloxy, N-(C1-C8)-alkylcarbamoyloxy, N,N-di-(C1-C8)-alkylcarbamoyl, N-(C3-C8)-cycloalkylcarbamoyl, N-(C6-C12)-arylamino, N-(C7-C11)-aralkylamino, N-alkyl-aralkylamino, N-alkyl-arylamino, (C3-C8)-cycloalkanoylamino, (C1-C8)-alkanoyl-amino, (C6-C12)-aroylamino, (C7-C11)-aralkanoylamino, (C1-C8)-alkanoyl-(C1-C8)-alkylamino,(C3-C8)-cycloalkanoyl-(C1-C8)-alkylamino, (C6-Cl2)-aroyl-(C1-C8)-alkylamino, (C7-C11)-aralkanoyl-(C1-C8)-alkylamino, (C1-C8)-alkylmer-capto, (C1-C8)-alkylsulfinyl, (C1-C8) alkylsulfonyl, (C1-C8)-alkylcarbonyl, (C3-C8)-cycloalkylcarbonyl, nitro, trifluoromethyl, phenylmercapto, phenylsulfonyl, phenyl-sulfinyl, sulfamoyl, N-(C1-C6)-alkylsulfamoyl, N,N-di-(C1-C6)-alkylsulfamoyl, (C1-C8)-alkyl-sulfonamido and arylsulfonamido, in which the aryl and aralkyl radicals present in the above substituents can also be heterocyc-lic in nature and/or, as is also the case for alkyl, can be substituted by 1,2,3,4 or 5 identical or different substituents from the series comprising halogen, cyano, nitro, trifluoromethyl, (C1-C6)-alkyl, hydroxyl, (C1-C6)-hydroxyalkyl and (C1-C6)-alkoxy, or by an unsubstituted or substituted (C6-C12)-aryloxy radical, (C7-C11)-aralkyloxy radical or heteroaryloxy radical, which carries 1, 2, 3, 4 or 5 identical or different substituents from the series comprising hydroxyl, halo-gen, cyano, nitro, trifluoromethyl, (C1-C6)-alkyl, (C1-C6)-hydroxyalkyl, (C1-C6)-alkoxy, [CH2-]xCfH(2f+1-g)Fg, -OCF2-CHFCl, (C1-C6)-alkylmercapto, (C1-C6)-alkylsulfinyl, (C1-C6)-alkylsulfonyl, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxycarbonyl, carbamoyl, N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (Cl-C6)-alkylcarbonyloxy, (C3-C8)-cycloalkyl, carboxyl, phenyl, benzyl, phenoxy, benzyloxy, NR'-R", phenylmercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C4)-alkylsulfamoyl, N,N-di-(C1-C4)-alkylsulfamoyl, aminoalkyl, N-(C1-C8)-alkyl-amino-(C1-C12)-alkyl and N-di-(C1-C8)-alkylamino-(C1-C12)-alkyl, is optionally substituted by up to 3 of the abovementioned identical or different substituents, and a CH2 group of the alkyl chain is optionally replaced by O, S, SO, SO2 or NR', or by a radical of the general formula II
-O-R8 (II) in which R6 is an amino acid bonded via its acyl radical, a derivative of this amino acid or an alcohol-protect-ive group, B are an unsubstituted or substituted (C6-C12)-aryl radical or (C7-C11)-aralkyl radical or a heteroaryl radical, which is mono- or polysubstituted, preferably mono- or disubstituted, by hydroxyl, halogen, cyano, carboxyl, amino, (C1-C8)-alkyl, (C1-C8)-alkoxy, (C1-C8)-alkoxycarbonyl, (C1-C8)-alkylcar-bonyl, (Cl-C8)-alkylcarbonyloxy, (C1-C8)-alXylamino, di-(C1-C8)-alkylamino, (C1-C5)-hydroxyalkyl, -O-[CH2-]xCfH(2f+1-f)Fg, -OCF2Cl, -OCF2-CHFC1, carbamoyl, N-(C1-C8)-alkylcarbamoyl, N,N-di-(C1-C8)-alkylcarbamoyl, (C1-C8)-alkylcarbonyloxy, (C3-C8)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, aminoalkyl, N-(C1-C8)-alkylamino (C1-C12)-alkyl or N,N-di-(C1-C8)-alkylamino-(C1-C12)-alkyl, (C1-C8)-alkoxycarbonyloxy, (C1-C8)-alkoxy-(C1-C8)-alkoxycarbonyloxy,(C6-C12)-aryloxy-carbonyloxy, (C7-C11)-aralkyloxycarbonyloxy, (C7-C11)-aralkylcarbonyloxy, cinnamoyl, cinnamoyloxy, (C6-C12)-arylcarbonyloxy, (C3-C8)-alkenylcarbonyloxy, (C3-C8)-alkynylcarbonyloxy, (C3-C8)-cycloalkylcarbonyloxy, (C1-C12)-alkoxy-(C1-C12) alkoxy, (C1-C12)-alkoxy-amino, (C1-C12)-alkoxy-N-(C1-C6)-alkylamino, (C1-C12)-alkoxy-N,N-(C1-C6)-dialkylamino, carbamoyloxy, N-(C1-C8)-alkylcar-bamoyloxy, N,N-di-(C1-C8)-alkylcarbamoyl, N-(C3-C8)-cyclo-alkylcarbamoyl, N-(C6-C12)-arylamino, N-(C7-C11)-aralkyl-amino, N-alkyl-aralkylamino, N-alkyl-arylamino, (C3-C8)-cycloalkanoylamino, (C1-C8)-alkanoylamino, (C6-C12)-aroyl-amino, (C7-C11)-aralkanoylamino, (C1-C8)-alkanoyl-(C1-C8)-alkylamino, (C3-C8)-cycloalkanoyl-(C1-C8)-alkylamino, (C6-C12)-aroyl-(C1-C8)-alkylamino, (C7-C11)-aralkanoyl-(C1-C8)-alkylamino, (C1-C8)-alkylmercapto, (C1-C8)-alkyl-sulf.inyl, (C1-C8)-alkylsulfonyl, (C1-C8)-alkylcarbonyl, (C3-C8) cycloalkylcarbonyl, nitro, trifluoromethyl, phenylmercapto, phenylsulfonyl, phenylsulfinyl, sul-famoyl, N-(C1-C6)-alkylsulfamoyl, N,N-di-(C1-C6)-alkylsul-famoyl, (C1-C8)-alkyl-sulfonamido or arylsulfonamido, C in the case where X = -N(R7), are an unsubstituted or substituted (C1-C12)-alkoxy radical, (C3-C8)-cycloalkoxy radical or (C6-C12)-aryloxy radical or a (C7-C11)-aralkyl-oxy radical, which is mono- or polysubstituted, preferab-ly mono- or disubstituted, by halogen, trifluoromethyl. (C1-C6)-alkoxy, hydroxyl, (C1-C6)-hydroxyalkyl, NR'R" or cyano, in which, in each case, R' and R" are identical or different and are hydrogen, (C6 C12)-aryl, (C1-C8)-alkyl, (C1-C8)-alkylcarbonyl, (C7-C11)-aralkylcarbonyl or (C6-C12)-arylcarbonyl or form a saturated heterocyclic ring, preferably a 5- or 6-membered ring, with the nitrogen, and R2, R5 and R4 or R3, if R4 or R3 has not already been defined abover are identical or different and D are hydrogen, at least one radical R2, R5 and R4 or R3 being other than hydrogen, halogen, in particular fluorine, chlorine or bromine, cyano, nitro, trifluoro-methyl, (C1-C12)-alkyl, -O-[CH2-]xCfH(2f+1-g)Fg, -OCF2Cl, -O-CF2-CHFCl,(C1-C8)-alkylmercapto,(C1-C8)-alkylsulfinyl, (C1-C8a)-alkylsulfonyl,(C1-C8)-alkylcarbonyl,carbamoyl,N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (C3-C8)-cycloalkyl, phenylmercapto, phenylsulfonyl, phenylsulfinyl, (C1-C12)-alkoxycarbanoyl, (C1-C12)-alkyl-carbanoyloxy, amino, N-(C1-C10)-alkylamino, di-N,N-(C1-C10)-alkylamino, N,N-(C3-C8)-alkanediylamino, such as, for example, pyrrolidino, piperidino or their hetero-cyclic derivatives morpholino and thiomorpholino, N-(C6-C12)-arylamino, N-(C6-C12)-aryl-N-(C1-C10)-alkylamino, N
(C7-C11)-aralkylamino, N-(C7-C11)-aralkyl-N-(C1-C10)-alkyl-amino, (C1-C12)-alkanoylamino, (C3-C8)-cycloalkanoylamino (C1-C12)-hydroxyalkanoylamino, (C1-C8)-alkoxy-(C1-C12)_ alkanoylamino, (C8-C12)-arylcarbonylamino, (C7-C11)-aralk-ylcarbonylamino, (C1-C8)-alkoxycarbonyloxy, (C1-C8)-alkoxy-(C1-C8)-alkoxycarbonyloxy, (C6-C12)-aryloxycarbonyloxy, (C7-C11)-aralkyloxycarbonyloxy, (C7-C11)-aralkylcarbonyloxy, (C6-C12)-arylcarbonyloxy, (C3-C8)-alkenylcarbonyloxy, (C3-C8)-alkynylcarbonyloxy,(C3-C8)-cycloalkylcarbonyloxy, (C1-C12)-alkoxy-(C1-C12)-alkoxyr (C1-C12)-alkoxy-amino, (C1-C12)-alkoxy-N-(C1-C6)-alkylamino, (C1-C12)-alkoxy-M,N-(C1-C6)-dialkylamino, carbamoyloxy, N-(C1-C8) alkylcar-bamoyloxy, N,N-di-(C1-C8)-alkylcarbamoyloxy, N-(C3-C8)-cycloalkylcarbamoyloxy, NR'R", (C1-C8)-alkylmercapto, (C1-C8)-alkylsulfinyl, (C1-C8)-alkylsulfonyl, (C1-C8)-alkylcarbonyl, (C3-C8)-cycloalkylcarbonyl, sulfamoyl, N-(C1-C6)-alkylsulfamoyl, N,N-di-(C1-C6)-alkylsulfamoyl, (C1-C8) alkylsulfonamido or arylsulfonamido, in which the aryl and aralkyl radicals present in the above substituents can also be heterocyclic in nature and/or are substituted, as is also the case for alkyl, with 1,
(I) in which R1 and R3 or R4 are -C(O)-X-R6, in which X is O or N(R7)- and R5 and R7 are identical or different, and A are a branched or unbranched, aliphatic or cycloali-phatic (C1-C12)-alkyl radical or (C1-C12)-alkenyl radi-cal or a (C1-C12)-alkynyl radical, which is unsubstituted or mono- or polysubstituted, preferably mono- or disubstituted, by halogen, in par-ticular fluorine, chlorine or bromine, hydroxyl, cyano, carboxyl, (C1-C8)-alkoxy, (C1-C8)-alkoxycarbonyl, (C1-C8)-alkoxycarbonyloxy, (C1-C6)-alkoxy-(C1-C8)-alkoxycarbonyl-oxy, (C6-C12)-aryloxycarbonyloxy, (C7-C11)-aralkyloxycar-bonyloxy, (C7-C11)-aralkylcarbonyloxy, cinnamoyl, cinna-moyloxy,(C6-C12)-arylcarbonyloxy,(C3-C8)-alkenylcarbonyl-oxy, (C3-C6)-alkynylcarbonyloxy, (C3-C8)-cycloalkylcarbon-yloxy, (C1-C12)-alkoxy-(C1-C12)-alkoxy, (C1-C12)-alkoxy-amino, (C1-C12)-alkoxy-N-(C1-C6)-alkylamino, (C1-C12)-alkoxy-N,N-(C1-C6)-dialkylamino, carbamoyloxy, N-(C1-C8)-alkylcarbamoyloxy, N,N-di-(C1-C8)-alkylcarbamoyl, N-(C3-C8)-cycloalkylcarbamoyl, N-(C6-C12)-arylamino, N-(C7-C11)-aralkylamino, N-alkyl-aralkylamino, N-alkyl-arylamino, (C3-C8)-cycloalkanoylamino, (C1-C8)-alkanoyl-amino, (C6-C12)-aroylamino, (C7-C11)-aralkanoylamino, (C1-C8)-alkanoyl-(C1-C8)-alkylamino,(C3-C8)-cycloalkanoyl-(C1-C8)-alkylamino, (C6-C12)-aroyl-(C1-C8)-alkylamino, (C7-C11)-aralkanoyl-(C1-C8)-alkylamino, (C1-C8)-alkylmercap-to, (C1-C8)-alkylsulfinyl, (C1-C8)-alkylsulfonyl, (C1-C8)-alkylcarbonyl, (C3-C8)-cycloalkylcarbonyl, nitro, tri-fluoromethyl, phenylmercapto, phenylsulfonyl, phenylsul-finyl, sulfamoyl, N-(C1-C6)-alkylsulfamoyl, N,N-di-(C1-C6)-alkylsulfamoyl, (C1-C8)-alkyl-sulfonamido or arylsulfon-amido, in which the aryl and aralkyl radicals present in the above substituents can also be heterocyclic in nature and/or, as is also the case for alkyl, are substituted by 1, 2, 3, 4 or 5 identical or different substituents from the series comprising halogen, cyano, nitro, trifluoro-methyl, (C1-C5)-alkyl, hydroxy, (C1-C6)-hydroxyalkyl, (C1-C6)-alkoxy, -O-[CH2-]xCfH(2f+1-g)Fg, -OCF2Cl, -O-CF2-CHFCl, trifluoromethyl, (C1-C6)-alkylmercapto, (C1-C6)-alkylsul-finyl, (C1-C6)-alkylsulfonyl, (C1-C6)-alkylcarbonyl-(C1-C6)-alkoxycarbonyl, carbamoyl, N-(C1-C4)-alkylcar-bamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (C1-C6)-alkylcar-bonyloxy, (C3-C8)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, NR'-R", phenylmercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C4)-alkylsulfamoyl and N,N-di-(C1-C4)-alkylsulfamoyl, in particular by up to 3 of the abovementioned identical or different substituents, and a CH2 group of the alkyl chain is optionally replaced by O, S, SO, SO2 or NR', or by an unsubstituted or substituted (C6-C12)-aryl radical or heteroaryl radical which carries 1, 2, 3, 4 or 5 identi-cal or different substituents from the series comprising halogen, nitro, cyano, carboxyl, hydroxyl, trifluorometh-yl, (C1-C6)-hydroxyalkyl, -O-[CH2]xCfH(2f+1-g)Fg, -OCF2Cl, -OCF2-CHFCl, (C1-C6)-alkylmercapto, (C1-C6)-alkylsulfinyl, (C1-C6)-alkylsulfonyl, (C1-C8)-alkoxy, (C1-C8)-alkyl, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxycarbonyl, carbamoyl, N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (C1-C6)-alkylcarbonyloxy, (C3-C8)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, NR'-R", phenylmercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C4)-alkylsulfamoyl, N,N-di-(C1-C4)-alkylsulfamoyl, (C1-C6)-alkoxycarbonyloxy, (C1-C8)-alkoxy-(C1-C8)-alkoxy-carbonyloxy, (C6-C12)-aryloxycarbonyloxy, (C7-C11)-aralkyl-oxycarbonyloxy, (C7-C11)-aralkylcarbonyloxy, cinnamoyl, cinnamoyloxy, (C6-Cl2)-arylcarbonyloxy,(C3-C8)-alkenylcar-bonyloxy, (C3-C8)-alkynylcarbonyloxy, (C3-C8)-cycloalkyl-carbonyloxy, (C1-C12)-alkoxy-(C1-C12)-alkoxy, (C1-C12)-alkoxy-amino, (C1-C12)-alkoxy-N-(C1-C6)-alkylamino, (C1-C12)-alkoxy-N,N-(C1-C6)-dialkylamino, carbamoyloxy, N-(C1-C8)-alkylcarbamoyloxy, N,N-di-(C1-C8)-alkylcarbamoyl, N-(C3-C8)-cycloalkylcarbamoyl, N-(C6-C12)-arylamino, N-(C7-C11)-aralkylamino, N-alkyl-aralkylamino, N-alkyl-arylamino, (C3-C8)-cycloalkanoylamino, (C1-C8)-alkanoyl-amino, (C6-C12)-aroylamino, (C7-C11)-aralkanoylamino, (C1-C8)-alkanoyl-(C1-C8)-alkylamino,(C3-C8)-cycloalkanoyl-(C1-C8)-alkylamino, (C6-Cl2)-aroyl-(C1-C8)-alkylamino, (C7-C11)-aralkanoyl-(C1-C8)-alkylamino, (C1-C8)-alkylmer-capto, (C1-C8)-alkylsulfinyl, (C1-C8) alkylsulfonyl, (C1-C8)-alkylcarbonyl, (C3-C8)-cycloalkylcarbonyl, nitro, trifluoromethyl, phenylmercapto, phenylsulfonyl, phenyl-sulfinyl, sulfamoyl, N-(C1-C6)-alkylsulfamoyl, N,N-di-(C1-C6)-alkylsulfamoyl, (C1-C8)-alkyl-sulfonamido and arylsulfonamido, in which the aryl and aralkyl radicals present in the above substituents can also be heterocyc-lic in nature and/or, as is also the case for alkyl, can be substituted by 1,2,3,4 or 5 identical or different substituents from the series comprising halogen, cyano, nitro, trifluoromethyl, (C1-C6)-alkyl, hydroxyl, (C1-C6)-hydroxyalkyl and (C1-C6)-alkoxy, or by an unsubstituted or substituted (C6-C12)-aryloxy radical, (C7-C11)-aralkyloxy radical or heteroaryloxy radical, which carries 1, 2, 3, 4 or 5 identical or different substituents from the series comprising hydroxyl, halo-gen, cyano, nitro, trifluoromethyl, (C1-C6)-alkyl, (C1-C6)-hydroxyalkyl, (C1-C6)-alkoxy, [CH2-]xCfH(2f+1-g)Fg, -OCF2-CHFCl, (C1-C6)-alkylmercapto, (C1-C6)-alkylsulfinyl, (C1-C6)-alkylsulfonyl, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxycarbonyl, carbamoyl, N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (Cl-C6)-alkylcarbonyloxy, (C3-C8)-cycloalkyl, carboxyl, phenyl, benzyl, phenoxy, benzyloxy, NR'-R", phenylmercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C4)-alkylsulfamoyl, N,N-di-(C1-C4)-alkylsulfamoyl, aminoalkyl, N-(C1-C8)-alkyl-amino-(C1-C12)-alkyl and N-di-(C1-C8)-alkylamino-(C1-C12)-alkyl, is optionally substituted by up to 3 of the abovementioned identical or different substituents, and a CH2 group of the alkyl chain is optionally replaced by O, S, SO, SO2 or NR', or by a radical of the general formula II
-O-R8 (II) in which R6 is an amino acid bonded via its acyl radical, a derivative of this amino acid or an alcohol-protect-ive group, B are an unsubstituted or substituted (C6-C12)-aryl radical or (C7-C11)-aralkyl radical or a heteroaryl radical, which is mono- or polysubstituted, preferably mono- or disubstituted, by hydroxyl, halogen, cyano, carboxyl, amino, (C1-C8)-alkyl, (C1-C8)-alkoxy, (C1-C8)-alkoxycarbonyl, (C1-C8)-alkylcar-bonyl, (Cl-C8)-alkylcarbonyloxy, (C1-C8)-alXylamino, di-(C1-C8)-alkylamino, (C1-C5)-hydroxyalkyl, -O-[CH2-]xCfH(2f+1-f)Fg, -OCF2Cl, -OCF2-CHFC1, carbamoyl, N-(C1-C8)-alkylcarbamoyl, N,N-di-(C1-C8)-alkylcarbamoyl, (C1-C8)-alkylcarbonyloxy, (C3-C8)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, aminoalkyl, N-(C1-C8)-alkylamino (C1-C12)-alkyl or N,N-di-(C1-C8)-alkylamino-(C1-C12)-alkyl, (C1-C8)-alkoxycarbonyloxy, (C1-C8)-alkoxy-(C1-C8)-alkoxycarbonyloxy,(C6-C12)-aryloxy-carbonyloxy, (C7-C11)-aralkyloxycarbonyloxy, (C7-C11)-aralkylcarbonyloxy, cinnamoyl, cinnamoyloxy, (C6-C12)-arylcarbonyloxy, (C3-C8)-alkenylcarbonyloxy, (C3-C8)-alkynylcarbonyloxy, (C3-C8)-cycloalkylcarbonyloxy, (C1-C12)-alkoxy-(C1-C12) alkoxy, (C1-C12)-alkoxy-amino, (C1-C12)-alkoxy-N-(C1-C6)-alkylamino, (C1-C12)-alkoxy-N,N-(C1-C6)-dialkylamino, carbamoyloxy, N-(C1-C8)-alkylcar-bamoyloxy, N,N-di-(C1-C8)-alkylcarbamoyl, N-(C3-C8)-cyclo-alkylcarbamoyl, N-(C6-C12)-arylamino, N-(C7-C11)-aralkyl-amino, N-alkyl-aralkylamino, N-alkyl-arylamino, (C3-C8)-cycloalkanoylamino, (C1-C8)-alkanoylamino, (C6-C12)-aroyl-amino, (C7-C11)-aralkanoylamino, (C1-C8)-alkanoyl-(C1-C8)-alkylamino, (C3-C8)-cycloalkanoyl-(C1-C8)-alkylamino, (C6-C12)-aroyl-(C1-C8)-alkylamino, (C7-C11)-aralkanoyl-(C1-C8)-alkylamino, (C1-C8)-alkylmercapto, (C1-C8)-alkyl-sulf.inyl, (C1-C8)-alkylsulfonyl, (C1-C8)-alkylcarbonyl, (C3-C8) cycloalkylcarbonyl, nitro, trifluoromethyl, phenylmercapto, phenylsulfonyl, phenylsulfinyl, sul-famoyl, N-(C1-C6)-alkylsulfamoyl, N,N-di-(C1-C6)-alkylsul-famoyl, (C1-C8)-alkyl-sulfonamido or arylsulfonamido, C in the case where X = -N(R7), are an unsubstituted or substituted (C1-C12)-alkoxy radical, (C3-C8)-cycloalkoxy radical or (C6-C12)-aryloxy radical or a (C7-C11)-aralkyl-oxy radical, which is mono- or polysubstituted, preferab-ly mono- or disubstituted, by halogen, trifluoromethyl. (C1-C6)-alkoxy, hydroxyl, (C1-C6)-hydroxyalkyl, NR'R" or cyano, in which, in each case, R' and R" are identical or different and are hydrogen, (C6 C12)-aryl, (C1-C8)-alkyl, (C1-C8)-alkylcarbonyl, (C7-C11)-aralkylcarbonyl or (C6-C12)-arylcarbonyl or form a saturated heterocyclic ring, preferably a 5- or 6-membered ring, with the nitrogen, and R2, R5 and R4 or R3, if R4 or R3 has not already been defined abover are identical or different and D are hydrogen, at least one radical R2, R5 and R4 or R3 being other than hydrogen, halogen, in particular fluorine, chlorine or bromine, cyano, nitro, trifluoro-methyl, (C1-C12)-alkyl, -O-[CH2-]xCfH(2f+1-g)Fg, -OCF2Cl, -O-CF2-CHFCl,(C1-C8)-alkylmercapto,(C1-C8)-alkylsulfinyl, (C1-C8a)-alkylsulfonyl,(C1-C8)-alkylcarbonyl,carbamoyl,N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (C3-C8)-cycloalkyl, phenylmercapto, phenylsulfonyl, phenylsulfinyl, (C1-C12)-alkoxycarbanoyl, (C1-C12)-alkyl-carbanoyloxy, amino, N-(C1-C10)-alkylamino, di-N,N-(C1-C10)-alkylamino, N,N-(C3-C8)-alkanediylamino, such as, for example, pyrrolidino, piperidino or their hetero-cyclic derivatives morpholino and thiomorpholino, N-(C6-C12)-arylamino, N-(C6-C12)-aryl-N-(C1-C10)-alkylamino, N
(C7-C11)-aralkylamino, N-(C7-C11)-aralkyl-N-(C1-C10)-alkyl-amino, (C1-C12)-alkanoylamino, (C3-C8)-cycloalkanoylamino (C1-C12)-hydroxyalkanoylamino, (C1-C8)-alkoxy-(C1-C12)_ alkanoylamino, (C8-C12)-arylcarbonylamino, (C7-C11)-aralk-ylcarbonylamino, (C1-C8)-alkoxycarbonyloxy, (C1-C8)-alkoxy-(C1-C8)-alkoxycarbonyloxy, (C6-C12)-aryloxycarbonyloxy, (C7-C11)-aralkyloxycarbonyloxy, (C7-C11)-aralkylcarbonyloxy, (C6-C12)-arylcarbonyloxy, (C3-C8)-alkenylcarbonyloxy, (C3-C8)-alkynylcarbonyloxy,(C3-C8)-cycloalkylcarbonyloxy, (C1-C12)-alkoxy-(C1-C12)-alkoxyr (C1-C12)-alkoxy-amino, (C1-C12)-alkoxy-N-(C1-C6)-alkylamino, (C1-C12)-alkoxy-M,N-(C1-C6)-dialkylamino, carbamoyloxy, N-(C1-C8) alkylcar-bamoyloxy, N,N-di-(C1-C8)-alkylcarbamoyloxy, N-(C3-C8)-cycloalkylcarbamoyloxy, NR'R", (C1-C8)-alkylmercapto, (C1-C8)-alkylsulfinyl, (C1-C8)-alkylsulfonyl, (C1-C8)-alkylcarbonyl, (C3-C8)-cycloalkylcarbonyl, sulfamoyl, N-(C1-C6)-alkylsulfamoyl, N,N-di-(C1-C6)-alkylsulfamoyl, (C1-C8) alkylsulfonamido or arylsulfonamido, in which the aryl and aralkyl radicals present in the above substituents can also be heterocyclic in nature and/or are substituted, as is also the case for alkyl, with 1,
2, 3, 4 or 5 identical or different substituents from the series comprising halogen, cyano, nitro, trifluoromethyl, (C1-C6)-alkyl, hydroxyl, (C1-C6)-hydroxyalkyl, (C1-C6)-alkoxy, -O-[CH2-]xCfH(2f+1-g)Fg, -OCF2Cl, -O-CF2-CHFCl, tri-fluoromethyl, (C1-C5)-alkylmercapto, (C1-C6)-alkylsulfinyl, (C1-C6)-alkylsulfonyl, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxycarbonyl, carbamoyl, N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (C1-C6)-alkylcarbonyloxy, (C3-C8)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, NR'-R", phenylmercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C4)-alkylsulfamoyl and N,N-di-(C1-C4)-alkylsulfamoyl, in particular by up to 3 of the abovemen-tioned identical or different substituents, and a CH2 group of the alkyl chain is optionally replaced by O, S, SO, SO2 or NR', or E are an alkyl, alkenyl or alkynyl radical having up to 9 carbon atoms, which is optionally substituted by 1, 2, 3, 4 or 5 identical or different substituents from the series comprising hydroxyl, halogen, cyano, nitro, trifluoromethyl, (C1-C6)-hydroxyalkyl, (C1-C6)-alkoxy, [CH2-]xCfH(2f+1-g)Fg, -OCF2CHFCl, (C1-C6)-alkylmercapto, (C1-C6)-alkylsulfinyl, (C1-C6)alkylsulfonyl, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxycarbonyl, carbamoyl, N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (C1-C6)-alkylcarbonyloxy, (C3-C8)-cycloalkyl, carboxyl, phenyl, benzyl, phenoxy, benzyloxy, phenylmercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C4)-alkylsulfamoyl, N,N-di-(C1-C4)-alkylsulfamoyl, amino, N-(C1-C10)-alkylamino, di-N,N-(C1-C10)-alkylamino, N,N-(C3-C8)-alkanediylamino, such as, for example, pyrroli-dino, piperidino or their heterocyclic derivatives morpholino and thiomorpholino, N-(C6-C12)-arylamino, N-(C6-C12)-aryl-N-(C1-C10)-alkylamino, N-(C7-C11)-aralkylamino, N-(C7-C11)-aralkyl-N-(C1-C11)-alkylamino,(C1-C12)-alkanoyl-amino, (C3-C8)-cyclo-alkanoylamino, (C1-C12)-hydroxyalkan-oylamino, (C1-C8)-alkoxy-(C1-C12)-alkanoylamino, (C6-C12)-arylcarbonylamino and (C7-C11)-aralkylcarbonylamino, in particular by up to 3 of the abovementioned identical or different substituents, and a CH2 group of the alkyl chain is optionally replaced by O, S, SO, SO2 or NR', or by an unsubstituted or substituted (C6-C12)-aryl radical, (C7-C11)-aralkyl radical or heteroaryl radical, which carries 1, 2, 3, 4 or 5 identical or different substituents from the series comprising hydroxyl, halo-gen, cyano, nitro, trifluoromethyl, (C1-C6)-hydroxyalkyl, (C1-C6)-alkyl, (C1-C6)-alkoxy, -O-[CH2-]xCfH(2f+1-g)Fg, -OCF2CHFCl, (C1-C6)-alkylmercapto, (C1-C6)-alkylsulfinyl, (C1-C6)-alkylsulfonyl, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxycarbonyl, carbamoyl, N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (C1-C6)-alkylcarbonyloxy, (C3-C8)-cycloalkyl, carboxyl, phenyl, benzyl, phenoxy, benzyloxy, phenylmercapto, phenylsulfonyl, phenylsul-finyl, sulfamoyl, N-(C1-C4) alkylsulfamoyl, amino, N-(C1-C10)-alkylamino, di-N,N-(C1-C10)-alkylamino, N,N-(C3-C8)-alkanediylamino, such as, for example, pyrroli-dino, piperidino or their heterocyclic derivatives morpholino and thiomorpholino, N-(C6-C12)-arylamino, N-(C6-C12)-aryl-N-(C1-C10)-alkylamino, N-(C7-C11)-aralkylamino, N-(C7-C11)-aralkyl-N-(C1-C10)-alkylamino,(C1-C12)-alkanoyl-amino, (C3-C8)-cyclo-alkanoylamino, (C1-C12)-hydroxyalkan-oylamino, (C1-C8)-alkoxy-(C1-C12)-alkanoylamino, (C6-C12)-arylcarbonylamino and (C7-C11)-aralkylcarbonylamino, in particular by up to 3 of the abovementioned identical or different substituents, and a CH2 group of the alkyl chain is optionally replaced by O, S, SO, SO2 or NR', or F denote a substituted or unsubstituted (C6-12)-aryl radical, (C7-C11)-aralkyl radical or heteroaryl radical, in which the aryl and heteroaryl radical mentioned is, in particular, phenyl, naphthyl, thienyl, furyl, pyrrolyl or pyridine, and which furthermore carries in the aryl part 1, 2, 3, 4 or 5 identical or different substituents from the series comprising hydrox-yl, halogen, cyano, nitror (C1-C6)-alkyl, (C1-C6)-alkoxy, carboxyl, trifluoromethyl, (C1-C6)-hydroxyalkyl, -O-[CH2-]xCfH(2f+1-g)Fg, -OCF2Cl, -OCF2CHFCl, (C1-C6)-alkylmer-capto, (C1-C6) alkylsulfonyl, (C1-C6)-alkylsulfinyl, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxycarbonyl, carbamoyl, N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (C1-C6)-alkylcarbonyloxy, (C3-C8)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, amino, N-(C1-C10)-alkylamino, di-N,N-(C1-C10)-alkylamino, N,N-(C3-C8)-alkanediylamino, such as, for example, pyrrolidino, piperidino, morpho-lino, thiomorpholino, (C1-C10)-alkanoylamino, (C6-C12)-arylcarbonylamino, (C7-C11)-aralkylcarbonylamino, phenyl-mercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C4)-alkylsulfamoyl or N,N-di-(C1-C4)-alkylsulfamoyl,in particular up to 3 of the abovementioned identical or different substituents, and in which a CH2 group of the aryl chain is optionally replaced by O, S, SO, SO2 or NR', or G are a substituent of the formulae -OR9 or -N(R9)2, in which R9 is hydrogen, alkyl, alkenyl or alkynyl, in each case having up to 9 carbon atoms, a (C6-C12)-aryl radical or a heteroaryl radical, which carries in the aryl part 1, 2, 3, 4 or 5 identical or different substituents from the series comprising hydrox-yl, halogen, cyano, nitro, carboxyl, (C1-C6)-alkyl, (C1-C6)-alkoxy, trifluoromethyl, (C1-C6)-hydroxyalkyl, -O-[CH2-]xCfH(2f+1-g)Fg, -OCF2Cl, -OCF2CHFCl, (C1-C6)-alkyl-mercapto, (C1-C6)-alkylsulfonyl, (C1-C6)-alkylsulfinyl, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxycarbonyl, carbamoyl, N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (C1-C6)-alkylcarbonyloxy, (C3-C8)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, amino, N-(C1-C10)-alkylamino, di-N,N-(C1-C10)-alkylamino, N,N-(C3-C8)-alkanediylamino, such as, for example, pyrrolidino, piperidino, morpho-lino, thiomorpholino, (C1-C10) alkanoylamino, (C6-C12)-arylcarbonylamino, (C7-C11)-aralkylcarbonylamino, phenyl-mercapto, phenylsulfonyl, phenylsulfinyl, sulfamoyl, N-(C1-C4)-alkylsulfamoyl or N,N-di-(C1-C4)-alkylsulfonoyl,in particular up to 3 of the abovementioned identical or different substituents, and in which a CH2 group of the aryl chain is optionally replaced by O, S, SO, SO2 or NR', and n = 0 or 1, f = 1 to 8, preferably 1 to 5, g = 0.1 to (2f + 1) and x is 0, 1, 2 or 3, preferably 0 or 1, or any derivative which contains a corresponding protect-ive group in its amino or hydroxyl groups, or a physio-logically active salt.
2. A compound as claimed in claim 1, in which R1 and R3 or R4 are -C(O)-X-R6, in which X is -N(R7)-.
2. A compound as claimed in claim 1, in which R1 and R3 or R4 are -C(O)-X-R6, in which X is -N(R7)-.
3. A compound as claimed in claim 1 or 2, in which R6 is hydrogen or methyl and R7 has the meaning given in claim 1, or R6 and R7 are hydrogen and/or methyl, if at least one group R1, R3 or R4 is a radical -C(O)-N(R7)-R6, in which R6 and/or R7 have the meaning given in claim 1.
4. A compound as claimed in claim 1 or 2, in which R6 and A are a branched or unbranched (C1-C12)-alkyl radical, which is unsubstitted or mono- or polysubstituted by halogen, in particular fluorine, chlorine, bromine, hydroxyl, cyano, carboxyl, (C1-C4)-alkoxy, (C1-C4)-alkoxy-carboxyl, (C1-C8)-alkoxycarbonyloxy, (C1-C8)-alkoxy-(C1-C9)-alkoxycarbonyloxy, (C6-C12)-axyloxycarbonyloxy, (C7-C1)-aralkyloxycarbonyloxy, (C7-C11)-aralkylcarbonyloxy, (C7-C11)-arylcarbonyloxy, (C3-C8)-cycloalkylcarbonyloxy, (C1-C12)-alkoxy-(C1-C12) alkoxy, carbamoyloxy, N-(C1-C8)-alkylcarbamoyloxy, N,N di-(C1-C8)-alkylcarbamoyl, N-(C3-C8)-cycloalkylcarbamoyl, N-(C7-C11)-aralkylcarbamoyloxy or N-(C6-C12)-arylcarbamoyloxy, in which the aryl and aralkyl radicals present in the above substituents can also be heterocyclic in nature, and/or, as is also the case for alkyl, are substituted by 1 or 2 identical or different substituents from the series comprising halo-gen, trifluoromethyl, hydroxyl, (C1-C3)-alkyl, (C1-C3)-hydroxyalkyl, (C1-C9)-alkoxy, -O-[CH2-]xCfH(2f+1-g)Fg, -OCF2Cl, -O-CF2-CHFCl, (C1-C3)-alkoxycarbonyl, carbamoyl, (C1-C6)-alkylcarbonyloxy, (C3-C8)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, or by an unsubstituted or substituted (C6-C12)-aryl radical or heteroaryl radical, which carries 1 or 2 identical or different substituents from the series comprising halo-gen, nitro, cyano, carboxyl, hydroxyl, trifluoromethyl, (C1-C3)-hydroxyalkyl, (C1-C3)-alkoxycarbonyl, carbamoyl, NR'R", N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4) alkylcar-bamoyl, (C1-C8) -alkoxy-(C1-C8)-alkyl, (C1-C3)-alkylcarbon-yloxy, aminoalkyl and N-(C1-C4)-alkylamino-(C1-C6)-alkyl, in which R' and R" are identical or different and are hydrogen, (C6-C12)-aryl or (C1-C4)-alkyl, or by an unsubstituted or substituted (C6-C10)-aryloxy radical or (C7-C11) aralkyloxy radical, which carries 1 or 2 identical or different substituents from the series comprising hydroxyl, halogen, trifluoromethyl, (C1-C3)-alkyl, (C1-C3)-hydroxyalkyl, (C1-C3)-alkoxy, (C1-C3)-alkylmercapto, (C1-C3)-alkylsulfinyl, (C1-C3)-alkylsulfonyl, (C1-C3)-alkylcarbonyl, (C1-C3)-alkoxycar-bonyl,carbamoyl,N-(C1-C4)-alkylcarbamoyl,N,N-di-(C1-C4)-alkylcarbamoyl, (C1-C3)-alkylcarbonyloxy and NR'R", in which R' and R" are identical or different and are hydrogen, (C6-C10)-aryl or (C1-C4)-alkyl, or by a radical of the formula II
-O-R8 (II) in which R8 is an amino acid bonded via its acyl radical, or is a derivative thereof, B denote a (C6-C12)-aryl or (C7-C11) aralkyl radical, preferably phenyl, benzyl or phenethyl, which are unsub-stituted or monosubstituted by halogen, cyano, carboxyl, hydroxyl, (C1-C8)-alkyl, (C1-C3)-alkoxy, (C1-C8)-alkylcar-bonyl, (C1-C4)-alkylcarbonyloxy, (C1-C4)-alkoxycarbonyl, (C1-C4)-hydroxyalkyl, amino, (C1-C5)-alkylamino, di-(C1-C5)-alkylamino, (C1-C5)-alkan-oylamino, carbamoyl, N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, carbamoyl, (-(C1-C4)-alkylcar-bamoyloxy or N,N-di-(C1-C4)-alkylcarbamoyloxy or C are an unsubstituted (C1-C6)-alkoxy radical, (C3-C8)-cycloalkoxy radical, (C6-C12)-aryloxy radical or (C7-C11)-aralkyloxy radical.
-O-R8 (II) in which R8 is an amino acid bonded via its acyl radical, or is a derivative thereof, B denote a (C6-C12)-aryl or (C7-C11) aralkyl radical, preferably phenyl, benzyl or phenethyl, which are unsub-stituted or monosubstituted by halogen, cyano, carboxyl, hydroxyl, (C1-C8)-alkyl, (C1-C3)-alkoxy, (C1-C8)-alkylcar-bonyl, (C1-C4)-alkylcarbonyloxy, (C1-C4)-alkoxycarbonyl, (C1-C4)-hydroxyalkyl, amino, (C1-C5)-alkylamino, di-(C1-C5)-alkylamino, (C1-C5)-alkan-oylamino, carbamoyl, N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, carbamoyl, (-(C1-C4)-alkylcar-bamoyloxy or N,N-di-(C1-C4)-alkylcarbamoyloxy or C are an unsubstituted (C1-C6)-alkoxy radical, (C3-C8)-cycloalkoxy radical, (C6-C12)-aryloxy radical or (C7-C11)-aralkyloxy radical.
5. A compound as claimed in any of claims 1 to 4, in which R2, R5 and R4 or R3, if R4 and R3 are not already defined in Claims 1 to 4 and are not to be hydrogen, are D halogen, in particular fluorine, chlorine or brom-ine, cyano, nitro, trifluoromethyl, (C1-C12)-alkyl, -O-[CH2-]xCfH(2f++1-g)Fg, -OCF2Cl, -O-CF2-CHFCl, (C1-C8)-alkyl-carbonyl, carbamoyl, N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (C3-C8) cycloalkyl,(C1-C12)-alkoxy-carbonyl, (C1-C12)-alkylcarbonyloxy, amino, N-(C1-C10)-alkylamino, di-N,N-(C1-C10)-alkylamino or N,N-(C3-C8)-alkanediylamino, such as, for example, pyrrolidino, piperidino or their heterocyclic darivatives morpholino and thiomorpholino, N (C6-C12)-arylamino, N-(C6-C12)-aryl-N-(C1-C8)-alkylamino, N (C7-C11)-aralkylamino, N-(C7-C11)-aralkyl-N-(C1-C10)-alkylamino, (C6-C12)-arylcarbonylamino, (C7-C11)-aralkylcarbonylamino, (C1-C6)-alkoxycarbonyloxy, (C6-C12)-aryloxycarbonyloxy, (C7-C11)-aralkylcarbonyloxy, (C6-C12)-arylcarbonyloxy, (C3-C6)-alkenylcarbonyloxy, (C3-C8)-cycloalkylcarbonyloxy, (C1-C12)-alkoxy-(C1-C12) alkoxy, (C1-C12)-alkoxy-amino, (C1-C12)-alkoxy-N-(C1-C6)-alkylamino, (C1-C12)-alkoxy-N,N-(C1-C6)-dialkylamino, carbamoyloxy, N-(C1-C6)-alkylcarbamoyloxy, N,N-di-(C1-C8)-alkylcarbamoyloxy, N-(C3-C8)-cycloalkylcarbamoyloxy, NR'R", (C1-C8)-alkylmercapto, (C1-C6)-alkylsulfinyl, (C1-C6)-alkylsulfonyl, (C1-C8)-alkylcarbonyl or (C3-C8)-cycloalkylcarbonyl, in which tha aryl and aralkyl radi-cals present in the above substituents can also be heterocyclic in nature and/or, as is also the case for alkyl, are substituted by 1, 2 or 3 identical or dif-ferent substituents from the series comprising halogen, trifluoromethyl, (C1-C6)-alkyl, hydroxyl, (C1-C6)-hydroxy-alkyl, (C1-C6)-alkoxy, -O-[CH2-]xCfH(2f+l-g)Fg, (C3-C8)-cyclo-alkyl, phenyl, benzyl, phenoxy, benzyloxy, NR'R", phenylmercapto, phenylsulfonyl, phenylsulfinyl, sul-famoyl, N-(C1-C4) alkylsulfamoyl or N,N-di-(C1-C4)-alkylsulfamoyl, or E an alkyl or alkenyl radical having up to 5 carbon atoms, which is optionally substituted by 1, 2 or 3 identical or different substituents from the series comprising hydroxyl, halogen, cyano, nitro, trifluoro-methyl, (C1-C6) hydroxyalkyl, (C1-C6)-alkoxy, [CH2-]xCfH(2f+1-g)Fg, -OCF2-CHFCl, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxycarbonyl, carbamoyl, N-(C1-C4)-alkylcar-bamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (C1-C6)-alkylcar-bonyloxy, (C3-C8)-cycloalkyl, carboxyl, phenyl, benzyl, phenoxy, benzyloxy, amino, N-(C1-C6)-alkylamino, di-N,N-(C1-C6)-alkylamino or N,N-(C3-C8)-alkanediylamino, such as, for example, pyrrolidino or piperidino, N-(C6-C12)-aryl-amino, N-(C6-C12)-aryl-N-(C1-C6)-alkylamino, N-(C7-C11)-aralkylamino, N-(C7-C11)-aralkyl-N-(C1-C10)-alkylamino, (C1-C6)-alkanoylamino, (C1-C8)-alkoxy-(C1-C6)-alkanoylamino, (C6-C12)-arylcarbonylamino and (C7-C11)-aralkylcarbonyl-amino, or by an unsubstituted or substituted (C6-C12)-aryl radical, (C7-C11)-aralkyl radical or heteroaryl radical, which carries 1, 2 or 3 identical or different substi-tuents from the series comprising hydroxyl, halogen, cyano, nitro, trifluoromethyl, (C1-C6)-hydroxyalkyl, (C1-C6)-alkoxy, (C1-C6)-alkoxy, [CH2-]xCfH(2f+1-g)Fg, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxycarbonyl, carbamoyl, N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (C1-C6)-alkylcarbonyloxy, (C3-C8)-cycloalkyl, carboxyl, phenyl, benzyl, phenoxy, benzyloxy, amino, N-(C1-C6)-alkylamino, di-N,N-(C1-C6)-alkylamino or N,N-(C3-C8)-alkanediylamino, such as, for example, pyrrolidino or piperidino,N-(C6-C12)-arylamino,N-(C6-C12)-aryl-N-(C1-C6)-alkylamino, N-(C7-C11) aralkylamino, N-(C7-C11) aralkyl-N-(C1-C10)-alkylamino, (C1-C6)-alkanoylamino, (C3-C8)-cyclo-alkanoylamino, (C1-C6)-hydroxyalkanoylamino, (C1-C6)-alkoxy-(C1-C6)-alkanoylamino, (C6-Cl2)-arylcarbonylamino and (C7-C11)-aralkylcarbonylamino, or F an unsubstituted or substituted (C6-C12)-aryl radi-cal, (C7-C11)-aralkyl radical or heteroaryl radical, in which the aryl and heteroaryl radical mentioned is, in particular, phenyl, naphthyl, thienyl, furyl, pyrrolyl or pyridine, and which furthermore carries 1, 2 or 3 identi-cal or different substituen-ts from the series comprising hydroxyl, halogen, cyano, nitro, (C1-C6)-alkyl, (C1-C6)-alkoxy, carboxyl, trifluoromethyl, (C1-C6)-hydroxyalkyl, -O-[CH2-]xCfH(2f+1-g)Fg, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxy carbonyl, carbamoyl, N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarkamoyl, (C1-C6)-alkylcarbonyloxy, (C3-C8)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, amino, N-(C1-C10)-alkylamino, di-N,N-(C1-C10)-alkylamino or N,N-(C3-C8)-alkanediylamino, such as, for example, pyrrolidino or piperidino, (C1-C10)-alkanoylamino, (C6-C12)-aryl-carbonylamino and ( C7-C11)- aralkylcarbonylamino, or G a substituent of the formula -OR9 or -N(R9)2, in which R9 is hydrogen, alkyl or alkenyl having in each case up to 6 carbon atoms, a (C6-C12)-aryl radical or a heteroaryl radical, which carries 1, 2 or 3 identical or different substituents from the series comprising halogen, hydrox-yl, cyano, nitro, carboxyl, trifluoromethyl, (C1-C6)-alkyl, (C1-C6)-hydroxyalkyl, (C1-C6)-alkoxy, -O-[CH2-]xCfH(2f+1-g)Fg, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxy-carbonyl, carbamoyl, N-(C1-C4)-alkylcarbamoyl, N,N-di-(C1-C4)-alkylcarbamoyl, (C1-C6)-alkylcarbonyloxy, (C3-C8)-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, amino, N-(C1-C10)-alkylamino, di-N,N-(C1-C10)-alkylamino or N,N-(C3-C8)-alkanediylamino, such as, for example, pyrrolidino or piperidino, (C1-C10)-alkanoylamino, (C6-C12)-aryl-carbonylamino and (C7-C11)-aralkylcarbonylamino.
6. A compound as claimed in any of claims 1 to 5, in which R2, R5 and R4 or R3, if R4 and R3 are not already defined above and are not to be hydrogen, are D halogen, in particular fluorine, chlorine or brom-ine, trifluoromethyl, (C1-C12)-alkyl, O-[CH2-]xCfH(2f+l-g)Fg, -OCF2Cl, O-CF2-CHFCl, (C1-C8)-alkylcarbonyl, (C3-C8)-cycloalkyl, amino, N-(C1-C10)-alkylamino, di-N,N-(C1-C10)-alkylamino,N-(C6-C12)-arylamino,N-(C6-C12)-aryl-N-(C1-C6)-alkylamino, N-(C7-C11)-aralkylamino or N-(C7-C11)-aralkyl-N-(C1-C10)-alkylamino, in which the aryl and aralkyl radicals present in the above substituents can also be heterocyclic in nature and/or, as is also the case for alkyl, can be substituted by 1 or 2 identical or dif-ferent substituents from the series comprising halogen, trifluoromethyl, (C1-C8)-alkyl, hydroxyl, (C1-C6)-hydroxy-alkyl, (C1-C6)-alkoxy, -O-[CH2-]xCfH(2f+1g)Fg and NR -R, or E an alkyl or alkenyl radical having up to 5 carbon atoms, which is optionally substituted by 1 or 2 identi-cal or different substituents from the series comprising hydroxyl, halogen, trifluoromethyl, (C1-C6)-hydroxyalkyl, (C1-C6)-alkoxy, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxycar-bonyl, (C1-C6)-alkylcarbonyloxy, phenyl, benzyl, phenoxy, benzyloxy, amino, N-(C1-C6)-alkylamino and di-N/N-(C1-C8)-alkylamino, or by an unsubstituted or substituted (C6-C12)-aryl radical, (C7-C11)-aralkyl radical or heteroaryl radical, which carries 1 or 2 identical or different substituents from the series comprising hydroxyl, halogen, trifluoromethyl, (C1-C6)-alkyl, (C1-C6)-hydroxyalkyl, (C1-C6) alkoxy, -O-[CH2-]xCfH(2f+1-g)Fg, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxy-carbonyl, phenyl, benzyl, phenoxy, benzyloxy, amino, N-(C1-C6)-alkylamino, di-N,N-(C1-C6)-alkylamino or N,N-(C3-C8)-alkanediylamino, such as, for example, pyrrolidino or piperidino, or F an unsubstituted or substituted (C6-C12)-aryl radi-cal, (C7-C11)-aralkyl radical or heteroaryl radical, in which the aryl and heteroaryl radical mentioned is, in particular, phenyl, naphthyl, thienyl, furyl, pyrrolyl or pyridine, and which furthermore carries 1, 2 or 3 identi-cal or different substituents from the series comprising hydroxyl, halogen, (C1-C6)-alkyl, (C1-C6)-alkoxy, carboxyl, trifluoromethyl, (C1-C6)-hydroxyalkyl,-O-[CH2-]xCfH(2f+1-g)Fg, (C1-C6)-alkylcarbonyl, (C1-C6)-alxoxycarbonyl, amino, N-(C1-C10)-alkylamino and di-N,N-(C1-C10)-alkylamino, or G a substituent of the formula -OR9 or -N(R9)2, in which R9 is hydrogen or alkyl having in each case up to 6 carbon atoms, a (C6-C12)-aryl radical or a heteroaryl radical, which contains 1 or 2 identical or different substituents from the series comprising halogen, tri-fluoromethyl, (C1-C6)-alkyl, (C1-C6)-alkoxy, -O-[CH2-]xCfH(2f+1-g)Fg, amino, N-(C1-C10)-alkylamino and di-N,N-(C1-C10)-alkylamino.
7. A compound as claimed in any of claims 1 to 6, in which R2, R5 and R4 or R3, if R4 and R3 are not already defined in any of claims 1 to 4 and are not to be hydrogen, are D halogen, in particular fluorine, chlorine or brom-ine, trifluoromethyl, (C1-C12)-alkyl, -O-[CH2-]xCfH(2f+l-g)Fg, -OCF2Cl, -O-CF2-CHFCl, (C1-C8)-alkylcarbonyl, (C3-C8)-cycloalkyl, amino, N-(C1-C10)-alkylamino, di-N,N-(C1-C10)-alkylamino,N-(C6-C12)-arylamino,N-(C6-C12)-aryl-N-(C1-C8)-alkylamino, N-(C7-C11)-aralkylamino or N-(C7-C11)-aralkyl-N-(C1-C10)-alkylamino, or:
E an alkyl or alkenyl radical having up to 5 carbon atoms, which is optionally substituted by 1 or 2 identi-/
cal or different substituents from the series comprising hydroxyl, halogen, trifluoromethyl, (C1-C6)-alkoxy, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxycarbonyl, (C1-C6)-alkylcarbonyloxy, phenyl, phenoxy, benzyloxy, amino, N-(C1-C6)-alkylamino and di-N,N-(C1-C6)-alkylamino, or by an unsubstituted or substituted (C6-C12)-aryl radical, (C7-C11)-aralkyl radical or heteroaryl radical, which carries 1 or 2 identical or different substituents from the series comprising hydroxyl, halogen, trifluoromethyl, (C1-C6)-alkyl, (C1-C6)-hydroxyalkyl, (C1-C6)-alkoxy, (C1-C6)-alkylcarbonyl and (C1-C6)-alkoxycarbonyl, or F an unsubstituted or substituted (C6-C12)-aryl radical or (C7-C11)-aralkyl radical, in which the aryl radical mentioned is, in particular, phenyl or naphthyl and which furthermore carries 1 or 2 identical or different substi-tuents from the series comprising hydroxyl, halogen, (C1-C6)-alkyl, (C1-C6)-alkoxy, carboxyl, trifluoromethyl, (C1-C6)-hydroxyalkyl, (C1-C5)-alkylcarbonyl and (C1-C-6)-alkoxycarbonyl, or G a substituent of the formula -OR9 or -N(R9)2, in which R9 is hydrogen or alkyl having in each case up to 6 carbon atoms, a (C6-C12)-aryl radical or a heteroaryl radical, which contains 1 or 2 identical or different substituents from the series comprising halogen, tri-fluoromethyl, (C1-C6)-alkyl, (C1-C6)-alkoxy, amino, N-(C1-C10)-alkylamino and di-N,N-(C1-C10)-alkylamino.
E an alkyl or alkenyl radical having up to 5 carbon atoms, which is optionally substituted by 1 or 2 identi-/
cal or different substituents from the series comprising hydroxyl, halogen, trifluoromethyl, (C1-C6)-alkoxy, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxycarbonyl, (C1-C6)-alkylcarbonyloxy, phenyl, phenoxy, benzyloxy, amino, N-(C1-C6)-alkylamino and di-N,N-(C1-C6)-alkylamino, or by an unsubstituted or substituted (C6-C12)-aryl radical, (C7-C11)-aralkyl radical or heteroaryl radical, which carries 1 or 2 identical or different substituents from the series comprising hydroxyl, halogen, trifluoromethyl, (C1-C6)-alkyl, (C1-C6)-hydroxyalkyl, (C1-C6)-alkoxy, (C1-C6)-alkylcarbonyl and (C1-C6)-alkoxycarbonyl, or F an unsubstituted or substituted (C6-C12)-aryl radical or (C7-C11)-aralkyl radical, in which the aryl radical mentioned is, in particular, phenyl or naphthyl and which furthermore carries 1 or 2 identical or different substi-tuents from the series comprising hydroxyl, halogen, (C1-C6)-alkyl, (C1-C6)-alkoxy, carboxyl, trifluoromethyl, (C1-C6)-hydroxyalkyl, (C1-C5)-alkylcarbonyl and (C1-C-6)-alkoxycarbonyl, or G a substituent of the formula -OR9 or -N(R9)2, in which R9 is hydrogen or alkyl having in each case up to 6 carbon atoms, a (C6-C12)-aryl radical or a heteroaryl radical, which contains 1 or 2 identical or different substituents from the series comprising halogen, tri-fluoromethyl, (C1-C6)-alkyl, (C1-C6)-alkoxy, amino, N-(C1-C10)-alkylamino and di-N,N-(C1-C10)-alkylamino.
8. A process for the preparation of the compound as claimed in any of claims 1 to 7, which comprises reacting a compound of the formula V or VI with an oxidizing agent in an organic solvent at a temperature of between -30 and +40°C to give a compound of the formula I.
9. A compound as claimed in any of claims 1 to 7 for inhibiting proline hydroxylase and lysine hydroxylase.
10. A compound as claimed in any of claims 1 to 7 for use as a fibrosuppressant and immunosuppressant.
11. A medicament comprising a compound of the formula I
and a tolerated pharmaceutical excipient.
and a tolerated pharmaceutical excipient.
12. The use of a compound of the formula I for influence ing the metabolism of collagen and collagen-like sub-stances and the biosynthesis of Clq.
13. The use of a compound of the formula I for the treatment of disturbances in the metabolism of collagen and collagen-like substances and the biosynthesis of Clq.
14. A process for the preparation of a medicament for influencing the metabolism of collagen and collagen-like substances and the biosynthesis of Clq, wherein the medicament comprises a compound of the formula I.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4142989.3 | 1991-12-24 | ||
DE4142989 | 1991-12-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2085954A1 true CA2085954A1 (en) | 1993-06-25 |
Family
ID=6448143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002085954A Abandoned CA2085954A1 (en) | 1991-12-24 | 1992-12-21 | Substituted pyridine n-oxides, processes for their preparation, and their use |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0548883A1 (en) |
JP (1) | JPH05255261A (en) |
AU (1) | AU3039192A (en) |
CA (1) | CA2085954A1 (en) |
FI (1) | FI925825A (en) |
IL (1) | IL104208A0 (en) |
NO (1) | NO924990L (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6444823B1 (en) * | 1996-06-20 | 2002-09-03 | Klinge Pharma Gmbh | Pyridyl alkane acid amides as cytostatics and immunosuppressives |
US6451816B1 (en) | 1997-06-20 | 2002-09-17 | Klinge Pharma Gmbh | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression |
US6506572B2 (en) | 1999-02-26 | 2003-01-14 | Klinge Pharma Gmbh | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy |
US6593344B1 (en) | 1997-12-17 | 2003-07-15 | Klinge Pharma Gmbh | Piperadinyl-substituted pyridylalkane, alkene and alkine carboxamides |
US6903118B1 (en) | 1997-12-17 | 2005-06-07 | Klinge Pharma Gmbh | Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides |
US7192967B1 (en) | 1997-12-17 | 2007-03-20 | Astellas Pharma Gmbh | Cyclic imide-substituted pyridylalkane, alkene, alkine carboxamides useful as cytostatic and immunosuppressive agents |
US7241745B2 (en) | 1996-06-20 | 2007-07-10 | Astellas Pharma Gmbh | Pyridyl alkene and pyridyl alkine acid amides as cytostatics and immunosupressives |
US7320993B1 (en) | 1997-12-17 | 2008-01-22 | Astellas Deutschland Gmbh | Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic useful as cytostatic and immuosuppressive agents |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2724561B1 (en) * | 1994-09-19 | 1996-12-13 | Oreal | USE OF 2,4-DIAMINO PYRIMIDINE 3-OXIDE OR ONE OF ITS SALTS IN THE TREATMENT OF MATURATION AND STRUCTURING DISORDERS OF COLLAGEN |
DE19746287A1 (en) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituted isoquinoline-2-carboxylic acid amides, their preparation and their use as medicaments |
FI124090B (en) * | 2012-06-07 | 2014-03-14 | Maricap Oy | A method for cleaning the piping of a pneumatic material handling system and a cleaning apparatus and system |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3703959A1 (en) * | 1987-02-10 | 1988-08-18 | Hoechst Ag | PYRIDINE-2,4- AND 2,5-DICARBONIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF, USE OF THE SAME AND MEDICINAL PRODUCTS BASED ON THESE COMPOUNDS |
DE3703963A1 (en) * | 1987-02-10 | 1988-08-18 | Hoechst Ag | PYRIDINE-2,4- AND 2,, 5-DICARBONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF, AND MEDICINAL PRODUCTS BASED ON THESE COMPOUNDS |
DE3703962A1 (en) * | 1987-02-10 | 1988-08-18 | Hoechst Ag | PYRIDINE-2,4- AND 2,5-DICARBONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, USE OF THE SAME AND MEDICINAL PRODUCTS BASED ON THESE COMPOUNDS |
DE4020570A1 (en) * | 1990-06-28 | 1992-01-02 | Hoechst Ag | 2,4- AND 2,5-SUBSTITUTED PYRIDINE-N-OXIDES, METHOD FOR THE PRODUCTION AND USE THEREOF |
-
1992
- 1992-12-21 CA CA002085954A patent/CA2085954A1/en not_active Abandoned
- 1992-12-21 EP EP92121706A patent/EP0548883A1/en not_active Withdrawn
- 1992-12-22 IL IL104208A patent/IL104208A0/en unknown
- 1992-12-22 FI FI925825A patent/FI925825A/en unknown
- 1992-12-23 AU AU30391/92A patent/AU3039192A/en not_active Abandoned
- 1992-12-23 NO NO92924990A patent/NO924990L/en unknown
- 1992-12-24 JP JP4343731A patent/JPH05255261A/en active Pending
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6444823B1 (en) * | 1996-06-20 | 2002-09-03 | Klinge Pharma Gmbh | Pyridyl alkane acid amides as cytostatics and immunosuppressives |
US7241745B2 (en) | 1996-06-20 | 2007-07-10 | Astellas Pharma Gmbh | Pyridyl alkene and pyridyl alkine acid amides as cytostatics and immunosupressives |
US6451816B1 (en) | 1997-06-20 | 2002-09-17 | Klinge Pharma Gmbh | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression |
US6593344B1 (en) | 1997-12-17 | 2003-07-15 | Klinge Pharma Gmbh | Piperadinyl-substituted pyridylalkane, alkene and alkine carboxamides |
US6903118B1 (en) | 1997-12-17 | 2005-06-07 | Klinge Pharma Gmbh | Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides |
US7192967B1 (en) | 1997-12-17 | 2007-03-20 | Astellas Pharma Gmbh | Cyclic imide-substituted pyridylalkane, alkene, alkine carboxamides useful as cytostatic and immunosuppressive agents |
US7320993B1 (en) | 1997-12-17 | 2008-01-22 | Astellas Deutschland Gmbh | Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic useful as cytostatic and immuosuppressive agents |
US6506572B2 (en) | 1999-02-26 | 2003-01-14 | Klinge Pharma Gmbh | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy |
Also Published As
Publication number | Publication date |
---|---|
NO924990D0 (en) | 1992-12-23 |
FI925825A0 (en) | 1992-12-22 |
FI925825A (en) | 1993-06-25 |
NO924990L (en) | 1993-06-25 |
IL104208A0 (en) | 1993-05-13 |
JPH05255261A (en) | 1993-10-05 |
AU3039192A (en) | 1993-07-01 |
EP0548883A1 (en) | 1993-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5607954A (en) | Sulfonamido- and sulfonamidocarbonylpyridine-2-carboxamides and their pyridine-n-oxides, process for their preparation and their use as pharmaceuticals | |
EP0661269B1 (en) | Substituted heterocyclic carboxylic acid amides, their preparation and their use as medicaments | |
EP0418797B1 (en) | Pyrimidin-4,6-dicarboxilic acid diamides, process for their preparation also medicine based on those compounds | |
US5260323A (en) | 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use | |
DE69823665T2 (en) | Heterocyclic compounds as factor Xa inhibitors | |
AU599746B2 (en) | Pyridine-2,4- and -2,5-dicarboxylic acid amides, processes for their preparation, the use thereof, and medicaments based on these compounds | |
EP0673932B1 (en) | Sulfonamidocarbonyl-pyridine-2-carboxamides as well as their pyridine-N-oxides, process for their preparation and their use as medicaments | |
EP0650960A1 (en) | Substituted heterocyclic carboxylic acid amide esters, their preparation and their us as medicaments | |
AU636990B2 (en) | 2,4- and 2,5-substituted pyridine-n-oxides, processes for their preparation and their use | |
EP0650961A1 (en) | Substituted heterocyclic carboxylic acid amides, their preparation, and their use as medicaments | |
CH629778A5 (en) | METHOD FOR PRODUCING NEW 1,4-DIHYDROPYRIDINE DERIVATIVES. | |
EP0673931A1 (en) | Sulfonamidocarbonyl-pyridine-2-carboxamides and their pyridine-N-oxides, process for their preparation and their use as medicaments | |
EP0533130A1 (en) | 2-Hydroxymethylpyridines, the corresponding pyridine-N-oxides and derivatives thereof, process for their preparation and their use | |
CA2085954A1 (en) | Substituted pyridine n-oxides, processes for their preparation, and their use | |
DE3485928T2 (en) | IMIDAZOPYRROLOPYRIDINE AND CONDENSED DERIVATIVES THEREOF AS INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF HERBICIDAL COMPOUNDS. | |
EP0541042A1 (en) | 2,4- and 2,5-pyridine-dicarboxylic acid derivatives, process for their preparation and their use | |
DE3881407T2 (en) | Cinnoline carboxylic acid amides and process for their preparation. | |
DE68910523T2 (en) | TRICYCLIC 3-OXO-PROPANNITRILE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF. | |
DE69629341T2 (en) | PYRROLOCARBAZOLDERIVATE | |
EP1470108B1 (en) | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | |
EP0234516A1 (en) | 1,6-Naphthyridine derivatives, process for their preparation and medicine containing them for the treatment of vascular diseases | |
KR960011377B1 (en) | Imidazole derivatives and antiulcer agents containing the same | |
EP0567997A1 (en) | 4- or 5-(sulf)imido- and (sulfon)amidopyridines and their pyridine-N-oxides, process for their preparation and their use as pharmaceutical | |
US4355166A (en) | Quinuclidinic ester and derivatives of phenoxycarboxylic acids | |
CA2473790C (en) | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |